0001144204-17-025638.txt : 20170509 0001144204-17-025638.hdr.sgml : 20170509 20170509162453 ACCESSION NUMBER: 0001144204-17-025638 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 41 CONFORMED PERIOD OF REPORT: 20170331 FILED AS OF DATE: 20170509 DATE AS OF CHANGE: 20170509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REPROS THERAPEUTICS INC. CENTRAL INDEX KEY: 0000897075 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 760233274 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-15281 FILM NUMBER: 17826774 BUSINESS ADDRESS: STREET 1: 2408 TIMBERLOCH PL STREET 2: SUITE B-7 CITY: WOODLANDS STATE: TX ZIP: 77380 BUSINESS PHONE: 2817193400 MAIL ADDRESS: STREET 1: 2408 TIMBERLOCH PLACE B-7 CITY: THE WOODLANDS STATE: TX ZIP: 77380 FORMER COMPANY: FORMER CONFORMED NAME: REPROS THERAPEUTICS INC DATE OF NAME CHANGE: 20060503 FORMER COMPANY: FORMER CONFORMED NAME: ZONAGEN INC DATE OF NAME CHANGE: 19930208 10-Q 1 v465639_10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2017

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ____________

Commission file number: 001-15281

REPROS THERAPEUTICS INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware	2408 Timberloch Place, Suite B-7	76-0233274
(State or other jurisdiction of	The Woodlands, Texas 77380	(IRS Employer
incorporation or	(Address of principal executive offices	Identification No.)
organization)	and zip code)

	(281) 719-3400
	(Registrant's telephone number,
	including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or emerging growth company. See definition of "accelerated filer", "large accelerated filer", "smaller reporting company" and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ¨

Accelerated filer ¨

Non-accelerated filer ¨

Smaller reporting company x

Emerging Growth Company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ¨.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

As of May 5, 2017, there were outstanding 26,732,074 shares of Common Stock, par value $.001 per share, of the Registrant.

REPROS THERAPEUTICS INC.

For the Quarter Ended March 31, 2017

INDEX

	Page
FACTORS AFFECTING FORWARD-LOOKING STATEMENTS	3

PART I. FINANCIAL INFORMATION

Item 1 Financial Statements (unaudited)	4

Unaudited Condensed Consolidated Balance Sheets as of March 31, 2017 and December 31, 2016	5
Unaudited Condensed Consolidated Statements of Operations for the three months ended March 31, 2017 and 2016	6
Unaudited Condensed Consolidated Statements of Stockholders' Equity for the three months ended March 31, 2017 and 2016	7
Unaudited Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2017 and 2016	8
Notes to Unaudited Condensed Consolidated Financial Statements	9
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	15
Item 3. Quantitative and Qualitative Disclosures About Market Risk	29
Item 4. Controls and Procedures	29

PART II. OTHER INFORMATION
Item 1. Legal Proceedings	30
Item 1A. Risk Factors	30
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	30
Item 3. Defaults Upon Senior Securities	30
Item 4. Mine Safety Disclosures	30
Item 5. Other Information	30
Item 6. Exhibits	30

SIGNATURES	31

FACTORS AFFECTING FORWARD-LOOKING STATEMENTS

This quarterly report on Form 10-Q includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words "may," "anticipate," "believe," "expect," "estimate," "project," "suggest," "intend" and similar expressions are intended to identify forward-looking statements. Such statements are subject to certain risks, uncertainties and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, expected, estimated, projected, suggested or intended. These risks and uncertainties include risks associated with the success of the clinical trials for Proellex®; the progress of the Company’s enclomiphene product candidate; uncertainty related to the Company's ability to obtain approval of the Company's products by the Food and Drug Administration and regulatory bodies in other jurisdictions, including the European Medicines Agency; uncertainty relating to the Company's patent portfolio; and other risks and uncertainties described in the Company's filings with the Securities and Exchange Commission. For additional discussion of such risks, uncertainties and assumptions, see "Part I. Financial Information - Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources" included elsewhere in this quarterly report on Form 10-Q and “Item 1A. Risk Factors” to Part I of Form 10-K for the fiscal year ended December 31, 2016.

PART I. FINANCIAL INFORMATION

Item 1.

Financial Statements

The following unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (which include only normal recurring adjustments) considered necessary for a fair statement of the interim periods presented have been included. The year-end balance sheet data was derived from audited financial statements, but does not include all the disclosures required by accounting principles generally accepted in the United States of America. Operating results for the three month periods ended March 31, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017. For further information, refer to the financial statements and footnotes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2016.

REPROS THERAPEUTICS INC.

(A development stage company)

REPROS THERAPEUTICS INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited and in thousands except share and per share amounts)

	March 31,			December 31,
	2017			2016

ASSETS

Current assets
Cash and cash equivalents	$	3,235		$	8,688
Restricted cash		916			-
Prepaid expenses and other current assets		304			66
Total current assets		4,455			8,754
Fixed assets, net		2			3
Non-current restricted cash		916			-
Total assets	$	5,373		$	8,757

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities
Accounts payable	$	1,657		$	1,880
Accrued expenses		1,179			779
Total current liabilities		2,836			2,659
Long-term liabilities:
Accrued severance		916			-
Total liabilities		3,752			2,659

Commitments & Contingencies (note 6)

Stockholders' Equity
Undesignated Preferred Stock, $.001 par value, 5,000,000 shares authorized, none issued and outstanding		-			-
Common Stock, $.001 par value, 75,000,000 shares authorized, 26,797,769 and 25,938,602 shares issued, respectively; 26,685,419 and 25,826,252 shares outstanding, respectively		27			26
Additional paid-in capital		328,413			326,981
Cost of treasury stock, 112,350 shares		(1,380	)		(1,380	)
Accumulated deficit		(325,439	)		(319,529	)
Total stockholders' equity		1,621			6,098
Total liabilities and stockholders' equity	$	5,373		$	8,757

The accompanying notes are an integral part of these condensed consolidated financial statements.

REPROS THERAPEUTICS INC.

(A development stage company)

REPROS THERAPEUTICS INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited and in thousands except per share amounts)

	Three Months Ended March 31,
	2017			2016

Revenues and other income
Interest income	$	7		$	17
Total revenues and other income		7			17
Expenses
Research and development		2,074			3,765
General and administrative		3,843			1,096
Total expenses		5,917			4,861
Net loss	$	(5,910	)	$	(4,844	)

Loss per share - basic and diluted	$	(0.22	)	$	(0.20	)

Shares used in loss per share calculation:
Basic		26,270			24,318
Diluted		26,270			24,318

The accompanying notes are an integral part of these condensed consolidated financial statements.

REPROS THERAPEUTICS INC.

(A development stage company)

REPROS THERAPEUTICS INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

(unaudited and in thousands except share and per share amounts)

					Additional										Total
	Common Stock				Paid-in		Treasury Stock					Accumulated			Stockholders'
	Shares		Amount		Capital		Shares		Amount			Deficit			Equity
Balance at December 31, 2016		25,938,602	$	26	$	326,981		112,350	$	(1,380	)	$	(319,529	)	$	6,098
Stock based compensation		-		-		436		-		-			-			436
Issuance of 828,057 shares of common stock at a weighted average share price of $1.20, net of offering costs of $31		828,057		1		996		-		-			-			997
Issuance of 20,000 shares of restricted common stock		20,000		-		-		-		-			-			-
Issuance of 11,110 share common stock for vested RSUs		11,110		-		-		-		-			-			-
Net loss		-		-		-		-		-			(5,910	)		(5,910	)
Balance at March 31, 2017		26,797,769	$	27	$	328,413		112,350	$	(1,380	)	$	(325,439	)	$	1,621

Balance at December 31, 2015		24,430,461	$	24	$	322,179		112,350	$	(1,380	)	$	(302,256	)	$	18,567
Stock based compensation		-		-		516		-		-			-			516
Net loss		-		-		-		-		-			(4,844	)		(4,844	)
Balance at March 31, 2016		24,430,461	$	24	$	322,695		112,350	$	(1,380	)	$	(307,100	)	$	14,239

The accompanying notes are an integral part of these consolidated financial statements.

REPROS THERAPEUTICS INC.

(A development stage company)

REPROS THERAPEUTICS INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited and in thousands)

	Three Months Ended March 31,
	2017			2016

Cash Flows from Operating Activities
Net loss	$	(5,910	)	$	(4,844	)
Depreciation		1			2
Noncash stock-based compensation		436			516
(Increase) decrease in prepaid expenses and other current assets		(238	)		(209	)
Increase (decrease) in accounts payable and accrued expenses		1,093			(812	)
Net cash used in operating activities		(4,618	)		(5,347	)

Cash Flows from Investing Activities
Capital expenditures		-			-
Net cash used in investing activities		-			-

Cash Flows from Financing Activities Proceeds from issuance of common stock, net of offering costs		997			-
Net cash provided by financing activities		997			-
Net decrease in cash, cash equivalents and restricted cash		(3,621	)		(5,347	)
Cash, cash equivalents and restricted cash at beginning of period		8,688			21,393
Cash, cash equivalents and restricted cash at end of period	$	5,067		$	16,046

The accompanying notes are an integral part of these condensed consolidated financial statements.

REPROS THERAPEUTICS INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2017

(Unaudited)

NOTE 1 — Organization, Operations, Liquidity and Recent Developments

Repros Therapeutics Inc. (the “Company,” “RPRX,” “Repros,” or “we,” “us” or “our”) was organized on August 20, 1987. We are a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders.

We are developing Proellex®, an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Uterine fibroids and endometriosis affect millions of women of reproductive age. Proellex® has shown statistically significant results in previous Phase 2 studies for uterine fibroids and endometriosis. We completed a low dose escalating study as permitted by the Food and Drug Administration (“FDA”) in late 2011, to determine both signals of efficacy and safety for low oral doses of the drug. There was no evidence of elevations of liver enzymes over baseline, suggesting these lower doses avoid the type of adverse events seen at much higher doses in earlier studies. On March 17, 2014, we announced that the FDA indicated that we may proceed to conduct Phase 1 and Phase 2 studies of low dose oral Proellex® for uterine fibroids and endometriosis while remaining on partial clinical hold. This guidance indicated that the highest allowed dose will be 12 mg daily. On December 29, 2014, we announced that we have initiated a Phase 2B study for low dose oral Proellex® in the treatment of uterine fibroids. This study was fully enrolled in January 2016 and on November 14, 2016, we announced positive clinical data from this study after two 18-week courses of treatment as compared to placebo. On April 10, 2017, the Company announced that it had a meeting with the FDA to discuss the progress and next steps in the development of Proellex® for the treatment of uterine fibroids. Shortly before the meeting, the Company was notified that the meeting would be a type C/Guidance meeting, rather than a type B/End of phase 2 meeting as previously anticipated. At the meeting, the FDA confirmed that Proellex® will continue on the current partial clinical hold while they consult with liver experts within the FDA regarding previously disclosed effects on the liver.

The Company has an active Investigational New Drug Application (“IND”) for the vaginal delivery of Proellex® for the treatment of uterine fibroids. Since the clinical hold relates only to oral delivery of Proellex®, this IND has no clinical hold issues. In the first quarter of 2012, we initiated a Phase 2 vaginal administration study for the treatment of uterine fibroids and subsequently reported the final study results in January 2013. We held an end of Phase 2 meeting with the FDA in May 2013, to discuss a Phase 3 study design for vaginally delivered Proellex as a treatment for uterine fibroids. The FDA recommended that a Phase 2B study should be conducted prior to commencing a Phase 3 program. On December 29, 2014, we announced that we have initiated a Phase 2B study for vaginally delivered Proellex® in the treatment of uterine fibroids. This study was fully enrolled in January 2016 and on November 14, 2016, we announced positive clinical data from this study after two 18-week courses of treatment as compared to placebo.

We are also developing enclomiphene, a single isomer of clomiphene citrate which is an orally active proprietary small molecule compound. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. Men with secondary hypogonadism exhibit low testosterone levels due to under stimulated testes but they are generally fertile. Enclomiphene is designed to treat the underlying mechanism, insufficient stimulation of the testes by the pituitary, which causes secondary hypogonadism. Secondary hypogonadism due to being overweight or obese is the single greatest cause of hypogonadism in general.

On February 2, 2015, we announced that we electronically submitted our New Drug Application (“NDA”) to the FDA for enclomiphene. The FDA accepted the NDA for review on April 1, 2015 and later assigned a Prescription Drug User Fee (“PDUFA”) goal date of November 30, 2015. In addition, the Division of Bone, Reproductive and Urologic Products (the “Division”) of the FDA scheduled an advisory committee meeting to review the NDA for November 3, 2015. However, the Division subsequently cancelled the scheduled advisory committee meeting due to questions that arose late in the review regarding the bioanalytical method validation that could affect interpretability of certain pivotal study data. On December 1, 2015, we announced that we had received a Complete Response Letter (“CRL”) from the FDA. A CRL informs companies that an NDA cannot be approved in its present form. In the CRL, the FDA stated that, based on recent scientific developments, the design of the enclomiphene Phase 3 studies is no longer adequate to demonstrate clinical benefit and recommended that Repros conduct an additional Phase 3 study or studies to support approval in the target population. The FDA also noted concerns regarding study entry criteria, titration and bioanalytical method validation in the Phase 3 program.

Subsequently, on February 4, 2016, the Company attended a meeting with the FDA reviewers and senior leaders to discuss resolution of issues identified during the NDA review. The meeting covered a broad range of topics surrounding the NDA data as well as emerging agency and expert thinking regarding the treatment of hypogonadism. The Company believes based on the meeting that the FDA is not closed to considering secondary hypogonadism as an indication. Additionally, in January 2016, the Company initiated a Phase 2 double-blind, placebo controlled, proof of concept study, ZA-205, in obese secondary hypogonadal men to assess the impact of enclomiphene on metabolic parameters and quality of life under a diet and exercise regimen. This study was fully enrolled in February 2016 and on August 15, 2016, we reported six month interim results from this study.

Additionally, on September 12, 2016, we reported that we successfully submitted a European centralized marketing authorization application (“MAA”) for enclomiphene for the treatment of secondary hypogonadism. This MAA was subsequently accepted by the European Medicines Agency (“EMA”) which, as previously reported, has assigned the United Kingdom as the primary rapporteur and France as the co-rapporteur for the application review.

On December 6, 2016, the Company participated in the industry presentation at the Bone, Reproductive and Urologic Drugs’ Advisory Committee meeting. The advisory panel provided the FDA with advice regarding a clinical and regulatory path to approval for products, such as enclomiphene, in subjects with obesity-related hypogonadism who wish to maintain spermatogenesis. The panel voted 16 to 5 that the achievement of testosterone improvement while maintaining evidence of spermatogenesis was not sufficient, in and of itself, to provide evidence of clinical benefit. At the meeting, numerous panel members suggested that an additional endpoint related to symptoms should be assessed.

Recent Developments

On February 1, 2017, Joseph S. Podolski left as our President and Chief Executive Officer, and also as a member of our Board of Directors.

Following Mr. Podolski’s departure, Larry Dillaha, M.D. was appointed to serve, on an interim basis, as the Company’s President and Chief Executive Officer. On April 10, 2017, the Company announced that Dr. Dillaha had been appointed as permanent President and Chief Executive Officer. Dr. Dillaha, age 53, has since November 2016 been the Chief Executive Officer and a member of the Board of Directors of CavtheRx, a pre-IND stage, virtual company focused on developing Caveolin Modulators for a variety of inflammatory indications. From April 2014 through January 2017, Dr. Dillaha was the Chief Operating Officer and Chief Medical Officer of New Haven Pharmaceuticals, a specialty pharmaceutical company. From April 2010 through March 2014, Dr. Dillaha was the Chief Medical Officer of Insys Therapeutics, from March 2006 through March 2010, Dr. Dillaha was the Chief Medical Officer of Sciele Pharma, both specialty pharmaceutical companies, and from 2002 through February 2006, Dr. Dillaha was Medical Director, Cardiovascular at Sanofi-Synthelabo/Sanofi. Before that, Dr. Dillaha was a physician in private practice. Dr. Dillaha received his undergraduate degree from the University of Tennessee, Knoxville and his M.D. from the University of Tennessee, Memphis.

In connection with his leaving and in accordance with the terms of his Employment Agreement, dated as of June 16, 2014 (the “Employment Agreement”), Mr. Podolski entered into a Release Agreement with the Company (the “Release Agreement”) dated as of February 1, 2017. The Release Agreement was previously filed with the Securities and Exchange Commission as an exhibit to the Company’s Current Report on Form 8-K filed on February 2, 2017. In accordance with the Employment Agreement, conditioned upon entering into the Release Agreement, Mr. Podolski was treated as having been terminated without Cause (as defined in the Employment Agreement) and will thus receive the following benefits in connection with his separation: (1) a severance payment equal to an amount equal to three times the amount that results from (x) the sum of (i) Mr. Podolski’s annual base salary (at the rate in effect immediately before the date of termination) and target bonus for the fiscal year in which the termination occurs, (ii) Mr. Podolski’s annual base salary for each of the two calendar years immediately prior to the calendar year in which the termination date occurs and (iii) the annual bonus that was actually earned and paid to Mr. Podolski for the two fiscal years that immediately precede the fiscal year in which the termination date occurs, divided by (y) three; (2) reimbursement of amounts paid for COBRA coverage for the eighteen (18) month period following the date of separation for Mr. Podolski, his spouse and his eligible dependents, less the amount that he would be required to contribute for medical and dental coverage if he remained an active employee of the Company; (3) all outstanding stock options held by Mr. Podolski that are not vested and exercisable as of the date of termination will become fully vested and exercisable on the date of termination and all outstanding stock options held by Mr. Podolski on his date of termination will remain exercisable for the shorter of (x) a period of two (2) years from the date of termination or (y) the remaining term of the option.

Pursuant to the Employment Agreement, which was previously filed with the Securities and Exchange Commission as an exhibit to the Company’s Current Report on Form 8-K filed on June 20, 2014, the Release Agreement indicates that Mr. Podolski is bound by certain restrictive covenants, including non-compete and non-solicitation provisions. The Release Agreement also contains a release by Mr. Podolski of all claims against the Company, subject to certain enumerated exceptions.

The Company recorded a charge in the first quarter of 2017 of $2.8 million related to Mr. Podolski’s departure.

Liquidity

On August 9, 2016, we entered into an Equity Distribution Agreement (the “Equity Distribution Agreement”) with Ladenburg Thalmann & Co. Inc. (“Ladenburg”), pursuant to which we may issue and sell from time to time through Ladenburg, as sales agent and/or principal, shares of our common stock having an aggregate offering price of up to $10 million (the “ATM Shares”). Ladenburg is not required to sell on our behalf any specific number or dollar amount of the ATM Shares, but Ladenburg, upon acceptance of written instructions from us, agreed to use its commercially reasonable efforts consistent with its customary trading and sales practices, to sell the ATM Shares up to the amount specified, and otherwise in accordance with the terms of a placement notice delivered to Ladenburg. We have no obligation to sell any ATM Shares under the Equity Distribution Agreement, and may at any time suspend sales under the Equity Distribution Agreement, provided that such suspension shall not affect either party’s obligations with respect to the ATM Shares sold prior to the receipt of notice of such suspension. Ladenburg receives a commission of 3% of the gross sales price of all ATM Shares sold through it under the Equity Distribution Agreement. The ATM Shares are issued pursuant to our shelf registration statement on Form S-3, as amended (File No. 333-197253). During the quarter ended March 31, 2017, we sold 828,057 ATM Shares at a weighted average share price of $1.20, for proceeds of approximately $997,000, net of expenses including approximately $31,000 in commissions to Ladenburg. Between April 1, 2017 and May 8, 2017, we sold an aggregate of 21,100 ATM Shares at a weighted average share price of $1.17, for proceeds of approximately $25,000, net of expenses including approximately $1,000 in commissions to Ladenburg.

As of March 31, 2017, we had accumulated losses of $325.4 million, approximately $3.2 million in cash and cash equivalents, and accounts payable and accrued expenses of approximately $3.8 million, in the aggregate. Included in our accrued expenses is $1.8 million related to the accrued severance payments due Mr. Podolski upon his termination, which are anticipated to be paid in the first quarter of 2018 and 2019. We anticipate that our current liquidity will be sufficient to continue the development of our product candidates and meet our obligations as they become due through the second quarter of 2017. We continue to explore potential additional financing alternatives, including corporate partnering opportunities, that would provide sufficient funds to enable us to continue to develop our two product candidates through FDA approval; however, there can be no assurance that we will be successful in raising any such additional funds on a timely basis or at all. The foregoing matters raise substantial doubt about our ability to continue as a going concern.

Basis of Presentation

These financial statements are unaudited; however, in the opinion of management, these statements reflect all adjustments necessary for a fair statement of the results for the periods reported. All such adjustments are of a normal recurring nature unless disclosed otherwise. These financial statements, including notes, have been prepared in accordance with the applicable rules of the SEC and do not include all of the information and disclosures required by U.S. GAAP for complete financial statements.

These interim financial statements should be read in conjunction with the financial statements and notes thereto included in our 2016 Annual Report on Form 10-K. The results of operations for the first quarter of 2017 are not necessarily indicative of the results to be expected for the full year.

Recent Accounting Pronouncements

In November 2016, the FASB issued ASU No. 2016-18, “Statement of Cash Flows (Topic 230): Restricted Cash”. The new standard requires restricted cash to be included with cash and cash equivalents when reconciling the beginning and ending amounts on the statement of cash flows, and requires additional disclosures in the notes to the financial statements. ASU 2016-18 is effective for fiscal years beginning after December 15, 2017 and interim periods within those fiscal years and early adoption is permitted. The Company adopted this standard during the quarter ended March 31, 2017. See Note 2 to the financial statements included herein.

In March 2016, the FASB issued ASU 2016-09, Compensation—Stock Compensation (ASC Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard simplifies the accounting for stock-based compensation, including amendments on how both taxes related to stock-based compensation and cash payments made to taxing authorities are recorded. ASU 2016-09 is effective for annual reporting periods beginning on or after December 15, 2016, and interim periods within those annual periods and early application is permitted, with any adjustments reflected as of the beginning of the fiscal year of adoption. The Company adopted ASU 2016-09 effective January 1, 2017. The adoption of this standard did not have a material effect on the Company’s financial statements.

In February 2016, FASB issued ASU 2016-02, Leases (ASC Topic 842), which supersedes ASC Topic 840, Leases. The new standard is intended to increase transparency and comparability of organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The new guidance is effective for financial statements issued for annual reporting periods beginning after December 15, 2018, and early application is permitted. The Company is currently evaluating the impact of this standard on our consolidated financial statements.

In November 2015, the FASB issued ASU No. 2015-17, “Balance Sheet Classification of Deferred Taxes” (“ASU 2015-17”), which requires entities to present deferred tax assets and deferred tax liabilities as noncurrent in a classified balance sheet. The ASU simplifies the current guidance in ASC Topic 740, Income Taxes, which requires entities to separately present deferred tax assets and liabilities as current and noncurrent in a classified balance sheet. ASU 2015-17 is effective for fiscal years beginning after December 15, 2016, and interim periods within those annual periods. The Company adopted ASU 2015-07 effective January 1, 2017. The adoption of this standard did not have a material effect on the Company’s financial statements.

In May 2014, the FASB issued Accounting Standards Update 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”). ASU 2014-09 is a comprehensive new revenue recognition model requiring a company to recognize revenue to depict the transfer of goods or services to a customer at an amount reflecting the consideration it expects to receive in exchange for those goods or services. In adopting ASU 2014-09, companies may use either a full retrospective or a modified retrospective approach. Additionally, this guidance requires improved disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. On July 9, 2015, the FASB voted to delay the effective date of this standard by one year. This deferral resulted in ASU 2014-09 being effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017, with early adoption being permitted for annual periods beginning after December 15, 2016. Entities have the option of using either a full retrospective or a modified retrospective approach to adopt the guidance. The Company is currently assessing the effects this guidance may have on its consolidated financial statements, as well as the method of transition that the Company will use in adopting the new standard.

NOTE 2 — Cash, Cash Equivalents and Restricted Cash

As of March 31, 2017, the Company maintained $1.8 million as restricted cash. The funds are being held in accordance with the Release Agreement entered into with Mr. Podolski on February 1, 2017.

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the balance sheets that sum to the total of the same such amounts shown in the statements of cash flows:

	March 31, 2017		March 31, 2016

Cash and cash equivalents	$	3,235	$	16,046
Restricted cash, current		916		—
Restricted cash, noncurrent		916		—
Total	$	5,067	$	16,046

NOTE 3 — Accrued Expenses

Accrued expenses consist of the following (in thousands):

	March 31, 2017		December 31, 2016

Current accrued expenses:
Personnel related costs	$	1,005	$	512
Research and development costs		126		174
Other		48		93
Total current accrued expenses	$	1,179	$	779

	March 31, 2017		December 31, 2016

Long-term accrued expenses:
Accrued severance	$	916	$	--
Total long-term accrued expenses	$	916	$	--

NOTE 4 — Loss Per Share

Basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per share is computed using the average shares outstanding for the period and applying the treasury stock method to potentially dilutive outstanding options. In all applicable periods, all potential common stock equivalents were anti-dilutive and, accordingly, were not included in the computation of diluted loss per share.

The following table presents information necessary to calculate loss per share for the three month periods ended March 31, 2017 and 2016 (in thousands, except per share amounts):

	Three Months Ended March 31,
	2017			2016

Net loss	$	(5,910	)	$	(4,844	)
Average common shares outstanding		26,270			24,318
Basic and diluted loss per share	$	(0.22	)	$	(0.20	)

Potential common stock of 3,097,690 common shares underlying stock options and restricted stock units for the period ended March 31, 2017, were excluded from the above calculation of diluted loss per share because they were anti-dilutive. Potential common stock of 2,554,857 underlying stock options for the period ended March 31, 2016, were also excluded from the above calculation of diluted loss per share because they were anti-dilutive.

NOTE 5 — Stock-Based Compensation

On February 1, 2017, the Board of Directors (the “Board”) granted Larry Dillaha, the Company’s then interim President and Chief Executive Officer a grant of 50,000 stock options to vest upon the successful completion of certain milestones. Additionally, the Board awarded to Katherine Anderson, the Company’s Chief Financial Officer, 10,000 restricted shares of common stock per month on the first day of each month beginning February 1, 2017 and ending on July 1, 2017, to vest on the last day of the month of grant. On February 13, 2017, the Board awarded Michael Wyllie, a non-employee director of the Company, and Larry Dillaha, a grant of 50,000 stock options each. Both option awards will vest upon the successful completion of certain milestones. On February 13, 2017, the Board awarded each board member a grant of 40,000 restricted stock unites, to settle in shares of the Company’s common stock and to vest in equal monthly installments over the three years following the date of grant.

NOTE 6 — Commitments and Contingencies

Therapeutic uses of our enclomiphene product candidate are covered in the United States by approximately ten issued U.S. patents and eleven pending patent applications. Foreign coverage of therapeutic uses of our enclomiphene product candidate includes approximately 85 issued foreign patents and more than 100 foreign pending patent applications. The issued patents and pending applications relate to methods for treating certain conditions including the treatment of testosterone deficiency in men, the treatment of diabetes mellitus Type 2, the treatment of metabolic syndrome and conditions associated therewith, and the treatment of infertility in hypogonadal men. Enclomiphene (the trans-isomer of clomiphene) is purified from clomiphene citrate. A third party individual holds two issued patents related to the use of anti-estrogen such as clomiphene citrate and others for use in the treatment of androgen deficiency and disorders related thereto. We requested re-examination of one of these patents by the U.S. Patent and Trademark Office (“PTO”) based on prior art. The patent holder amended the claims in the re-examination proceedings, which led the PTO to determine that the amended claims were patentable in view of those publications under consideration and a re-examination certificate was issued. We subsequently filed a second request for re-examination by the PTO in light of a number of additional publications. The request was granted and all of the claims were finally rejected by the PTO in the re-examination. The patent holder appealed the rejections to the PTO Board of Patent Appeals and Interferences (the “PTO Board”) which ultimately reversed the rejections of several dependent claims in view of those publications under consideration. The patent holder filed a Notice of Appeal to the Federal Circuit on September 28, 2010 contesting the rejections maintained by the PTO Board. A decision was rendered by the Court of Appeals for the Federal Circuit on December 12, 2011, affirming the rejection of the appealed claims. The PTO issued an Ex Parte Reexamination Certificate on April 29, 2013, canceling the rejected claims and confirming the patentability of the remaining claims. Nevertheless, we believe that our development of enclomiphene does not infringe any of the remaining claims and that all of the remaining claims are invalid on various grounds including additional prior art publications. We also believe that the second of these two patents is invalid in view of published prior art not considered by the PTO. If necessary, we intend to vigorously defend any and all claims that may be brought by the holder of such patents in a court of competent jurisdiction in order to develop enclomiphene further. Adverse determinations in litigation proceedings could require us to seek licenses which may not be available on commercially reasonable terms, or at all, or subject us to significant liabilities, in which case we may not be able to successfully commercialize or out-license enclomiphene until such patents expire or are otherwise no longer in force.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") that involve risk and uncertainties. Any statements contained in this quarterly report that are not statements of historical fact may be forward-looking statements. When we use the words "may," "anticipates," "believes," "plans," "expects" and similar expressions, we are identifying forward-looking statements. Forward-looking statements involve risks and uncertainties which may cause our actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements. The following discussion of financial condition should be read in conjunction with the accompanying consolidated financial statements and related notes.

Repros Therapeutics Inc.

The Company was organized on August 20, 1987. We are a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders.

We are developing Proellex®, an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Uterine fibroids and endometriosis affect millions of women of reproductive age. Proellex® has shown statistically significant results in previous Phase 2 studies for uterine fibroids and endometriosis. We completed a low dose escalating study as permitted by the Food and Drug Administration (“FDA”) in late 2011, to determine both signals of efficacy and safety for low oral doses of the drug. There was no evidence of elevations of liver enzymes over baseline, suggesting these lower doses avoid the type of adverse events seen at much higher doses in earlier studies. On March 17, 2014, we announced that the FDA indicated that we may proceed to conduct Phase 1 and Phase 2 studies of low dose oral Proellex® for uterine fibroids and endometriosis while remaining on partial clinical hold. This guidance indicated that the highest allowed dose will be 12 mg daily. On December 29, 2014, we announced that we have initiated a Phase 2B study for low dose oral Proellex® in the treatment of uterine fibroids. This study was fully enrolled in January 2016 and on November 14, 2016, we announced positive clinical data from this study after two 18-week courses of treatment as compared to placebo. On April 10, 2017, the Company announced they had a meeting with the FDA to discuss the progress and next steps in the development of Proellex® for the treatment of uterine fibroids. Shortly before the meeting, the Company was notified that the meeting would be a type C/Guidance meeting, rather than a type B/End of phase 2 meeting as previously anticipated. At the meeting, the FDA confirmed that Proellex® will continue on the current partial clinical hold while they consult with liver experts within the FDA regarding previously disclosed effects on the liver.

In December 2011, we completed a Phase 2B study of enclomiphene in men with secondary hypogonadism, but naïve to testosterone treatment, at the recommendation of the FDA. Top line results of this study demonstrated that enclomiphene was generally well tolerated compared to placebo and that there were no drug related serious adverse events that led to discontinuation. We met with the FDA in May 2012 to discuss the design of pivotal Phase 3 efficacy studies for enclomiphene as well as the components of the overall drug development program required for a New Drug Application (“NDA”) submission and agreed on registration requirements for enclomiphene oral therapy for the treatment of secondary hypogonadism. In July 2012, we announced that we reached an agreement with the FDA for the design of the pivotal efficacy studies for enclomiphene for the treatment of secondary hypogonadism. The pivotal studies were conducted under a Special Protocol Assessment (“SPA”). We have completed both Phase 3 pivotal efficacy studies. On March 27, 2013, we announced that the top-line results from our first pivotal Phase 3 study, ZA-301, met both co-primary endpoints mandated by the FDA, and we announced on September 16, 2013, that we met both co-primary endpoints in the second pivotal study, ZA-302. Additionally, on September 16, 2013, we announced the results from ZA-300, a six-month safety study. This study identified no new safety issues. On October 22, 2013, we announced that we received guidance from the FDA instructing the Company to request a meeting to discuss the adequacy of studies ZA-301 and ZA-302. In addition to this guidance, the FDA further noted that they would allow us to run head-to-head studies against approved testosterone replacement products. These head-to-head studies, ZA-304 and ZA-305, were initiated in January 2014 and subsequently completed in September and August 2014, respectively. Both of these head-to-head studies achieved superiority for both co-primary endpoints and most secondary endpoints as compared to the approved testosterone replacement product. On October 21, 2014, we announced the results from ZA-303, a 52 week, single-blind, placebo-controlled Phase 3 study to evaluate the effects on bone mineral density. In this study, no new safety signals were identified, including no evidence of negative effects on bone mineral density. On February 2, 2015, we announced that we electronically submitted our NDA to the FDA for enclomiphene. The FDA accepted the NDA for review on April 1, 2015 and later assigned a Prescription Drug User Fee (“PDUFA”) goal date of November 30, 2015. In addition, the Division of Bone, Reproductive and Urologic Products (the “Division”) of the FDA scheduled an advisory committee meeting to review the NDA for November 3, 2015. However, the Division subsequently cancelled the scheduled advisory committee meeting due to questions that arose late in the review regarding the bioanalytical method validation that could affect interpretability of certain pivotal study data. On December 1, 2015, we announced that we had received a Complete Response Letter (“CRL”) from the FDA. A CRL informs companies that an NDA cannot be approved in its present form. In the CRL, the FDA stated that, based on recent scientific developments, the design of the enclomiphene Phase 3 studies is no longer adequate to demonstrate clinical benefit and recommended that Repros conduct an additional Phase 3 study or studies to support approval in the target population. The FDA also noted concerns regarding study entry criteria, titration and bioanalytical method validation in the Phase 3 program.

Additionally, on September 12, 2016, we reported that we successfully submitted a European centralized marketing authorization application (“MAA”) for enclomiphene for the treatment of secondary hypogonadism. This MAA was subsequently accepted by the European Medicines Agency (“EMA”) and, as previously reported, has assigned the United Kingdom as the primary rapporteur and France as the co-rapporteur for the application review.

Recent Developments

On February 1, 2017, Joseph S. Podolski left as our President and Chief Executive Officer, and also as a member of our Board of Directors.

The Company recorded a charge in the first quarter of 2017 of $2.8 million related to Mr. Podolski’s departure.

Liquidity

As of December 31, 2016, we had accumulated losses of $325.4 million, approximately $3.2 million in cash and cash equivalents, and accounts payable and accrued expenses of approximately $3.8 million, in the aggregate. Included in our accrued expenses is $1.8 million related to the accrued severance payments due Mr. Podolski upon his termination, which are anticipated to be paid in the first quarter of 2018 and 2019. We anticipate that our current liquidity will be sufficient to continue the development of our product candidates and meet our obligations as they become due through the second quarter of 2017. We continue to explore potential additional financing alternatives, including corporate partnering opportunities, that would provide sufficient funds to enable us to continue to develop our two product candidates through FDA approval; however, there can be no assurance that we will be successful in raising any such additional funds on a timely basis or at all. The foregoing matters raise substantial doubt about our ability to continue as a going concern.

Proellex®

Product Overview

Proellex®, our product candidate for female reproductive health, is a new chemical entity that acts as a selective blocker of the progesterone receptor and is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis. The National Uterine Fibroids Foundation estimates that 80% of all women in the U.S. have uterine fibroids, and one in four of these women have symptoms severe enough to require treatment. According to the Endometriosis Association, endometriosis affects 6.3 million women in the U.S. and Canada and millions more worldwide.

The current standards of care for uterine fibroids and endometriosis consist of surgery or short-term treatment with gonadotropin-releasing hormone (“GnRH”) agonists drugs, such as Lupron®. GnRH agonists induce a low estrogen, menopausal-like state and promote bone loss and are not recommended for use for more than six months without add-back hormonal therapy.

We have conducted numerous studies with Proellex® dosing approximately 900 women with the drug. All Proellex® studies completed to date exhibited strong efficacy signals, whether in uterine fibroids or endometriosis. In a 120 patient study of Proellex® as a treatment of uterine fibroids conducted in the United States (roughly 40 subjects per arm), both a 12.5 and 25 mg dose of Proellex® were compared to placebo. In this study each of the 12.5 and 25 mg doses achieved highly statistically significant results when compared to placebo when menstrual bleeding was assessed (p<0.0001). The two doses also achieved highly statistically significant improvement in quality of life measures using the Uterine Fibroid Symptom Quality of Life questionnaire developed and validated by Georgetown University and used in the development of device like treatments of uterine fibroids such as uterine artery embolization. There was no statistical difference in efficacy measures between the two doses. Importantly, in the Phase 2 U.S. trial, a significant percentage of women stopped menstruating (amenorrhea). Over 80% of women on both the 12.5 and 25 mg doses exhibited amenorrhea during the three month trial, whereas all women on placebo exhibited at least one menses. The key symptom of uterine fibroids is excessive menstrual bleeding. The induction of amenorrhea continues to be the primary endpoint in our uterine fibroids clinical studies.

Up until the summer of 2009, all side effects exhibited in the studies were considered manageable and the benefit of Proellex® far outweighed the risk. However, in Phase 3 efficacy and larger Phase 3 safety studies in diverse populations, a small number of subjects exhibited serious adverse effects associated with elevated liver enzymes. As a result of these findings, we elected to stop the trials and the FDA subsequently placed Proellex® on full clinical hold. All women that experienced elevated liver enzymes and returned for follow-up visits returned to baseline conditions with no overnight hospitalization necessary. An analysis of all the subjects that experienced such serious adverse effects showed that the effect only occurred in a small percentage of subjects that were exposed to the 50 mg dose of the drug for any period of time. Based on these findings, we petitioned the FDA to allow us to conduct a low dose study to demonstrate both safety and signals of efficacy in low oral doses of Proellex®, up to 12 mg administered daily. The FDA upgraded the full clinical hold to a partial hold to allow the low dose study to be conducted. In addition, we are exploring vaginal delivery as an alternative administrative route to bypass first-pass liver effects and reduce systemic exposure.

Low Dose Oral Study

Pursuant to the terms of the partial clinical hold currently in place as a result of the liver toxicity exhibited by Proellex®, the FDA allowed us to run a single study to test low oral doses of Proellex® for signals of safety and efficacy. The study tested five different doses of Proellex® (1, 3, 6, 9 and 12 mg), with 1 mg being the first dose tested. Each dose was then compared to placebo with weekly assessments of liver function during both the placebo and drug period. Subjects were dosed with the active drug for 10 weeks, which allowed for adequate time to determine the impact of a given dose on trends in liver function. Each dose was tested in up to 12 different subjects and assessment of pharmacokinetic parameters was obtained at the start of dosing and the end of the dosing period to determine overall and maximum drug exposure for a given dose. We also monitored changes in menstrual bleeding patterns and ovulation as well as changes in endometrial thickness. The FDA required that an independent Drug Safety Monitoring Board be established and that the informed consent clearly state the liver toxicity previously experienced with Proellex®. We have completed this study and have announced that there was no evidence of elevations of liver enzymes over baseline, suggesting these lower doses avoid the type of adverse events seen at much higher doses in earlier studies.

On July 16, 2012, we announced that we held a teleconference with the FDA to discuss the development of low dose oral Proellex® as a treatment for endometriosis. Subsequently, on October 8, 2012, we announced that the FDA has agreed to reclassify the full clinical hold to a partial clinical hold on low dose oral Proellex® to allow us to conduct a Phase 2 study in the treatment of endometriosis. We initiated this 60 subject, four month active dosing study in November 2012 and it was fully enrolled in January 2016. On September 7, 2016, we announced positive clinical data for the first course of treatment in this Phase 2 study.

On October 31, 2013, the Company held a meeting with the FDA to discuss the clinical development plan for low dose oral Proellex® in the treatment of uterine fibroids. During the meeting, the FDA provided guidance for endpoints it believed acceptable for the treatment of uterine fibroids in an efficacy study and instructed the Company to submit a request for lifting the full clinical hold. The Company has followed the FDA’s recommendations and submitted the study protocol and the request for the full hold lift. Additionally, on March 17, 2014, we announced that the FDA indicated that we may proceed to conduct Phase 1 and Phase 2 studies of low dose oral Proellex® for endometriosis and uterine fibroids while remaining on partial clinical hold. This guidance indicated that the highest allowed dose will be 12 mg daily. On December 29, 2014, we announced that we have initiated a Phase 2B study for low dose oral Proellex® in the treatment of uterine fibroids. This study was fully enrolled in January 2016 and on November 14, 2016, we announced positive clinical data from this study after two 18-week courses of treatment as compared to placebo. On January 30, 2017, we announced the FDA has granted the Company an end of phase 2 meeting to discuss the phase 3 requirements for Proellex in the treatment of uterine fibroids. Subsequently, on April 10, 2017, the Company announced that it had a meeting with the FDA to discuss the progress and next steps in the development of Proellex® for the treatment of uterine fibroids. Shortly before the meeting, the Company was notified that the meeting would be a type C/Guidance meeting, rather than a type B/End of phase 2 meeting as previously anticipated. At the meeting, the FDA confirmed that Proellex® will continue on the current partial clinical hold while they consult with liver experts within the FDA regarding previously disclosed effects on the liver. Further, the FDA agreed to accept additional information from the Company and its panel of liver experts for consideration by the FDA’s internal advisory liver team. The Company expects to submit the additional information and a proposed clinical protocol within a month. The Company intends to announce further information following receipt of additional guidance from the FDA.

Vaginal Administration

We are assessing vaginal administration of Proellex® to avoid first pass liver effects and achieve higher reproductive tract concentrations of the drug while minimizing systemic exposure. We reported results from two in vivo animal studies which confirmed reduced maximum circulating concentrations of the drug when administered vaginally, as well as efficacy signals at substantially lower doses than oral administration. The Company has an active IND for the vaginal delivery of Proellex® for the treatment of uterine fibroids. Since the clinical hold relates only to the oral delivery of Proellex®, this IND has no clinical hold issues. In the first quarter of 2012, we initiated a Phase 2 vaginal administration study for the treatment of uterine fibroids. In January 2013, we reported the final study results which indicated the 12 mg dose achieved statistically significant improvement in menstrual bleeding, uterine fibroid symptoms and reduction in fibroid volume even with the low number of subjects enrolled into the study (n=12 @ 12 mg). Based on these findings, the Company believes the 12 mg dose is appropriate for further development. We held an end of Phase 2 meeting with the FDA in May 2013, to discuss a Phase 3 study design for the vaginally delivered Proellex as a treatment for uterine fibroids. The FDA recommended that a Phase 2B study should be conducted prior to commencing a Phase 3 program. On December 29, 2014, we announced that we have initiated a Phase 2B study for vaginally delivered Proellex® in the treatment of uterine fibroids. This study was fully enrolled in January 2016 and on November 14, 2016, we announced positive clinical data from this study after two 18-week courses of treatment as compared to placebo.

Enclomiphene

Product Overview

We are developing enclomiphene, a single isomer of clomiphene citrate which is an orally active proprietary small molecule compound. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. Men with secondary hypogonadism exhibit low testosterone levels due to under stimulated testes but they are generally fertile. Enclomiphene is designed to treat the underlying mechanism, insufficient stimulation of the testes by the pituitary, which causes secondary hypogonadism. Secondary hypogonadism due to being overweight or obese is the single greatest cause of hypogonadism in general.

Testosterone is an important male hormone. Testosterone deficiency in men is linked to several negative physical and mental conditions, including loss of muscle tone, reduced sexual desire and deterioration of memory and certain other cognitive functions. Testosterone production normally decreases as men age and this decline can be accelerated by obesity, sometimes leading to testosterone deficiency. The leading therapy for low testosterone is AndroGel®, a commercially available testosterone replacement marketed by AbbVie Inc. (“AbbVie”) for the treatment of low testosterone, which we believe has had and continues to have significant sales in North America.

Based on our own clinical trial screening data, we believe over 70% of men that have low testosterone suffer from secondary hypogonadism, a pituitary defect which is characterized by suboptimal levels of LH (luteinizing hormone) and FSH (follicle stimulating hormone). LH and FSH are the pituitary hormones that stimulate testicular testosterone and sperm production, respectively. Men with secondary hypogonadism can be readily distinguished from those that have primary testicular failure via assessment of the levels of secretions of pituitary hormones, as men with primary testicular failure experience elevated secretions of pituitary hormones. In secondary hypogonadism, the low levels of LH and FSH fail to provide adequate hormone signaling to the testes, causing testosterone levels to drop to a level where we believe pituitary secretions fall under the influence of estrogen, which is enhanced in obese men, thus further suppressing the testicular stimulation from the pituitary.

Enclomiphene acts centrally to restore testicular function and, hence, normal testosterone in the body. The administration of exogenous testosterone can restore serum testosterone levels, but does not restore testicular function and thereby generally leads to the cessation of, or significant reduction in, sperm production. Enclomiphene, by contrast, restores levels of both LH and FSH, which stimulate testicular testosterone and sperm production, respectively.

Treatment for Secondary Hypogonadism in Men Wishing to Preserve Testicular Function (Reproductive Status)

On November 8, 2010, we held a Type B meeting with the FDA to discuss whether the FDA would review our protocols for a Phase 3 trial of enclomiphene in men with secondary hypogonadism under an SPA. In the meeting, the FDA recommended that a Phase 2B study in men with secondary hypogonadism but naïve to testosterone treatment be conducted if we desired the protocols to be reviewed under an SPA. The FDA further opined that such Phase 2B study would provide for a more solid data base for design of Phase 3 studies and eventual approval of such studies under an SPA.

We completed the Phase 2B trial which consisted of four arms; placebo, two doses of enclomiphene and topical testosterone. In this study, at baseline the men exhibited morning testosterone less than 250 ng/dl and there was no statistical difference between the groups in testosterone at baseline. At the end of the three month dosing period, median morning testosterone levels were placebo, 196 ng/dl, 12.5 mg enclomiphene, 432 ng/dl, 25 mg enclomiphene, 416 ng/dl and Testim®, 393 ng/dl. A comparison of final median morning testosterone in all three of the active arms to placebo showed them to be highly statistically different and there was no statistical difference observed between these active arms. This trial also showed that enclomiphene was able to maintain sperm counts in men being treated for their low testosterone levels, whereas Testim® resulted in suppressed sperm levels.

On July 9, 2012, we announced that we reached an agreement with the FDA for the design of the pivotal efficacy studies for enclomiphene for the treatment of secondary hypogonadism. The pivotal studies were conducted under an SPA. On March 27, 2013, we announced that the top-line results from our first pivotal Phase 3 study, ZA-301, met both co-primary endpoints mandated by the FDA and we announced on September 16, 2013, that we met both co-primary endpoints in the second pivotal study, ZA-302.

The 500 subject, six month, open label safety study, ZA-300, completed enrollment in February 2013 at 28 U.S. clinical sites. On September 16, 2013, we reported top-line results of this study. Additionally, we completed enrollment into a one year, 150 subject DEXA study, ZA-303, in January 2013 at 10 U.S. clinical sites. On October 21, 2014, we announced that this study identified no new safety signals, including no evidence of negative effects on bone mineral density.

On October 22, 2013, we announced that we received guidance from the FDA instructing the Company to request a meeting to discuss the adequacy of studies ZA-301 and ZA-302. In addition to this guidance, the FDA further noted they would allow us to run head-to-head studies against approved testosterone replacement products. These head-to-head studies, ZA-304 and ZA-305, were initiated in January 2014 and subsequently completed in September and August 2014, respectively. Both of these head-to-head studies achieved superiority for both co-primary endpoints and most secondary endpoints as compared to the approved testosterone replacement product.

On February 2, 2015, we announced that we electronically submitted our NDA to the FDA for enclomiphene. The FDA accepted the NDA for review on April 1, 2015 and later assigned a PDUFA goal date of November 30, 2015. In addition, the Division of the FDA scheduled an advisory committee meeting to review the NDA for November 3, 2015. However, the Division subsequently cancelled the scheduled advisory committee meeting due to questions that arose late in the review regarding the bioanalytical method validation that could affect interpretability of certain pivotal study data. On December 1, 2015, we announced that we had received a CRL from the FDA. A CRL informs companies that an NDA cannot be approved in its present form. In the CRL, the FDA stated that, based on recent scientific developments, the design of the enclomiphene Phase 3 studies is no longer adequate to demonstrate clinical benefit and recommended that Repros conduct an additional Phase 3 study or studies to support approval in the target population. The FDA also noted concerns regarding study entry criteria, titration and bioanalytical method validation in the Phase 3 program. Subsequently, on February 4, 2016, the Company attended a meeting with the FDA reviewers and senior leaders to discuss resolution of issues identified during the NDA review. The meeting covered a broad range of topics surrounding the NDA data as well as emerging agency and expert thinking regarding the treatment of hypogonadism. The Company believes based on the meeting that the FDA is not closed to considering secondary hypogonadism as an indication. Additionally, in January 2016, the Company initiated a Phase 2 double-blind, placebo controlled, proof of concept study, ZA-205, in obese secondary hypogonadal men to assess the impact of enclomiphene on metabolic parameters and quality of life under a diet and exercise regimen. This study was fully enrolled in February 2016 and on August 15, 2016, we reported six month interim results from this study.

Business Strategy

We plan to focus our clinical program on the clinical development program for low dose oral Proellex® in the treatment of uterine fibroids. We anticipate that our current liquidity will be sufficient to continue the development of our product candidates and meet our obligations as they become due through the second quarter of 2017. We continue to explore potential additional financing alternatives, including corporate partnering opportunities, that would provide sufficient funds to enable us to continue to develop our two product candidates through FDA approval; however, there can be no assurance that we will be successful in raising any such additional funds on a timely basis or at all.

Corporate Information

We were organized as a Delaware corporation in August 1987. Our principal executive offices are located at 2408 Timberloch Place, Suite B-7, The Woodlands, Texas, 77380, and our telephone number is (281) 719-3400. We maintain an internet website at www.reprosrx.com. The information on our website or any other website is not incorporated by reference into this quarterly report and does not constitute a part of this quarterly report. Our Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and all amendments to such reports are made available free of charge through the Investor Relations section of our website as soon as reasonably practicable after they have been filed or furnished with the Securities and Exchange Commission.

General

We currently have 21 full-time employees. We utilize the services of contract research organizations, contract manufacturers and various consultants to assist us in performing clinical and regulatory services for the clinical development of our products. We are substantially dependent on our various contract groups to adequately perform the activities required to obtain regulatory approval of our products.

We have accumulated net operating losses through March 31, 2017 and the value of the tax asset associated with these accumulated net operating losses may be substantially diminished in value due to various tax regulations, including change in control provisions in the tax code. Additionally, during 2013, the Company completed an analysis of its section 382 limit. Based on this analysis, the Company concluded that the amount of net operating loss (“NOL”) carryforwards and the credits available to offset taxable income is limited under section 382. See “Critical Accounting Policies and the Use of Estimates – Income Taxes,” below.

Losses have resulted principally from costs incurred in conducting clinical trials for our product candidates, in research and development activities related to efforts to develop our products and from the associated administrative costs required to support those efforts. There can be no assurance that we will be able to successfully complete the transition from a development stage company to the successful introduction of commercially viable products. Our ability to achieve profitability will depend on, among other things, successfully completing the clinical development of our products in a reasonable time frame and at a reasonable cost, obtaining regulatory approvals, establishing marketing, sales and manufacturing capabilities or collaborative arrangements with others that possess such capabilities, and, if applicable, continuing to raise sufficient funds to finance our activities. There can be no assurance that we will be able to achieve profitability.

Critical Accounting Policies and the Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Accrued Expenses

We estimate accrued expenses as part of our process of preparing financial statements. Examples of areas in which subjective judgments may be required include costs associated with services provided by contract organizations for clinical trials, preclinical development and manufacturing of clinical materials. We accrue for costs incurred as the services are being provided by monitoring the status of the trials or services provided and the invoices received from our external service providers. In the case of clinical trials, a portion of the estimated cost normally relates to the projected cost to treat a patient in our trials, and we recognize this cost over the estimated term of the study based on the number of patients enrolled in the trial on an ongoing basis, beginning with patient enrollment. As actual costs become known to us, we adjust our accruals. To date, our estimates have not differed significantly from the actual costs incurred. However, subsequent changes in estimates may result in a material change in our accruals, which could also materially affect our balance sheet and results of operations.

Research and Development Expenses

Research and development, or R&D, expenses include salaries and related employee expenses, contracted regulatory affairs activities, insurance coverage for clinical trials and prior product sales, contracted research and consulting fees, facility costs and internal research and development supplies. We expense research and development costs in the period they are incurred. These costs consist of direct and indirect costs associated with specific projects as well as fees paid to various entities that perform research on our behalf.

Stock-Based Compensation

We had one stock-based compensation plan at March 31, 2017, the 2011 Equity Incentive Plan. Accounting for stock-based compensation generally requires the recognition of the cost of employee services for stock-based compensation based on the grant date fair value of the equity or liability instruments issued. We use the Black-Scholes option pricing model to estimate the fair value of our stock options. Expected volatility is determined using historical volatilities based on historical stock prices for a period equal to the expected term. The expected volatility assumption is adjusted if future volatility is expected to vary from historical experience. The expected term of options represents the period of time that options granted are expected to be outstanding and falls between the options' vesting and contractual expiration dates. The Company’s historical stock option exercise experience does not provide a reasonable basis upon which to estimate expected term. As such, the simplified method was used to calculate the expected term. The risk-free interest rate is based on the yield at the date of grant of a zero-coupon U.S. Treasury bond whose maturity period equals the option's expected term.

Income Taxes

Our losses from inception to date have resulted principally from costs incurred in conducting clinical trials and in research and development activities related to efforts to develop our products and from the associated administrative costs required to support those efforts. We have recorded a deferred tax asset for our NOLs; however, as the Company has incurred losses since inception, and since there is no certainty of future profits, a valuation allowance has been provided in full on our deferred tax assets in the accompanying consolidated financial statements. Additionally, during 2013, the Company completed an analysis of its section 382 limit. Based on this analysis, the Company concluded that the amount of NOL carryforwards and the credits available to offset taxable income is limited under section 382. Accordingly, if the Company generates taxable income in any year in excess of its then annual limitation, the Company may be required to pay federal income taxes even though it has unexpired NOL carryforwards. Additionally, because U.S. tax laws limit the time during which NOLs and tax credit carryforwards may be applied against future taxable income and tax liabilities, the Company may not be able to take full advantage of its NOLs and tax credit carryforwards for federal income tax purposes. Future public and private stock placements may create additional limitations on the Company’s NOLs, credits and other tax attributes.

Recent Accounting Pronouncements

Results of Operations

Comparison of the three month periods ended March 31, 2017 and 2016

Revenues and Other Income

Total revenues and other income decreased to $7,000 for the three month period ended March 31, 2017 as compared to $17,000 for the same period in the prior year. All revenue in both periods was from interest income, and the decrease was primarily due to lower cash balances for the three month period ended March 31, 2017 as compared to the comparable period in the prior year.

Research and Development Expenses

R&D expenses include contracted services relating to our clinical product development activities which include preclinical studies, clinical trials, expenses associated with our patent portfolio, regulatory affairs, including FDA filing fees, and bulk manufacturing scale-up activities and bulk active ingredient purchases for preclinical and clinical trials primarily relating to our two products in clinical development, which are Proellex® and enclomiphene. Research and development expenses also include internal operating expenses relating to our general research and development activities. R&D expenses decreased 45%, or $1.7 million, to $2.1 million for the three month period ended March 31, 2017, as compared to $3.8 million for the same period in the prior year. Our primary R&D expenses for the three month periods ended March 31, 2017 and 2016 are shown in the following table (in thousands):

	Three months ended March 31,
Research and Development	2017		2016		Variance			Change (%)
Proellex® clinical development	$	520	$	1,156	$	(636	)		(55	)%
Enclomiphene clinical development		330		1,181		(851	)		(72	)%
Payroll and benefits		638		712		(74	)		(10	)%
Operating and occupancy		586		716		(130	)		(18	)%
Total	$	2,074	$	3,765	$	(1,691	)		(45	)%

The clinical development expenses related to Proellex® decreased for the three month period ended March 31, 2017, as compared to the prior year period, due to decreased expenses associated with our Phase 2b clinical trials for the treatment of uterine fibroids and endometriosis. The clinical development expenses related to enclomiphene decreased for the three month period ended March 31, 2017, as compared to the prior year period, due to decreased expenses associated with our Phase 2 proof of concept study, ZA-205.

Payroll and benefits expenses decreased 10%, or approximately $74,000, to $638,000 for the three month period ended March 31, 2017, as compared to $712,000 for the same period in the prior year. Included in payroll and benefits expense is a charge for non-cash stock-based compensation of $118,000 for the three month period ended March 31, 2017 as compared to a charge of $193,000 for the same period in the prior year. Additionally, salaries for the three month period ended March 31, 2017 were $408,000 as compared to $422,000 for the same period in the prior year.

Operating and occupancy expenses decreased 18%, or approximately $130,000, to $586,000 for the three month period ended March 31, 2017 as compared to $716,000 for the same period in the prior year, primarily due to decreased legal expenses and other outside services.

To date through March 31, 2017 we have incurred approximately $71.8 million for the development of Proellex® and approximately $73.8 million for the development of enclomiphene. These accumulated costs exclude any internal operating expenses and expenses associated with the patent portfolio.

General and Administrative Expenses

General and administrative (“G&A”) expenses increased 251%, or approximately $2.7 million, to $3.8 million for the three month period ended March 31, 2017 as compared to $1.1 million for the same period in the prior year. Our primary G&A expenses for the three month periods ended March 31, 2017 and 2016 are shown in the following table (in thousands):

	Three months ended March 31,
General and Administrative	2017		2016		Variance			Change (%)
Payroll and benefits	$	3,413	$	620	$	2,793			450	%
Operating and occupancy		430		476		(46	)		(10	)%
Total	$	3,843	$	1,096	$	2,747			251	%

G&A payroll and benefits expenses include salaries, bonuses, non-cash stock-based compensation expense, fringe benefits and severance pay. Included in payroll and benefits expense is a charge for non-cash stock-based compensation of $318,000 for the three month period ended March 31, 2017 as compared to a charge of $323,000 for the same period in the prior year. Additionally, payroll and benefits include a charge of $2.8 million for the three month period ended March 31, 2017 related to the departure of Mr. Podolski.

G&A operating and occupancy expenses, which include expenses to operate as a public company, remained relatively constant at $430,000 for the three month period ended March 31, 2017 as compared to $476,000 for the same period in the prior year.

Off-Balance Sheet Arrangements

As of March 31, 2017, we did not have any off-balance sheet arrangements.

Liquidity and Capital Resources

Since our inception, we have financed our operations primarily with proceeds from private placements and public offerings of equity securities and with funds received under collaborative agreements.

Our primary use of cash to date has been in operating activities to fund research and development, including preclinical studies and clinical trials, and general and administrative expenses. We had cash and cash equivalents of approximately $3.2 million as of March 31, 2017 as compared to $8.7 million as of December 31, 2016. All cash and cash equivalents as of March 31, 2017 and December 31, 2016 were held in an account backed by U.S. government securities.

Net cash of approximately $4.6 million and $5.3 million was used in operating activities during the three month periods ended March 31, 2017 and 2016, respectively. The major use of cash for operating activities for the three month period ended March 31, 2017 was to fund our clinical development programs and associated administrative costs. No cash was used in investing activities during the three month period ended March 31, 2017. Cash provided by financing activities for the three month period ended March 31, 2017 was approximately $997,000 due to the 828,057 ATM Shares sold at a weighted average share price of $1.20, net of related expenses.

We have experienced negative cash flows from operations since inception. We will require substantial funds for R&D, including preclinical studies and clinical trials of our product candidates, and to commence sales and marketing efforts, if appropriate, if the FDA or other regulatory approvals are obtained. Based on our current and planned clinical activities, we believe that our current liquidity will be sufficient to continue the development of our product candidates and meet our obligations as they become due through the second quarter of 2017. We continue to explore potential additional financing alternatives, including corporate partnering opportunities, that would provide sufficient funds to enable us to continue to develop our two product candidates through FDA approval; however, there can be no assurance that we will be successful in raising any such additional funds on a timely basis or at all. Our capital requirements will depend on many factors, which are discussed in detail in “Item 1A., Risk Factors” of Form 10-K for the fiscal year ended December 31, 2016. The uncertainties relating to the foregoing matters raise substantial doubt about our ability to continue as a going concern.

Our results of operations may vary significantly from quarter to quarter and year to year, and depend on, among other factors, our ability to raise additional capital on acceptable terms or at all, our ability to be successful in our clinical trials, the regulatory approval process in the United States and other foreign jurisdictions and the ability to complete strategic licenses and product development agreements. The timing of our revenues may not match the timing of our associated product development expenses. To date, R&D expenses have usually exceeded revenue in any particular period and/or fiscal year.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Interest Rate Risk. We had cash and cash equivalents of approximately $3.2 million at March 31, 2017 which is held in an account backed by U.S. government securities. Although this cash account is subject to fluctuations in interest rates and market conditions, no significant gain or loss on this account is expected to be recognized in earnings. We do not invest in derivative securities.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

Based on their evaluation as of the end of the period covered by this Quarterly Report on Form 10-Q, our Principal Executive Officer and Principal Financial Officer have concluded that our disclosure controls and procedures (as defined in Rule 13a-15(e)) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), were effective as of March 31, 2017.

Changes in Internal Control over Financial Reporting

In connection with the evaluation described above, we identified no change in internal control over financial reporting that occurred during the quarter ended March 31, 2017 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

See Note 6 of the Notes to the Condensed Consolidated Financial Statements.

Item 1A. Risk Factors

There were no material changes from the risk factors previously disclosed in the registrant’s Form 10-K for the fiscal year ended December 31, 2015 in response to “Item 1A. Risk Factors” to Part I of Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None

Item 3. Defaults Upon Senior Securities.

None

Item 4. Mine Safety Disclosures.

None

Item 5. Other Information

None

Item 6. Exhibits

10.1

Release Agreement, dated February 1, 2017, between the Company and Joseph S. Podolski (filed as Exhibit 99.1 to the Company’s Current Report on Form 8-K dated February 2, 2017 and incorporated herein by reference).

31.1*

Certification Pursuant to Rule 13(a)-14(a) or 15(d)-14(a) of the Exchange Act, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Principal Executive Officer).

31.2*

Certification Pursuant to Rule 13(a)-14(a) or 15(d)-14(a) of the Exchange Act, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Principal Financial Officer).

32.1**

Certification Furnished Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Principal Executive Officer) (This exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section. Further, this exhibit shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.)

32.2**

Certification Furnished Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Principal Financial Officer) (This exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section. Further, this exhibit shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.)

101.INS*

XBRL Instance Document

101.SCH*

XBRL Taxonomy Extension Schema Document

101.CAL*

XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF*

XBRL Taxonomy Extension Definition Linkbase Document

101.LAB*

XBRL Taxonomy Extension Label Linkbase Document

101.PRE*

XBRL Taxonomy Extension Presentation Linkbase Document

Filed herewith.

Furnished herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	REPROS THERAPEUTICS INC.

Date: May 9, 2017	By:	/s/ Larry M. Dillaha, M.D.
		Larry M. Dillaha, M. D.
		President and Chief Executive Officer
		(Principal Executive Officer)

Date: May 9, 2017	By:	/s/ Katherine A. Anderson
		Katherine A. Anderson
		Chief Financial Officer
		(Principal Financial Officer)

EX-31.1 2 v465639_ex31-1.htm EXHIBIT 31.1

EXHIBIT 31.1

I, Larry M. Dillaha, M.D., certify that:

1. I have reviewed this quarterly report of Repros Therapeutics Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: May 9, 2017	By:	/s/ Larry M. Dillaha, M.D.
		Larry M. Dillaha, M.D.
		President and Chief Executive Officer
		Repros Therapeutics Inc.
		(Principal Executive Officer)

EX-31.2 3 v465639_ex31-2.htm EXHIBIT 31.2

EXHIBIT 31.2

I, Katherine A. Anderson, certify that:

1. I have reviewed this quarterly report of Repros Therapeutics Inc.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: May 9, 2017	By:	/s/ Katherine A. Anderson
		Katherine A. Anderson
		Chief Financial Officer
		Repros Therapeutics Inc.
		(Principal Financial Officer)

EX-32.1 4 v465639_ex32-1.htm EXHIBIT 32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Repros Therapeutics Inc. (the "Company") on Form 10-Q for the quarter ended March 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Larry M. Dillaha, M.D., Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: May 9, 2017	By:	/s/ Larry M. Dillaha, M.D.
		Larry M. Dillaha, M.D.
		President and Chief Executive Officer
		Repros Therapeutics Inc.
		(Principal Executive Officer)

A signed original of this written statement required by Section 906 has been provided to Repros and will be retained by Repros and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 5 v465639_ex32-2.htm EXHIBIT 32.2

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Repros Therapeutics Inc. (the "Company") on Form 10-Q for the quarter ended March 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Katherine A. Anderson, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: May 9, 2017	By:	/s/ Katherine A. Anderson
		Katherine A. Anderson
		Chief Financial Officer
		Repros Therapeutics Inc.
		(Principal Financial Officer)

EX-101.INS 6 rprx-20170331.xml XBRL INSTANCE DOCUMENT 0000897075 2016-01-01 2016-03-31 0000897075 2017-01-01 2017-03-31 0000897075 2016-03-31 0000897075 2017-03-31 0000897075 2017-05-05 0000897075 2016-12-31 0000897075 2015-12-31 0000897075 rprx:LadenburgThalmannCoIncMember 2016-08-09 0000897075 rprx:LadenburgThalmannCoIncMember 2016-08-01 2016-08-09 0000897075 rprx:LadenburgThalmannCoIncMember 2017-01-01 2017-03-31 0000897075 rprx:LadenburgThalmannCoIncMember 2017-03-31 0000897075 rprx:LadenburgThalmannCoIncMember us-gaap:SubsequentEventMember 2017-05-01 2017-05-08 0000897075 rprx:LadenburgThalmannCoIncMember us-gaap:SubsequentEventMember 2017-05-08 0000897075 rprx:UndesignatedPreferredStockMember 2017-03-31 0000897075 rprx:UndesignatedPreferredStockMember 2016-12-31 0000897075 us-gaap:CommonStockMember 2016-12-31 0000897075 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0000897075 us-gaap:TreasuryStockMember 2016-12-31 0000897075 us-gaap:RetainedEarningsMember 2016-12-31 0000897075 us-gaap:CommonStockMember 2015-12-31 0000897075 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0000897075 us-gaap:TreasuryStockMember 2015-12-31 0000897075 us-gaap:RetainedEarningsMember 2015-12-31 0000897075 us-gaap:CommonStockMember 2017-03-31 0000897075 us-gaap:AdditionalPaidInCapitalMember 2017-03-31 0000897075 us-gaap:TreasuryStockMember 2017-03-31 0000897075 us-gaap:RetainedEarningsMember 2017-03-31 0000897075 us-gaap:CommonStockMember 2016-03-31 0000897075 us-gaap:AdditionalPaidInCapitalMember 2016-03-31 0000897075 us-gaap:TreasuryStockMember 2016-03-31 0000897075 us-gaap:RetainedEarningsMember 2016-03-31 0000897075 us-gaap:CommonStockMember 2017-01-01 2017-03-31 0000897075 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-03-31 0000897075 us-gaap:TreasuryStockMember 2017-01-01 2017-03-31 0000897075 us-gaap:RetainedEarningsMember 2017-01-01 2017-03-31 0000897075 us-gaap:CommonStockMember 2016-01-01 2016-03-31 0000897075 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-03-31 0000897075 us-gaap:TreasuryStockMember 2016-01-01 2016-03-31 0000897075 us-gaap:RetainedEarningsMember 2016-01-01 2016-03-31 0000897075 us-gaap:MaximumMember 2017-03-31 0000897075 us-gaap:MaximumMember 2016-03-31 0000897075 rprx:PresidentAndCeoMember us-gaap:EmployeeStockOptionMember 2017-01-30 2017-02-01 0000897075 us-gaap:ChiefFinancialOfficerMember us-gaap:EmployeeStockOptionMember 2017-01-30 2017-02-01 0000897075 us-gaap:DirectorMember us-gaap:EmployeeStockOptionMember 2017-02-10 2017-02-13 0000897075 us-gaap:BoardOfDirectorsChairmanMember us-gaap:RestrictedStockUnitsRSUMember 2017-02-10 2017-02-13 0000897075 rprx:ForeignMember 2017-01-01 2017-03-31 0000897075 rprx:ThirdPartyMember 2017-01-01 2017-03-31 0000897075 rprx:PresidentAndCeoMember 2017-03-31 0000897075 rprx:PresidentAndCeoMember 2017-01-01 2017-03-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure

8688000

3235000

66000

304000

8754000

4455000

3000

2000

8757000

5373000

1880000

1657000

779000

1179000

2836000

26000

27000

326981000

328413000

5373000

1380000

6098000

1621000

8757000

-325439000

-319529000

2659000

17000

7000

17000

7000

3765000

2074000

1096000

3843000

4861000

5917000

-4844000

-5910000

-0.20

-0.22

24318000

26270000

24318000

26270000

2000

1000

516000

436000

209000

238000

-812000

1093000

-5347000

-4618000

997000

-5347000

-3621000

997000

325400000

3800000

0.03

10000000

828057

1.20

997000

21100

1.17

25000

31000 1000 174000 126000 512000 1005000

93000

48000

10-Q false 2017-03-31 2017 Q1 REPROS THERAPEUTICS INC. 0000897075 --12-31 Smaller Reporting Company RPRX 26732074

916000

3752000

2659000

0.001

5000000

0.001

75000000

26797769

25938602

26685419

25826252

112350

18567000

26000

326981000

-1380000

-319529000

24000

322179000

-1380000

-302256000

25938602

112350

24430461

112350

14239000

27000

328413000

-1380000

-325439000

24000

322695000

-1380000

-307100000

26797769

112350

24430461

112350

436000

516000

997000

1000

996000

828057

20000

0 0 0 0 0

-5910000

-4844000

11110 0

20000

828057

11110

1.20

31000

8688000

21393000

5067000

16046000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt">NOTE 1  Organization, Operations, Liquidity and Recent Developments</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt">  </font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Repros Therapeutics Inc. (the “Company,” “RPRX,” “Repros,” or “we,” “us” or “our”) was organized on August 20, 1987. We are a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We are developing Proellex®, an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Uterine fibroids and endometriosis affect millions of women of reproductive age. Proellex® has shown statistically significant results in previous Phase 2 studies for uterine fibroids and endometriosis. We completed a low dose escalating study as permitted by the Food and Drug Administration (“FDA”) in late 2011, to determine both signals of efficacy and safety for low oral doses of the drug. There was no evidence of elevations of liver enzymes over baseline, suggesting these lower doses avoid the type of adverse events seen at much higher doses in earlier studies. On March 17, 2014, we announced that the FDA indicated that we may proceed to conduct Phase 1 and Phase 2 studies of low dose oral Proellex® for uterine fibroids and endometriosis while remaining on partial clinical hold. This guidance indicated that the highest allowed dose will be 12 mg daily. On December 29, 2014, we announced that we have initiated a Phase 2B study for low dose oral Proellex® in the treatment of uterine fibroids. This study was fully enrolled in January 2016 and on November 14, 2016, we announced positive clinical data from this study after two 18-week courses of treatment as compared to placebo. On April 10, 2017, the Company announced <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">that it</font> had a meeting with the FDA to discuss the progress and next steps in the development of Proellex® for the treatment of uterine fibroids. Shortly before the meeting, the Company was notified that the meeting would be a type C/Guidance meeting, rather than a type B/End of phase 2 meeting as previously anticipated. At the meeting, the FDA confirmed that Proellex® will continue on the current partial clinical hold while they consult with liver experts within the FDA regarding previously disclosed effects on the liver.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company has an active Investigational New Drug Application (“IND”) for the vaginal delivery of Proellex® for the treatment of uterine fibroids. Since the clinical hold relates only to oral delivery of Proellex®, this IND has no clinical hold issues. In the first quarter of 2012, we initiated a Phase 2 vaginal administration study for the treatment of uterine fibroids and subsequently reported the final study results in January 2013. We held an end of Phase 2 meeting with the FDA in May 2013, to discuss a Phase 3 study design for vaginally delivered Proellex as a treatment for uterine fibroids. The FDA recommended that a Phase 2B study should be conducted prior to commencing a Phase 3 program. On December 29, 2014, we announced that we have initiated a Phase 2B study for vaginally delivered Proellex® in the treatment of uterine fibroids. This study was fully enrolled in January 2016 and on November 14, 2016, we announced positive clinical data from this study after two 18-week courses of treatment as compared to placebo.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We are also developing enclomiphene, a single isomer of clomiphene citrate which is an orally active proprietary small molecule compound. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. Men with secondary hypogonadism exhibit low testosterone levels due to under stimulated testes but they are generally fertile. Enclomiphene is designed to treat the underlying mechanism, insufficient stimulation of the testes by the pituitary, which causes secondary hypogonadism. Secondary hypogonadism due to being overweight or obese is the single greatest cause of hypogonadism in general.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On February 2, 2015, we announced that we electronically submitted our <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">New Drug Application (“</font>NDA<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">”)</font> to the FDA for enclomiphene. The FDA accepted the NDA for review on April 1, 2015 and later assigned a Prescription Drug User Fee (“PDUFA”) goal date of November 30, 2015. In addition, the Division of Bone, Reproductive and Urologic Products (the “Division”) of the FDA scheduled an advisory committee meeting to review the NDA for November 3, 2015. However, the Division subsequently cancelled the scheduled advisory committee meeting due to questions that arose late in the review regarding the bioanalytical method validation that could affect interpretability of certain pivotal study data. On December 1, 2015, we announced that we had received a Complete Response Letter (“CRL”) from the FDA. A CRL informs companies that an NDA cannot be approved in its present form. In the CRL, the FDA stated that, based on recent scientific developments, the design of the enclomiphene Phase 3 studies is no longer adequate to demonstrate clinical benefit and recommended that Repros conduct an additional Phase 3 study or studies to support approval in the target population. The FDA also noted concerns regarding study entry criteria, titration and bioanalytical method validation in the Phase 3 program.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Subsequently, on February 4, 2016, the Company attended a meeting with the FDA reviewers and senior leaders to discuss resolution of issues identified during the NDA review. The meeting covered a broad range of topics surrounding the NDA data as well as emerging agency and expert thinking regarding the treatment of hypogonadism. The Company believes based on the meeting that the FDA is not closed to considering secondary hypogonadism as an indication. Additionally, in January 2016, the Company initiated a Phase 2 double-blind, placebo controlled, proof of concept study, ZA-205, in obese secondary hypogonadal men to assess the impact of enclomiphene on metabolic parameters and quality of life under a diet and exercise regimen. This study was fully enrolled in February 2016 and on August 15, 2016, we reported six month interim results from this study.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Additionally, on September 12, 2016, we reported that we successfully submitted a European centralized marketing authorization application (“MAA”) for enclomiphene for the treatment of secondary hypogonadism. This MAA was subsequently accepted by the European Medicines Agency (“EMA”) <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> which</font>, as previously reported, has assigned the United Kingdom as the primary rapporteur and France as the co-rapporteur for the application review.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On December 6, 2016, the Company participated in the industry presentation at the Bone, Reproductive and Urologic Drugs’ Advisory Committee meeting. The advisory panel provided the FDA with advice regarding a clinical and regulatory path to approval for products, such as enclomiphene, in subjects with obesity-related hypogonadism who wish to maintain spermatogenesis.  The panel voted 16 to 5 that the achievement of testosterone improvement while maintaining evidence of spermatogenesis was not sufficient, in and of itself, to provide evidence of clinical benefit. At the meeting, numerous panel members suggested that an additional endpoint related to symptoms should be assessed. </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Recent Developments</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt">  </font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On February 1, 2017, Joseph S. Podolski left as our President and Chief Executive Officer, and also as a member of our Board of Directors.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Following Mr. Podolski’s departure, Larry Dillaha, M.D. was appointed to serve, on an interim basis, as the Company’s President and Chief Executive Officer. On April 10, 2017, the Company announced that Dr. Dillaha had been appointed as permanent President and Chief Executive Officer. Dr. Dillaha, age 53, has since November 2016 been the Chief Executive Officer and a member of the Board of Directors of CavtheRx, a pre-IND stage, virtual company focused on developing Caveolin Modulators for a variety of inflammatory indications. From April 2014 through January 2017, Dr. Dillaha was the Chief Operating Officer and Chief Medical Officer of New Haven Pharmaceuticals, a specialty pharmaceutical company. From April 2010 through March 2014, Dr. Dillaha was the Chief Medical Officer of Insys Therapeutics, from March 2006 through March 2010, Dr. Dillaha was the Chief Medical Officer of Sciele Pharma, both specialty pharmaceutical companies, and from 2002 through February 2006, Dr. Dillaha was Medical Director, Cardiovascular at Sanofi-Synthelabo/Sanofi. Before that, Dr. Dillaha was a physician in private practice. Dr. Dillaha received his undergraduate degree from the University of Tennessee, Knoxville and his M.D. from the University of Tennessee, Memphis.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In connection with his leaving and in accordance with the terms of his Employment Agreement, dated as of June 16, 2014 (the “Employment Agreement”), Mr. Podolski entered into a Release Agreement with the Company (the “Release Agreement”) dated as of February 1, 2017. The Release Agreement was previously filed with the Securities and Exchange Commission as an exhibit to the Company’s Current Report on Form 8-K filed on February 2, 2017. In accordance with the Employment Agreement, conditioned upon entering into the Release Agreement, Mr. Podolski was treated as having been terminated without Cause (as defined in the Employment Agreement) and will thus receive the following benefits in connection with his separation: (1) a severance payment equal to an amount equal to three times the amount that results from (x) the sum of (i) Mr. Podolski’s annual base salary (at the rate in effect immediately before the date of termination) and target bonus for the fiscal year in which the termination occurs, (ii) Mr. Podolski’s annual base salary for each of the two calendar years immediately prior to the calendar year in which the termination date occurs and (iii) the annual bonus that was actually earned and paid to Mr. Podolski for the two fiscal years that immediately precede the fiscal year in which the termination date occurs, divided by (y) three; (2) reimbursement of amounts paid for COBRA coverage for the eighteen (18) month period following the date of separation for Mr. Podolski, his spouse and his eligible dependents, less the amount that he would be required to contribute for medical and dental coverage if he remained an active employee of the Company; (3) all outstanding stock options held by Mr. Podolski that are not vested and exercisable as of the date of termination will become fully vested and exercisable on the date of termination and all outstanding stock options held by Mr. Podolski on his date of termination will remain exercisable for the shorter of (x) a period of two (2) years from the date of termination or (y) the remaining term of the option.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Pursuant to the Employment Agreement, which was previously filed with the Securities and Exchange Commission as an exhibit to the Company’s Current Report on Form 8-K filed on June 20, 2014, the Release Agreement indicates that Mr. Podolski is bound by certain restrictive covenants, including non-compete and non-solicitation provisions. The Release Agreement also contains a release by Mr. Podolski of all claims against the Company, subject to certain enumerated exceptions.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company recorded a charge in the first quarter of 2017 of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.8</font> million related to Mr. Podolski’s departure.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt">  </font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Liquidity</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt">  </font></b></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On August 9, 2016, we entered into an Equity Distribution Agreement (the “Equity Distribution Agreement”) with Ladenburg Thalmann & Co. Inc. (“Ladenburg”), pursuant to which we may issue and sell from time to time through Ladenburg, as sales agent and/or principal, shares of our common stock having an aggregate offering price of up to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font> million (the “ATM Shares”). Ladenburg is not required to sell on our behalf any specific number or dollar amount of the ATM Shares, but Ladenburg, upon acceptance of written instructions from us, agreed to use its commercially reasonable efforts consistent with its customary trading and sales practices, to sell the ATM Shares up to the amount specified, and otherwise in accordance with the terms of a placement notice delivered to Ladenburg. We have no obligation to sell any ATM Shares under the Equity Distribution Agreement, and may at any time suspend sales under the Equity Distribution Agreement, provided that such suspension shall not affect either party’s obligations with respect to the ATM Shares sold prior to the receipt of notice of such suspension. Ladenburg receives a commission of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3</font>% of the gross sales price of all ATM Shares sold through it under the Equity Distribution Agreement. The ATM Shares are issued pursuant to our shelf registration statement on Form S-3, as amended (File No. 333-197253). During the quarter ended March 31, 2017, we sold <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 828,057</font> ATM Shares at a weighted average share price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.20</font>, for proceeds of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">997,000</font>, net of expenses including approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">31,000</font> in commissions to Ladenburg. Between April 1, 2017 and May 8, 2017, we sold an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 21,100</font> ATM Shares at a weighted average share price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.17</font>, for proceeds of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25,000</font>, net of expenses including approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,000</font> in commissions to Ladenburg.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">As of March 31, 2017, we had accumulated losses of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">325.4</font> million, approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.2</font> million in cash and cash equivalents, and accounts payable and accrued expenses of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.8</font> million, in the aggregate. Included in our accrued expenses is $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.8</font> million related to the accrued severance payments due Mr. Podolski upon his termination, which are anticipated to be paid in the first quarter of 2018 and 2019. We anticipate that our current liquidity will be sufficient to continue the development of our product candidates and meet our obligations as they become due through the second quarter of 2017. We continue to explore potential additional financing alternatives, including corporate partnering opportunities, that would provide sufficient funds to enable us to continue to develop our two product candidates through FDA approval; however, there can be no assurance that we will be successful in raising any such additional funds on a timely basis or at all. The foregoing matters raise substantial doubt about our ability to continue as a going concern.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt">  </font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Basis of Presentation</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt">  </font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">These financial statements are unaudited; however, in the opinion of management, these statements reflect all adjustments necessary for a fair statement of the results for the periods reported. All such adjustments are of a normal recurring nature unless disclosed otherwise. These financial statements, including notes, have been prepared in accordance with the applicable rules of the SEC and do not include all of the information and disclosures required by U.S. GAAP for complete financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">These interim financial statements should be read in conjunction with the financial statements and notes thereto included in our 2016 Annual Report on Form 10-K. The results of operations for the first quarter of 2017 are not necessarily indicative of the results to be expected for the full year.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Recent Accounting Pronouncements</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt">  </font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In November 2016, the FASB issued ASU No. 2016-18, “Statement of Cash Flows (Topic 230): Restricted Cash”. The new standard requires restricted cash to be included with cash and cash equivalents when reconciling the beginning and ending amounts on the statement of cash flows, and requires additional disclosures in the notes to the financial statements. ASU 2016-18 is effective for fiscal years beginning after December 15, 2017 and interim periods within those fiscal years and early adoption is permitted. The Company adopted this standard during the quarter ended March 31, 2017. See Note 2 to the financial statements included herein.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In March 2016, the FASB issued ASU 2016-09, CompensationStock Compensation (ASC Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard simplifies the accounting for stock-based compensation, including amendments on how both taxes related to stock-based compensation and cash payments made to taxing authorities are recorded. ASU 2016-09 is effective for annual reporting periods beginning on or after December 15, 2016, and interim periods within those annual periods and early application is permitted, with any adjustments reflected as of the beginning of the fiscal year of adoption. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The Company adopted ASU 2016-09 effective January 1, 2017. The adoption</font> of this standard <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">did not have a material effect</font> on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">the Company’s</font> financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In February 2016, FASB issued ASU 2016-02, Leases (ASC Topic 842), which supersedes ASC Topic 840, Leases. The new standard is intended to increase transparency and comparability of organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The new guidance is effective for financial statements issued for annual reporting periods beginning after December 15, 2018, and early application is permitted. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The Company is</font> currently evaluating the impact of this standard on our consolidated financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In November 2015, the FASB issued ASU No. 2015-17, “Balance Sheet Classification of Deferred Taxes” (“ASU 2015-17”), which requires entities to present deferred tax assets and deferred tax liabilities as noncurrent in a classified balance sheet. The ASU simplifies the current guidance in ASC Topic 740, Income Taxes, which requires entities to separately present deferred tax assets and liabilities as current and noncurrent in a classified balance sheet. ASU 2015-17 is effective for fiscal years beginning after December 15, 2016, and interim periods within those annual periods. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The Company adopted ASU 2015-07 effective January 1, 2017. The</font> adoption of this <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">standard did not</font> have <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">a material</font> effect on the <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Company’s financial statements</font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In May 2014, the FASB issued Accounting Standards Update 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”). ASU 2014-09 is a comprehensive new revenue recognition model requiring a company to recognize revenue to depict the transfer of goods or services to a customer at an amount reflecting the consideration it expects to receive in exchange for those goods or services. In adopting ASU 2014-09, companies may use either a full retrospective or a modified retrospective approach. Additionally, this guidance requires improved disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. On July 9, 2015, the FASB voted to delay the effective date of this standard by one year. This deferral resulted in ASU 2014-09 being effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017, with early adoption being permitted for annual periods beginning after December 15, 2016. Entities have the option of using either a full retrospective or a modified retrospective approach to adopt the guidance. The Company is currently assessing the effects this guidance may have on its consolidated financial statements, as well as the method of transition that the Company will use in adopting the new standard.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt">NOTE 2  Cash, Cash Equivalents and Restricted Cash</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt">  </font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">As of March 31, 2017, the Company maintained $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.8</font> million as restricted cash. The funds are being held in accordance with the Release Agreement entered into with Mr. Podolski on February 1, 2017.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the balance sheets that sum to the total of the same such amounts shown in the statements of cash flows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March 31, 2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March 31, 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Cash and cash equivalents</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,235</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>16,046</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Restricted cash, current</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>916</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Restricted cash, noncurrent</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>916</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>5,067</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>16,046</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

16046000

1800000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The following table presents information necessary to calculate loss per share for the three month periods ended March 31, 2017 and 2016 (in thousands, except per share amounts):</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Three Months Ended March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Net loss</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(5,910)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(4,844)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Average common shares outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>26,270</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>24,318</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Basic and diluted loss per share</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(0.22)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(0.20)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

26270

24318

3097690

2554857

50000

10000

50000

40000

100

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt">Recent Developments</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt">  </font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On February 1, 2017, Joseph S. Podolski left as our President and Chief Executive Officer, and also as a member of our Board of Directors.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Following Mr. Podolski’s departure, Larry Dillaha, M.D. was appointed to serve, on an interim basis, as the Company’s President and Chief Executive Officer. On April 10, 2017, the Company announced that Dr. Dillaha had been appointed as permanent President and Chief Executive Officer. Dr. Dillaha, age 53, has since November 2016 been the Chief Executive Officer and a member of the Board of Directors of CavtheRx, a pre-IND stage, virtual company focused on developing Caveolin Modulators for a variety of inflammatory indications. From April 2014 through January 2017, Dr. Dillaha was the Chief Operating Officer and Chief Medical Officer of New Haven Pharmaceuticals, a specialty pharmaceutical company. From April 2010 through March 2014, Dr. Dillaha was the Chief Medical Officer of Insys Therapeutics, from March 2006 through March 2010, Dr. Dillaha was the Chief Medical Officer of Sciele Pharma, both specialty pharmaceutical companies, and from 2002 through February 2006, Dr. Dillaha was Medical Director, Cardiovascular at Sanofi-Synthelabo/Sanofi. Before that, Dr. Dillaha was a physician in private practice. Dr. Dillaha received his undergraduate degree from the University of Tennessee, Knoxville and his M.D. from the University of Tennessee, Memphis.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In connection with his leaving and in accordance with the terms of his Employment Agreement, dated as of June 16, 2014 (the “Employment Agreement”), Mr. Podolski entered into a Release Agreement with the Company (the “Release Agreement”) dated as of February 1, 2017. The Release Agreement was previously filed with the Securities and Exchange Commission as an exhibit to the Company’s Current Report on Form 8-K filed on February 2, 2017. In accordance with the Employment Agreement, conditioned upon entering into the Release Agreement, Mr. Podolski was treated as having been terminated without Cause (as defined in the Employment Agreement) and will thus receive the following benefits in connection with his separation: (1) a severance payment equal to an amount equal to three times the amount that results from (x) the sum of (i) Mr. Podolski’s annual base salary (at the rate in effect immediately before the date of termination) and target bonus for the fiscal year in which the termination occurs, (ii) Mr. Podolski’s annual base salary for each of the two calendar years immediately prior to the calendar year in which the termination date occurs and (iii) the annual bonus that was actually earned and paid to Mr. Podolski for the two fiscal years that immediately precede the fiscal year in which the termination date occurs, divided by (y) three; (2) reimbursement of amounts paid for COBRA coverage for the eighteen (18) month period following the date of separation for Mr. Podolski, his spouse and his eligible dependents, less the amount that he would be required to contribute for medical and dental coverage if he remained an active employee of the Company; (3) all outstanding stock options held by Mr. Podolski that are not vested and exercisable as of the date of termination will become fully vested and exercisable on the date of termination and all outstanding stock options held by Mr. Podolski on his date of termination will remain exercisable for the shorter of (x) a period of two (2) years from the date of termination or (y) the remaining term of the option.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Pursuant to the Employment Agreement, which was previously filed with the Securities and Exchange Commission as an exhibit to the Company’s Current Report on Form 8-K filed on June 20, 2014, the Release Agreement indicates that Mr. Podolski is bound by certain restrictive covenants, including non-compete and non-solicitation provisions. The Release Agreement also contains a release by Mr. Podolski of all claims against the Company, subject to certain enumerated exceptions.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company recorded a charge in the first quarter of 2017 of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.8</font> million related to Mr. Podolski’s departure.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt"> Liquidity</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt">  </font></b></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On August 9, 2016, we entered into an Equity Distribution Agreement (the “Equity Distribution Agreement”) with Ladenburg Thalmann & Co. Inc. (“Ladenburg”), pursuant to which we may issue and sell from time to time through Ladenburg, as sales agent and/or principal, shares of our common stock having an aggregate offering price of up to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font> million (the “ATM Shares”). Ladenburg is not required to sell on our behalf any specific number or dollar amount of the ATM Shares, but Ladenburg, upon acceptance of written instructions from us, agreed to use its commercially reasonable efforts consistent with its customary trading and sales practices, to sell the ATM Shares up to the amount specified, and otherwise in accordance with the terms of a placement notice delivered to Ladenburg. We have no obligation to sell any ATM Shares under the Equity Distribution Agreement, and may at any time suspend sales under the Equity Distribution Agreement, provided that such suspension shall not affect either party’s obligations with respect to the ATM Shares sold prior to the receipt of notice of such suspension. Ladenburg receives a commission of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3</font>% of the gross sales price of all ATM Shares sold through it under the Equity Distribution Agreement. The ATM Shares are issued pursuant to our shelf registration statement on Form S-3, as amended (File No. 333-197253). During the quarter ended March 31, 2017, we sold <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 828,057</font> ATM Shares at a weighted average share price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.20</font>, for proceeds of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">997,000</font>, net of expenses including approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">31,000</font> in commissions to Ladenburg. Between April 1, 2017 and May 8, 2017, we sold an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 21,100</font> ATM Shares at a weighted average share price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.17</font>, for proceeds of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25,000</font>, net of expenses including approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,000</font> in commissions to Ladenburg.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">As of March 31, 2017, we had accumulated losses of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">325.4</font> million, approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.2</font> million in cash and cash equivalents, and accounts payable and accrued expenses of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.8</font> million, in the aggregate. Included in our accrued expenses is $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.8</font> million related to the accrued severance payments due Mr. Podolski upon his termination, which are anticipated to be paid in the first quarter of 2018 and 2019. We anticipate that our current liquidity will be sufficient to continue the development of our product candidates and meet our obligations as they become due through the second quarter of 2017. We continue to explore potential additional financing alternatives, including corporate partnering opportunities, that would provide sufficient funds to enable us to continue to develop our two product candidates through FDA approval; however, there can be no assurance that we will be successful in raising any such additional funds on a timely basis or at all. The foregoing matters raise substantial doubt about our ability to continue as a going concern.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

1800000

2800000

916000 0

916000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt">NOTE 3  Accrued Expenses</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Accrued expenses consist of the following (in thousands):</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March 31, 2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December 31, 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="45%"> <div>Current accrued expenses:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Personnel related costs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,005</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>512</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Research and development costs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>126</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>174</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Other</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>48</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>93</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Total current accrued expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,179</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>779</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March 31, 2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December 31, 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Long-term accrued expenses:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Accrued severance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>916</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>--</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Total long-term accrued expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>916</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>--</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Accrued expenses consist of the following (in thousands):</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March 31, 2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December 31, 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="45%"> <div>Current accrued expenses:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Personnel related costs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,005</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>512</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Research and development costs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>126</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>174</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Other</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>48</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>93</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Total current accrued expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,179</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>779</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March 31, 2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December 31, 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Long-term accrued expenses:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Accrued severance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>916</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>--</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Total long-term accrued expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>916</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>--</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

EX-101.SCH 7 rprx-20170331.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 105 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:definitionLink link:calculationLink 106 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 107 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - Organization, Operations, Liquidity and Recent Developments link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - Cash, Cash Equivalents and Restricted Cash link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - Accrued Expenses link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - Loss Per Share link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - Stock-Based Compensation link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - Organization, Operations, Liquidity and Recent Developments (Policies) link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Tables) link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - Loss Per Share (Tables) link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - Organization, Operations, Liquidity and Recent Developments (Additional Information) (Details) link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Details) link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Additional Information) (Details) link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - Accrued Expenses (Details) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - Loss Per Share (Calculation of Loss Per Share) (Details) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - Loss Per Share (Additional Information) (Details) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - Stock-Based Compensation (Additional Information) (Details) link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - Commitments and Contingencies (Additional Information) (Details) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 rprx-20170331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 rprx-20170331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 rprx-20170331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information [Abstract] Document Information [Table] Class of Stock [Axis] Accrued Expenses [Abstract] Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Expenses Earnings Per Share [Abstract] Earnings Per Share [Text Block] Loss Per Share Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock-Based Compensation Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Schedule Of Accrued Liabilities Table [Text Block] Accrued Expenses Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Calculation of Loss Per Share Organization, Consolidation and Presentation of Financial Statements [Abstract] Schedule of Product Information [Table] Legal Entity [Axis] Entity [Domain] Subsidiary, Sale of Stock [Axis] Sale of Stock, Name of Transaction [Domain] Subsequent Event Type [Axis] Development Stage Enterprise Deficit Accumulated During Development Stages Deficit accumulated during the development stage Cumulative net losses reported during the development stage. Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash and cash equivalents Statement Of Financial Position [Abstract] Statement [Table] Class of Stock [Domain] Statement [Line Items] Assets [Abstract] ASSETS Assets Current [Abstract] Current assets Document Type Restricted Cash and Cash Equivalents, Current Restricted cash Restricted cash, current Property, Plant and Equipment, Net, Total Fixed assets, net Net Fixed Assets Restricted Cash and Cash Equivalents, Noncurrent Non-current restricted cash Restricted cash, noncurrent Liabilities and Stockholders Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities Current [Abstract] Current liabilities Accounts Payable Current Accounts payable Accrued Expenses Accrued expenses Total current accrued expenses Liabilities, Current, Total Total current liabilities Liabilities, Noncurrent [Abstract] Long-term liabilities: Commitments and Contingencies Commitments & Contingencies (note 6) Preferred Stock Value Undesignated Preferred Stock, $.001 par value, 5,000,000 shares authorized, none issued and outstanding Common Stock Value Common Stock, $.001 par value, 75,000,000 shares authorized, 26,797,769 and 25,938,602 shares issued, respectively; 26,685,419 and 25,826,252 shares outstanding, respectively Additional Paid in Capital, Total Additional paid-in capital Treasury Stock Value Cost of treasury stock, 112,350 shares Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Stockholders Equity Attributable to Parent, Total Total stockholders' equity Balance Shareholders’ Equity Total stockholders’ equity Balance Stockholders Equity [Abstract] Stockholders' Equity Schedule Of Accrued Liabilities [Table] Schedule of Accrued Liabilities [Table] Schedule Of Accrued Liabilities [Line Items] Schedule of Accrued Liabilities [Line Items] Accrued Personnel Expense Current Personnel related costs Accrued Personnel Expense Current Accrued Research and Development Expense Current Research and development costs Accrued Research and Development Expense, Current Other Accrued Liabilities Current Other Net Income (Loss) Attributable to Parent, Total Net loss Net loss Net loss Weighted Average Number Of Shares Outstanding, Basic and Diluted Average common shares outstanding Shares used in loss per share calculation Earnings Per Share, Basic and Diluted, Total Basic and diluted loss per share Loss per share - basic and diluted Net loss per share - basic and diluted Loss per share - basic and diluted Earnings Per Share Disclosure [Table] Range [Axis] Class of Warrant or Right, Number of Securities Called by Warrants or Rights Anti-dilutive shares of common stock excluded from computation of earning per share Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Plan Name [Axis] Plan Name [Domain] Vesting [Axis] Vesting [Domain] Related Party [Axis] Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Stock Options, Granted Commitments and Contingencies [Table] Commitments and Contingencies [Table] Related Party [Domain] Third Party [Member] Third Party [Member] Third Party [Member] Geographical [Axis] Geographical [Domain] Foreign [Member] Foreign [Member] Foreign Title of Individual [Axis] Gain Contingency, Patents Found Infringed upon, Number Number of patents Undesignated Preferred Stock [Member] Preferred Stock, Par or Stated Value Per Share Preferred Stock, par value Preferred Stock Shares Authorized Preferred Stock, shares authorized Preferred Stock Shares Issued Preferred Stock, issued Preferred Stock Shares Outstanding Preferred Stock, outstanding Common Stock, Par or Stated Value Per Share Common Stock, par value Common Stock Shares Authorized Common Stock, shares authorized Common Stock, Shares, Issued Common Stock, shares issued Common Stock, Shares, Outstanding Common Stock, shares outstanding Treasury Stock Shares Treasury stock, shares Income Statement [Abstract] Revenues [Abstract] Revenues and other income Investment Income, Interest Interest income Revenues, Total Total revenues and other income Total revenues and other income Costs and Expenses [Abstract] Expenses Expenses: Research and Development Expense, Total Research and development Research and development General and Administrative Expense, Total General and administrative General and Administrative Costs and Expenses, Total Total expenses Total expenses Total expenses Weighted Average Number Of Shares Outstanding [Abstract] Shares used in loss per share calculation: Weighted Average Number of Shares Outstanding, Basic, Total Basic Weighted average common shares outstanding Weighted Average Number of Shares Outstanding, Diluted Diluted Weighted Average Number of Shares Outstanding, Diluted Statement Of Stockholders' Equity [Abstract] Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] Treasury Stock [Member] Treasury Stock [Member] Shares, Issued Balance (in shares) Balance (in shares) Adjustments To Additional Paid In Capital, Share-Based Compensation, Stock Options, Requisite Service Period Recognition Stock based compensation Stock Issued During Period, Value, Other Issuance of common stock at a weighted average share price of net of offering costs Issuance [Axis] Eequity issuances [Domain] Range [Domain] Auction Market Preferred Securities, Stock Series [Axis] Statement Of Cash Flows [Abstract] Net Cash Provided By Used In Operating Activities [Abstract] Cash Flows from Operating Activities Depreciation, Depletion and Amortization, Nonproduction, Total Depreciation Share-based Compensation, Total Noncash stock-based compensation Increase (Decrease) in Prepaid Expense and Other Assets, Total (Increase) decrease in prepaid expenses and other current assets Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total Increase (decrease) in accounts payable and accrued expenses Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Net Cash Provided By Used In Investing Activities [Abstract] Cash Flows from Investing Activities Payments to Acquire Property, Plant, and Equipment, Total Capital expenditures Net Cash Provided by (Used in) Investing Activities, Total Net cash used in investing activities Net cash used in investing activities Net Cash Provided By Used In Financing Activities [Abstract] Cash Flows from Financing Activities Proceeds From Issuance Of Common Stock Proceeds from issuance of common stock, net of offering costs Net Cash Provided by (Used in) Financing Activities, Total Net cash provided by financing activities Cash and Cash Equivalents, Period Increase (Decrease), Total Net decrease in cash, cash equivalents and restricted cash Organization Consolidation and Presentation Of Financial Statements Disclosure [Text Block] Organization and Operations Accounts Payable and Accrued Liabilities, Current Accounts payable and accrued expenses Auction Market Preferred Securities, Stock Series, Title [Domain] Gain Contingency, Patents Found Not Infringed upon, Number Number of pending patent applications Commitments and Contingencies [Line Items] Commitments and Contingencies [Line Items] Commitments and Contingencies [Line Items] Relationship to Entity [Domain] Retained Earnings [Member] Accumulated Deficit [Member] Stock Issued During Period, Shares, Other Issuance of common stock at a weighted average share price of net of offering costs (in shares) Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Issuance of shares of common stock for the cashless exercise of stock options Issuance of shares restricted common stock Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Issuance of shares restricted common stock (in shares) Stock Issued During Period, Value, For Vested Restricted Stock Units Issuance of share common stock for vested RSUs Value of stock related to vested Restricted Stock units issued during the period. Earnings Per Share Disclosure [Line Items] Earnings Per Share Disclosure [Line Items] Maximum [Member] Net Cash Provided by (Used in) Operating Activities, Total Net cash used in operating activities Net cash used in operating activities Shares Issued, Price Per Share Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Ladenburg Thalmann Co Inc [Member] Ladenburg Thalmann Co. Inc [Member] Commission Revenue percentage Represent percentage of commission on sales revenue. Stock Issuance Cost Represent amount of stock issuance cost for issue of stock. Proceeds from Issuance Initial Public Offering Stock Issued During Period, Shares, New Issues Issuance of common stock (in shares) Subsequent Event Type [Domain] Subsequent Event [Member] Recent Developments [Policy Text Block] Recent Developments Disclosure of accounting policy for recent developments. Amendment Flag Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Trading Symbol Entity Common Stock, Shares Outstanding Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Total Total assets Total assets Liabilities and Equity, Total Total liabilities and stockholders' equity Due to Employees, Noncurrent Accrued severance Liabilities Total liabilities Assets, Current, Total Total current assets Stock Issued During Period, Shares, For Vested Restricted Stock Units Issuance of share common stock for vested RSUs (in shares) Number of shares issued during the period related to vesting of restricted stock units. Cash, Cash Equivalents, and Short-term Investments Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Total Cash and Cash Equivalents [Abstract] Cash and Cash Equivalents Disclosure [Text Block] Cash, Cash Equivalents and Restricted Cash Schedule of Cash and Cash Equivalents [Table Text Block] Schedule of Cash and Cash Equivalents Restricted Cash and Cash Equivalents Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Award Type [Axis] President And CEO [Member] Option Indexed to Issuer's Equity [Axis] Equity Award [Domain] Board of Directors Chairman [Member] Restricted Stock Units (RSUs) [Member] Chief Financial Officer [Member] Director [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Option Indexed to Issuer's Equity, Type [Domain] Employee Stock Option [Member] Liquidity [Policy Text Block] Liquidity Disclosure of accounting policy for liquidity of equity instrument. Basis of Accounting, Policy [Policy Text Block] Basis of Presentation New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Severance Costs Severance Payments Employee-related Liabilities Product Information [Line Items] Product Information [Line Items] Document Information [Line Items] Accrued Liabilities, Current [Abstract] Current accrued expenses: Accounts Payable and Accrued Liabilities, Noncurrent [Abstract] Long-term accrued expenses: Accrued Severance Noncurrent Accrued severance Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due after one year related to severance. Accounts Payable and Accrued Liabilities, Noncurrent Total long-term accrued expenses EX-101.PRE 11 rprx-20170331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2017	May 05, 2017
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q1
Entity Registrant Name	REPROS THERAPEUTICS INC.
Entity Central Index Key	0000897075
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	RPRX
Entity Common Stock, Shares Outstanding		26,732,074

XML 13 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Current assets
Cash and cash equivalents	$ 3,235	$ 8,688
Restricted cash	916	0
Prepaid expenses and other current assets	304	66
Total current assets	4,455	8,754
Fixed assets, net	2	3
Non-current restricted cash	916	0
Total assets	5,373	8,757
Current liabilities
Accounts payable	1,657	1,880
Accrued expenses	1,179	779
Total current liabilities	2,836	2,659
Long-term liabilities:
Accrued severance	916	0
Total liabilities	3,752	2,659
Commitments & Contingencies (note 6)
Stockholders' Equity
Undesignated Preferred Stock, $.001 par value, 5,000,000 shares authorized, none issued and outstanding	0	0
Common Stock, $.001 par value, 75,000,000 shares authorized, 26,797,769 and 25,938,602 shares issued, respectively; 26,685,419 and 25,826,252 shares outstanding, respectively	27	26
Additional paid-in capital	328,413	326,981
Cost of treasury stock, 112,350 shares	(1,380)	(1,380)
Accumulated deficit	(325,439)	(319,529)
Total stockholders' equity	1,621	6,098
Total liabilities and stockholders' equity	$ 5,373	$ 8,757

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2017	Dec. 31, 2016
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, shares authorized	75,000,000	75,000,000
Common Stock, shares issued	26,797,769	25,938,602
Common Stock, shares outstanding	26,685,419	25,826,252
Treasury stock, shares	112,350	112,350
Undesignated Preferred Stock [Member]
Preferred Stock, par value	$ 0.001	$ 0.001
Preferred Stock, shares authorized	5,000,000	5,000,000
Preferred Stock, issued	0	0
Preferred Stock, outstanding	0	0

XML 15 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenues and other income
Interest income	$ 7	$ 17
Total revenues and other income	7	17
Expenses
Research and development	2,074	3,765
General and administrative	3,843	1,096
Total expenses	5,917	4,861
Net loss	$ (5,910)	$ (4,844)
Loss per share - basic and diluted	$ (0.22)	$ (0.20)
Shares used in loss per share calculation:
Basic	26,270	24,318
Diluted	26,270	24,318

XML 16 R5.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2015	$ 18,567	$ 24	$ 322,179	$ (1,380)	$ (302,256)
Balance (in shares) at Dec. 31, 2015		24,430,461		112,350
Stock based compensation	516	$ 0	516	$ 0	0
Net loss	(4,844)	0	0	0	(4,844)
Balance at Mar. 31, 2016	14,239	$ 24	322,695	$ (1,380)	(307,100)
Balance (in shares) at Mar. 31, 2016		24,430,461		112,350
Balance at Dec. 31, 2016	6,098	$ 26	326,981	$ (1,380)	(319,529)
Balance (in shares) at Dec. 31, 2016		25,938,602		112,350
Stock based compensation	436	$ 0	436	$ 0	0
Issuance of common stock at a weighted average share price of net of offering costs	$ 997	$ 1	996	$ 0	0
Issuance of common stock at a weighted average share price of net of offering costs (in shares)	828,057	828,057		0
Issuance of shares restricted common stock	$ 0	$ 0	0	$ 0	0
Issuance of shares restricted common stock (in shares)	20,000	20,000		0
Issuance of share common stock for vested RSUs	$ 0	$ 0	0	$ 0	0
Issuance of share common stock for vested RSUs (in shares)	11,110	11,110		0
Net loss	$ (5,910)	$ 0	0	$ 0	(5,910)
Balance at Mar. 31, 2017	$ 1,621	$ 27	$ 328,413	$ (1,380)	$ (325,439)
Balance (in shares) at Mar. 31, 2017		26,797,769		112,350

XML 17 R6.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) $ in Thousands	3 Months Ended
	Mar. 31, 2017 USD ($) $ / shares shares
Shares Issued, Price Per Share \| $ / shares	$ 1.20
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs \| $	$ 31
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures	20,000
Stock Issued During Period, Shares, For Vested Restricted Stock Units	11,110
Stock Issued During Period, Shares, Other	828,057

XML 18 R7.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash Flows from Operating Activities
Net loss	$ (5,910)	$ (4,844)
Depreciation	1	2
Noncash stock-based compensation	436	516
Changes in operating assets and liabilities:
(Increase) decrease in prepaid expenses and other current assets	(238)	(209)
Increase (decrease) in accounts payable and accrued expenses	1,093	(812)
Net cash used in operating activities	(4,618)	(5,347)
Cash Flows from Investing Activities
Capital expenditures	0	0
Net cash used in investing activities	0	0
Cash Flows from Financing Activities
Proceeds from issuance of common stock, net of offering costs	997	0
Net cash provided by financing activities	997	0
Net decrease in cash, cash equivalents and restricted cash	(3,621)	(5,347)
Cash, cash equivalents and restricted cash at beginning of period	8,688	21,393
Cash, cash equivalents and restricted cash at end of period	$ 5,067	$ 16,046

XML 19 R8.htm IDEA: XBRL DOCUMENT

Organization, Operations, Liquidity and Recent Developments

3 Months Ended

Mar. 31, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Operations

NOTE 1 — Organization, Operations, Liquidity and Recent Developments

Recent Developments

On February 1, 2017, Joseph S. Podolski left as our President and Chief Executive Officer, and also as a member of our Board of Directors.

The Company recorded a charge in the first quarter of 2017 of $2.8 million related to Mr. Podolski’s departure.

Liquidity

Basis of Presentation

Recent Accounting Pronouncements

XML 20 R9.htm IDEA: XBRL DOCUMENT

Cash, Cash Equivalents and Restricted Cash

3 Months Ended

Mar. 31, 2017

Cash and Cash Equivalents [Abstract]

Cash, Cash Equivalents and Restricted Cash

NOTE 2 — Cash, Cash Equivalents and Restricted Cash

As of March 31, 2017, the Company maintained $1.8 million as restricted cash. The funds are being held in accordance with the Release Agreement entered into with Mr. Podolski on February 1, 2017.

	March 31, 2017		March 31, 2016

Cash and cash equivalents	$	3,235	$	16,046
Restricted cash, current		916		—
Restricted cash, noncurrent		916		—
Total	$	5,067	$	16,046

- Definition

The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.

+ References + Details

XML 21 R10.htm IDEA: XBRL DOCUMENT

Accrued Expenses

3 Months Ended

Mar. 31, 2017

Accrued Expenses [Abstract]

Accrued Expenses

NOTE 3 — Accrued Expenses

Accrued expenses consist of the following (in thousands):

	March 31, 2017		December 31, 2016

Current accrued expenses:
Personnel related costs	$	1,005	$	512
Research and development costs		126		174
Other		48		93
Total current accrued expenses	$	1,179	$	779

	March 31, 2017		December 31, 2016

Long-term accrued expenses:
Accrued severance	$	916	$	--
Total long-term accrued expenses	$	916	$	--

XML 22 R11.htm IDEA: XBRL DOCUMENT

Loss Per Share

3 Months Ended

Mar. 31, 2017

Earnings Per Share [Abstract]

Loss Per Share

NOTE 4 — Loss Per Share

The following table presents information necessary to calculate loss per share for the three month periods ended March 31, 2017 and 2016 (in thousands, except per share amounts):

	Three Months Ended March 31,
	2017		2016

Net loss	$	(5,910)	$	(4,844)
Average common shares outstanding		26,270		24,318
Basic and diluted loss per share	$	(0.22)	$	(0.20)

XML 23 R12.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

3 Months Ended

Mar. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock-Based Compensation

NOTE 5 – Stock-Based Compensation

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

XML 24 R13.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

3 Months Ended

Mar. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

NOTE 6 — Commitments and Contingencies

XML 25 R14.htm IDEA: XBRL DOCUMENT

Organization, Operations, Liquidity and Recent Developments (Policies)

3 Months Ended

Mar. 31, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Recent Developments

Recent Developments

On February 1, 2017, Joseph S. Podolski left as our President and Chief Executive Officer, and also as a member of our Board of Directors.

The Company recorded a charge in the first quarter of 2017 of $2.8 million related to Mr. Podolski’s departure.

Liquidity

Liquidity

Basis of Presentation

Basis of Presentation

Recent Accounting Pronouncements

Recent Accounting Pronouncements

XML 26 R15.htm IDEA: XBRL DOCUMENT

Cash, Cash Equivalents and Restricted Cash (Tables)

3 Months Ended

Mar. 31, 2017

Cash and Cash Equivalents [Abstract]

Schedule of Cash and Cash Equivalents

	March 31, 2017		March 31, 2016

Cash and cash equivalents	$	3,235	$	16,046
Restricted cash, current		916		—
Restricted cash, noncurrent		916		—
Total	$	5,067	$	16,046

XML 27 R16.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Tables)

3 Months Ended

Mar. 31, 2017

Accrued Expenses [Abstract]

Accrued Expenses

Accrued expenses consist of the following (in thousands):

	March 31, 2017		December 31, 2016

Current accrued expenses:
Personnel related costs	$	1,005	$	512
Research and development costs		126		174
Other		48		93
Total current accrued expenses	$	1,179	$	779

	March 31, 2017		December 31, 2016

Long-term accrued expenses:
Accrued severance	$	916	$	--
Total long-term accrued expenses	$	916	$	--

XML 28 R17.htm IDEA: XBRL DOCUMENT

Loss Per Share (Tables)

3 Months Ended

Mar. 31, 2017

Earnings Per Share [Abstract]

Calculation of Loss Per Share

The following table presents information necessary to calculate loss per share for the three month periods ended March 31, 2017 and 2016 (in thousands, except per share amounts):

	Three Months Ended March 31,
	2017		2016

Net loss	$	(5,910)	$	(4,844)
Average common shares outstanding		26,270		24,318
Basic and diluted loss per share	$	(0.22)	$	(0.20)

XML 29 R18.htm IDEA: XBRL DOCUMENT

Organization, Operations, Liquidity and Recent Developments (Additional Information) (Details) - USD ($)			3 Months Ended
	May 08, 2017	Aug. 09, 2016	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Product Information [Line Items]
Deficit accumulated during the development stage			$ 325,400,000
Cash and cash equivalents			3,235,000	$ 16,046,000	$ 8,688,000
Accounts payable and accrued expenses			$ 3,800,000
Shares Issued, Price Per Share			$ 1.20
Proceeds From Issuance Of Common Stock			$ 997,000	$ 0
President And CEO [Member]
Product Information [Line Items]
Severance Costs			2,800,000
Employee-related Liabilities			1,800,000
Ladenburg Thalmann Co. Inc [Member]
Product Information [Line Items]
Commission Revenue percentage		3.00%
Stock Issuance Cost			$ 31,000
Proceeds from Issuance Initial Public Offering		$ 10,000,000
Stock Issued During Period, Shares, New Issues			828,057
Shares Issued, Price Per Share			$ 1.20
Proceeds From Issuance Of Common Stock			$ 997,000
Ladenburg Thalmann Co. Inc [Member] \| Subsequent Event [Member]
Product Information [Line Items]
Stock Issuance Cost	$ 1,000
Stock Issued During Period, Shares, New Issues	21,100
Shares Issued, Price Per Share	$ 1.17
Proceeds From Issuance Of Common Stock	$ 25,000

XML 30 R19.htm IDEA: XBRL DOCUMENT

Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016	Mar. 31, 2016	Dec. 31, 2015
Cash and cash equivalents	$ 3,235	$ 8,688	$ 16,046
Restricted cash, current	916	0	0
Restricted cash, noncurrent	916	0	0
Total	$ 5,067	$ 8,688	$ 16,046	$ 21,393

- Definition

Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.

+ References + Details

XML 31 R20.htm IDEA: XBRL DOCUMENT

Cash, Cash Equivalents and Restricted Cash (Additional Information) (Details) $ in Millions	Mar. 31, 2017 USD ($)
Restricted Cash and Cash Equivalents	$ 1.8

XML 32 R21.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Current accrued expenses:
Personnel related costs	$ 1,005	$ 512
Research and development costs	126	174
Other	48	93
Total current accrued expenses	1,179	779
Long-term accrued expenses:
Accrued severance	916	0
Total long-term accrued expenses	$ 916	$ 0

XML 33 R22.htm IDEA: XBRL DOCUMENT

Loss Per Share (Calculation of Loss Per Share) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Net loss	$ (5,910)	$ (4,844)
Average common shares outstanding	26,270	24,318
Basic and diluted loss per share	$ (0.22)	$ (0.20)

XML 34 R23.htm IDEA: XBRL DOCUMENT

Loss Per Share (Additional Information) (Details) - shares	Mar. 31, 2017	Mar. 31, 2016
Maximum [Member]
Earnings Per Share Disclosure [Line Items]
Anti-dilutive shares of common stock excluded from computation of earning per share	3,097,690	2,554,857

XML 35 R24.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Additional Information) (Details) - shares	Feb. 13, 2017	Feb. 01, 2017
President And CEO [Member] \| Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		50,000
Board of Directors Chairman [Member] \| Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	40,000
Chief Financial Officer [Member] \| Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period		10,000
Director [Member] \| Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	50,000

XML 36 R25.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Additional Information) (Details)	3 Months Ended
	Mar. 31, 2017
Foreign [Member]
Commitments and Contingencies [Line Items]
Number of patents	85
Number of pending patent applications	100
Third Party [Member]
Commitments and Contingencies [Line Items]
Number of patents	2

EXCEL 37 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 38 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 39 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 41 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 49 103 1 false 16 0 false 4 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.zonagen.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.zonagen.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.zonagen.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.zonagen.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 105 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://www.zonagen.com/role/ConsolidatedStatementsOfStockholdersEquity CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 106 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) Sheet http://www.zonagen.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) Statements 6 false false R7.htm 107 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.zonagen.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 108 - Disclosure - Organization, Operations, Liquidity and Recent Developments Sheet http://www.zonagen.com/role/OrganizationOperationsLiquidityAndRecentDevelopments Organization, Operations, Liquidity and Recent Developments Notes 8 false false R9.htm 109 - Disclosure - Cash, Cash Equivalents and Restricted Cash Sheet http://www.zonagen.com/role/CashCashEquivalentsAndRestrictedCash Cash, Cash Equivalents and Restricted Cash Notes 9 false false R10.htm 110 - Disclosure - Accrued Expenses Sheet http://www.zonagen.com/role/AccruedExpenses Accrued Expenses Notes 10 false false R11.htm 111 - Disclosure - Loss Per Share Sheet http://www.zonagen.com/role/LossPerShare Loss Per Share Notes 11 false false R12.htm 112 - Disclosure - Stock-Based Compensation Sheet http://www.zonagen.com/role/StockbasedCompensation Stock-Based Compensation Notes 12 false false R13.htm 113 - Disclosure - Commitments and Contingencies Sheet http://www.zonagen.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 13 false false R14.htm 114 - Disclosure - Organization, Operations, Liquidity and Recent Developments (Policies) Sheet http://www.zonagen.com/role/OrganizationOperationsLiquidityAndRecentDevelopmentsPolicies Organization, Operations, Liquidity and Recent Developments (Policies) Policies 14 false false R15.htm 115 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Tables) Sheet http://www.zonagen.com/role/CashCashEquivalentsAndRestrictedCashTables Cash, Cash Equivalents and Restricted Cash (Tables) Tables http://www.zonagen.com/role/CashCashEquivalentsAndRestrictedCash 15 false false R16.htm 116 - Disclosure - Accrued Expenses (Tables) Sheet http://www.zonagen.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://www.zonagen.com/role/AccruedExpenses 16 false false R17.htm 117 - Disclosure - Loss Per Share (Tables) Sheet http://www.zonagen.com/role/LossPerShareTables Loss Per Share (Tables) Tables http://www.zonagen.com/role/LossPerShare 17 false false R18.htm 118 - Disclosure - Organization, Operations, Liquidity and Recent Developments (Additional Information) (Details) Sheet http://www.zonagen.com/role/OrganizationOperationsLiquidityAndRecentDevelopmentsAdditionalInformationDetails Organization, Operations, Liquidity and Recent Developments (Additional Information) (Details) Details http://www.zonagen.com/role/OrganizationOperationsLiquidityAndRecentDevelopmentsPolicies 18 false false R19.htm 119 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Details) Sheet http://www.zonagen.com/role/CashCashEquivalentsAndRestrictedCashDetails Cash, Cash Equivalents and Restricted Cash (Details) Details http://www.zonagen.com/role/CashCashEquivalentsAndRestrictedCashTables 19 false false R20.htm 120 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Additional Information) (Details) Sheet http://www.zonagen.com/role/CashCashEquivalentsAndRestrictedCashAdditionalInformationDetails Cash, Cash Equivalents and Restricted Cash (Additional Information) (Details) Details http://www.zonagen.com/role/CashCashEquivalentsAndRestrictedCashTables 20 false false R21.htm 121 - Disclosure - Accrued Expenses (Details) Sheet http://www.zonagen.com/role/AccruedExpensesDetails Accrued Expenses (Details) Details http://www.zonagen.com/role/AccruedExpensesTables 21 false false R22.htm 122 - Disclosure - Loss Per Share (Calculation of Loss Per Share) (Details) Sheet http://www.zonagen.com/role/LossPerShareCalculationOfLossPerShareDetails Loss Per Share (Calculation of Loss Per Share) (Details) Details http://www.zonagen.com/role/LossPerShareTables 22 false false R23.htm 123 - Disclosure - Loss Per Share (Additional Information) (Details) Sheet http://www.zonagen.com/role/LossPerShareAdditionalInformationDetails Loss Per Share (Additional Information) (Details) Details http://www.zonagen.com/role/LossPerShareTables 23 false false R24.htm 124 - Disclosure - Stock-Based Compensation (Additional Information) (Details) Sheet http://www.zonagen.com/role/StockbasedCompensationAdditionalInformationDetails Stock-Based Compensation (Additional Information) (Details) Details http://www.zonagen.com/role/StockbasedCompensation 24 false false R25.htm 125 - Disclosure - Commitments and Contingencies (Additional Information) (Details) Sheet http://www.zonagen.com/role/CommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies (Additional Information) (Details) Details http://www.zonagen.com/role/CommitmentsAndContingencies 25 false false All Reports Book All Reports rprx-20170331.xml rprx-20170331.xsd rprx-20170331_cal.xml rprx-20170331_def.xml rprx-20170331_lab.xml rprx-20170331_pre.xml true true ZIP 43 0001144204-17-025638-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-17-025638-xbrl.zip M4$L#!!0 ( #2#J4IKP<6O)EL $BJ P 1 "TR,#$W,#,S,2YX M;6SMO6USVTB2(/Q](_8_X+0[.W8$)?-%%"FYVQ>T7CR:EBV=)$_/WA-/.$"B M2&(:!#@H0!+GXO[[9695 040)$@*E$ 9$SW=(@E4969E9>5[_?(_GR:.\P=R!9]GNZ->][_<7^]T]XW]^^O=_^^5_[.\;7YC+?#-@EM&? M&6=F8-[[YN /KMXW&@>-@V,#_JAW][^:L_UFO=$Q_K]&\^3P"/[Y_XW_<_/U M_QKG=_?&OO'X^'A@P0@!C7 P\";&_KZ:Y[/)80X8Y^^?;Z^,YD%#_O;4]QW[ M!/]M -@N/_&G_M.O>^,@F)Y\^(!#_LMSS1%S<;P/.'N]U6KLR8<=V_TC\3 . M=.#Y(WBRWOJ /_=A8O4X_FK9T0OZPTX=-AN=96^()]0+%IOZ;(!+ MN_"=XP^F/_ ]AWV('U:O#[S0#?Q9DEB<#0Y&WL,'^2.NQ]%^O;$?K\@@]'W@ MMD7OR5\S7K28G?T._("/'R8?9T^#Q@)K^+OK4M_'YH,]\@L%D"347RT\O?]C[5 MX7_=XTZ]T_[E0_IE-=6'U%P)"*;,MSTK#0'L9C\ M((/EU"]%4V976$VC3&>[E&G_@']VEC)M^&=+E&DT=WDW-9K;XYF(,NW=HTR[ M ,J@+G%F3YA+=DN^-D'[K/NC?DS<]./*!)SZH3^Z'YO.Q'3=4^_2'7QEDS[S M006]8B/3.2?L>D\V?V$2IX\\-@(\@V@^^8,%@#Q-'7M@!P)NPU+T^'4/<#B9 M0P(5LY-EF/_R(7/@&-,/61 ]_]3I[M>/M[!/<+TC#;):^[*L?5HW[FZB&^LL MLW7=N&*9,K%,F;7^BE5>FU5>1&M'C3T2$_!W=Y.U_W$7]CG[9PC8G3_ O\1S M(4>_3NJG^]F45>RB@[3*W-)'=K*0F L>>&WIUMY$NL%+W6U)MXK#*PXO4"CK MK+HU)]./[Z[%N#UR,X(\$&P;P.V)WZIB<7P_I@=UDQ&BM M%Z-$;)E'F#=V5B?]2!5;[!1;O) 3[>C'J3>9>.YB/CC_9PCPPU-3SX6/_(WP M0C9:ZK$YHKQM'NA9EHUN1-.Y,6WKTCTUIW9@.A4_J,>6$NAM\\:]STP>^K-* M0B0X(H,L;YL/;EE@VBZSSDW?M=T1KUA!/99-F;?,#>U*:RBOUE!$D'$E'JBT MAIW3&EZ,-RJMH=1:PXOQ0:4U[(#6L%UNT#R3E=906JUARXE^,0]46L/.:0TO MQAN5UE!JK>'%^*#2&G9 :W@A;J@B%"76&EZH<***4.R@UO!BO%%I#:76&EZ, M#RJM80>TANUQPX(,]DI[*)?V4.:,]@4L5"D?NZ%\["!K5;I+^727'62C2O4I MJ^JS$\R4:#12:4QEUIC*VE(ER4*5QK2#&M-NL%:E,95<8]H--JHTIIW0F$K& M3*DXY5?SR9Z$$YUW;DUWM*/UG!$#Q"BHKQ*(ONUH8[6F;\,7W*HK,[FI3.8? MYY.IX\T8HT/R>HH*F+[.XIM+UV)/S+KW+CD/F<^%M!3_IMKN&Y]Q6J>>:YTR M3Q_AW@X<=CV$(>P'VPI-9[>Y9@$Z5#69287%;+3)]*NM1\S1"Y?W-V:[L VG>OAT!XP/Y>IB]E+;VYK1.Z"Q42M]DB9 M]TCS1T/;(XV6V"-GML\&@5=MBV=NBR0=JYV0V@G-_<8F.Z'1>KF=\-DS?>MZ MJ!:2GXY-VY^8;O[.N&4\\.U!('LK?'?M@-_>?==?[#W"X+O;$&?%3;")=@]\JM\8=[(-Z=C>[#KBO\2E$CY3U"A"J8M M"_"/;=^Z =!F"8\"/J.'4 M;_H4.-J"\;_?G2T87-[*= )/;#[V#T#XQQT"F)J%.("E5P%?_19.\&(OST^S MV,J@Z01/CY@QX1ESO8GM+I\RC]3I.><'5;]JF*] PVDX1[HD2/C 2NN#UPR< M.Z0#IB\9B'Q<)A_C]H/_H'W]8#H43 Q.3=^?V>[H;Z83,D,R["U>D)2^VH)@ MOD"]P/K1V#-PF [_=6^_M?>I>]3M@N3YY<-:LRLR/1-D[087 M'>3F6SMEN=UBJS#N@V1'YCSLR^P];=-8T<^=X@\:Y#D3G?IE M MHDV."&\6ZEI]D(DD6$R9',ZT&B94&O29 \ M$9Q?"_ S=,!6SN'0/&H?KZG37-(-X&C,7+H#;$N 1(?ODG"M. " MZ@1L>>I\DB\7S?M,^)+W."?@RSD;-@/OECTP-V1\?7+E'0>=%)N)>=:\< M;@[K%^8RWW3@V9XUL5V;![X9V ]L8\KF'!N-^G%2W4Z=XT;:DED.T38(>/ MV+<0([C70WJ57XJ_+P**5@;(X&K!Q:_OS>ZPW^&=H^6YA>L/YJY!S+>FAO92@* MAW_Q,ASEG-B%P+]@Y83'[WF[X2CG1,_GGPPH"H=_"?US#OUMPB]+8Y]'_YQS M/Q_^#"@*AW$_7..]N/CE63I"DAD)Q[>4'9Q^M!9?QGR#O&Y0V$=<+: RI(5 MR3FQ]UOI8.!S4(&%'#!F\0O?FV"U*JPBNQYJ*0?KPY]S/J"HD!>PCTY M9_$FT%*%@.9VOPO @#['F,[4MW$]*%*GQ^Y"'_9/^HW54^R.EIW$;4R6H)Q0 M)'U1L.4DPF5JBNLF5766'="(5K>^-&=O&1")M<(UM#E6?\C0$VR@ 3P$B&8 MV_U1/Q:]>JY,B[G]T!_=CTUG8KKNJ0>;3E1]6,R^8B/3.:>R#BH=2>"F']Z4 M-I_T8M8/ZBVY6DN@6V5_7,(LMNG)J9N-QEQVTE9Y^M6( MT5EY&S0Z+[ -2L$@2[0GV#G-]F8;AXZ]B)/P,0P?;TV^+=&> (E6(U:QP3W79%3:U]T 1I!&)V<>6(12N*SM%^AV< 'W_]LFYJ'M??[;CO405_<*1LZ:^L/G =/X; MQ, %?+.^X^ZX+B9/3IL:=?'$ KX-IV[L??I?C:R)M5'UJ<4)=LM&E"3G!M_, MR?K4/@:MZO;\YO;ZSKC_R_EM[^;\^_WEZ9UQ^>WT0,"2-5FBI=G4YX[/MS[M*^N2E\V\CSB%[;#_%/X:>3Y&Z#= MWOMT!S($QC!NV113%=R1@9%WTYWI5$A,HT-Q[YN8)'(WF_0]9_WYCV#Y;V[_ M+J9*C)6QQK$ZF9,YH_2Q=L:,R[. A.%SU&EAWFV"#99,GI$A+'N@%=L5X#C' MHWF<2O18$X["T5A4J[QZ=''+&'SSW,&ZY:#UG-CBNHL0PU D](N*)>NK1Q8W M!_PL9/>>:H*Y&9%SU.\TD1?-N#ED"PFX>FAP5: 69H(LI5!>$XM..YG@LB2O M8RD "PF15Q>]I(9H>1GRC>E?^]0GT*)=O9(7]#NN=3^+3%<9D/%4\?D M_'I(#\Q9U(WZT2H.H1;Y\K$]TWIX%(5]O#(%8[^2.VP[V(NSM1<&8\^W_Y5. M)M_JFB]/I27%H#T?VE@&_'-1W=H"'[\*JL)3^G(KFFA/L@#-' 0%R,]!;EMK MF.AZLFWDEBO:VUJ^YK,Q7**CKXWFUA9RA?#BYFAJ9LLFQVH*U)7"A?,'PPI M% +WP@9![=> >YVC+ 7O"L&YSIR 7C+ULZ!<2-45+.EBHM[E&]^7SH5A3AJ1Y6*YR@S:.C;ONPL8R MJ\FGM61P"LX5#L-FN]L\:K:7D7()G(FV)>+I-#9]^/F\0F M)^B4T46J<(PVO)8UB4=>>%R+\NLTP$NWFLUK%W38;&U#+&HNJ0+X(:_!Z#9T4@V#@H^JG(,WH_MFX1@5 MP>9Y;8JV=51I:!1T5.5V.,IH;U@P+D4<6'F]D;:BT6D8%+M-TJV4,C2ZH^/V M=C$J9)ODV-1;WR:%&3Z'><6@K7JG45\;EU4C4P5LD%5*+N:\D9OK%44+W!7< MO<5I=,6*IE7\P 5J=$7OX14M0OF?](Q0]2;'K0;;8S&[#0UB("VWY+0/ MN1VP.^8_B.(7V[-NV< ;N?9&K8(:>8V6TKV"7@B1$M.O@,V1USVJHK>W-65\ MW>98U0(4(E#SVGI5%/>*-W/RVHW][$1?W,BBD=?,+-W@KZ)?$>?BZA?M5/0N M^ES,\1M6##^W (6;_Q >7!49KJ^I9?7H"_= MF",7A*W 7, IDM?)+R-WXN71+%9XYS7_.S[."+N^/-)%",PU^@2^$I8%":F\ MAH);0%2FY+WD7ETA\+M6HZ=MHEL(^Z[@D5ZU =#:/!R7%XK$^$?3M[ZQX'IX MX?E#9@?A7#KC2@?+ZI=2/A>XUT"V""Y?7TOQ"9A.0ND6SJK) HW\P(\3X'M=>A52'[;KW*L<(HE>PEEL&B M\,[?8#SJB*6/^AV W>!,3W>IS-@XSP/IY1 K8H_D.(-WB1K%GM6=?(_MSE"F M$/F0KPOO##V*.H/SE=]B2**$[MKW#18A(5;768N]*['@_;RLL>5V\2AB]^6U MOMP>] 7ME;P6F&M>=KGV-: %[(2\SIC;@[W@G;"Z^ZU@/ K9"?D:RY:@+VHG MY%W>L=H=M,M.%J&%ET&_[*Z4Y]EHY!R5*R#TDG0IA(]72",MCBHO:H^F$%VE M,\%KFN$;1AV/5VAGL+F#_P78.(7."ET/BMVI6=G%*U]4D0(^I5T4??7$2K'R MF"!Z5_1-EB*O7*2Q?K[* N"RKJU*=\5T85$]/[AG_D1 M=9/=IE<'8BO@IQI)'.?U8&BT4AV]7P?^A=R4HV^TZT?SUYZ](OAI[LFK^CRJ M'QX5!/^U/S)=>;WRJ>=RS[$M=?7R#4@*>(<^PEDC+K/#C25/?'YF\X'C@5K M[@&QSXZWP<5HC>/NWJ?_S1NO8GIUL07->,.9/'0V/NO4?#12 UW>G7>NSWI>\%8 MC+1_T?MZ>?7?)ZFA/M)O=Y?_^UQ,]3$"PW;%_Z?!GF$Z]LC]=0_ECSV8[[7F[JL_AD![-7%J0'KXV_7]N=$P_LN<3#_^1Z/=^&CHRU\SY*6IP 8U MX\H&7K*P-LUT+>.6X;5:AG8M R>L<<:(!/V=(H8BPU']XPNB1 %;, MP(8W-%Q8)\L/1]P(/", $R;G]WX'G,<]B21[!Q^K,&: D>9C@-"S9K8K@T+ MZ@-S<.8PL<9]/,/ - +>0':!U1^A4N^#20O,, '@60'WT@(5JP%T^/4>L MHY@J#/ R/F8,[;[OV18G3F*N!:^ 8>!QFQ\8WW.?,C,3P#@:ZBYN&!-IS M PZ:B1W@@_T94?#"\RP:] RVH]&3JR-.(^.=)B4NSGH)*0&0XV6<(!4:C1IN M8POFA\$!6.12PA8T)Z0:&R+6 W&B<7/(@ADAAY B6Q"X7*T]RH4#$J2,1)'K M&0QO]P4[@@9SV(,X*_&3 POA T'^-<-MX.&'/E#1 3!J!@]'(W$9,PX,%($) MX0$QF_D ]!1,A/?'P%BF!:\CW1Y(;>0,UAP$TR0-Q;#NXSR:FC>Y&%-I3T\=[ M+HT!D)($.U:CX[+ XR-04-"L2^.!Z!&AX+ C@=B6P*\1]A+1A\0:1J3D6&9 MMC,CBIW!SD:/EM$\7DPT^&9L/N!D>/.FX'%)B\^2L14S+:6%[>:+#(F@&!69 M;QCBSF6N[\%H%H[Q5],-37^&X!X1*8%8WX#Q" _$ '](X3$%*I/(B*@)NKYI M#'UO C!%$YI# ,<('CVCT=U_9 R5^M!76R."V^3BE/4%KTP=.'W['A&T-_5M M!X0S00&,B A+A4,#)U.NR_/$^'/J1/ES[<\<5?P_RW,G)?]IB>P@<8[!>N$B M31BCO?=H@SA0K(^" JR7D/-(T(,L%$SI@OT",+$I5XN54AL6"B0I?3'H]&%D\*>(HL?&+U@'DBD'TB&H>U/%'09%*'-AM:@ M[89,Z5_JNHC,;2WW/SQ'#3'P9!*+)J7K$YP:(!#Q*[DN"(G/1J9/[4XU'"QA MF0)XC(Y1K@"@H2K-K42HW&MLCRH+\JM0;(3;PAZ9PKM', KU8#IU4."G=0. M,J$;J$WY8(YL',!BM/RS9^YA&S<:<7.">WV&B@AR&C @R!>A4BR=LB;$+L!- MJ(.*D1S2IBMA#X 2-!_L.#C2_@ER/Q Z*DC7)LGXC$,IPMI,*E/Q4;6:YLJC M*S0!+9_NN&*6! >'%^-IBJ1V,K5(*QPS!W4[/.R)#"GIDY#+-NHOXMV:+J05 M6BTYGV@@3VA(/''7"V(#>(K4*-I,#D$2-P*63Q9P4KF:.X)BW.6C^),7BGXV!C6**H28 -HS-=8M=' JPGV##L0"Y MD>/->\;$ ^L]=(3U";P'6LNY-B6.DBGM.,,]C..,9U-O!$<,")L)K3YF(PW#\5<@(J;Z_DPMQ'@^01SFS[L&7> \O7 ^$JOH.F9/0%[ M&MM].R!+ 0?PE(/!09IQPP)U":8"1,BPLR>A(VP;]$1PHQ\&0D5"6H\ 04&> M(>A&H#W-XRXDI=@UPL6%E*#1';SX#5 <@)((D-4 =QZBD6PS6FDQ-1X:TB96 M( B;?6H'H8T+49/K-3!#W+?9>,/!F4T/B6^?D:+Q?Z*-#T?;!>O[XH2@LZ"]X&0C1QLPNW)%A7WI M!@*17Z@]F*LK)HC^[:Q7Y.2Z$IJT2'$/2F4#99(N&F,UQ!R@HU$J6=_DHVC; MP/1>9%P+.M-AC/+!AQ-2;G30%T!.#7R;ZM4%&;X#O+!(+$&#F[/O%TEOVL@3 MQS3MJ^B ;PE#ODV*J"G#[<(6/+,?;"XEQ&+4(,D0)$B!PG"!V-FA:B*H'%@/: '?D;J%C)/;!>3@"8RZ92+T5!8_,5[ M!%'KIS!(*+H#M*9)^R'1$P.P>'8IQV $+OR"0H7TT1E$+DJIBTD08[L5O^S; MG@GJW$Q$+R8L&'L6Z'@J&BO&&I#R*1W#M@N+#B9O(&X%) MC (> B;Y<^\$+ M(MT53P(L95RQ AM-9Z?3V*FEZ"2V/ MUN_ Z!GP.T ,RS&1>IR+OD-!(9>6:H" !.35F ('/0C%$Q-[IB(.C8LYB6PA M&##V1O @\O[5R/%*"JHO@I:.M^'%Z3GAVR(R2SZ?LQ87 @L#89:([G MCG"S6< JN*CD<9X 683B$NFZ?1AB: AXD7,7 MI^+A% TP22)X6.GWIC]B :C<4WEB:]($U3&@K&BT"!P"G!GSGI@$Z($L[=MH M&9A &5M9BPA^'F]*&-(6S\X?:V_HA+[39%L-]T9T7D>V6\)'"_N;N'6!]U2( M,.9+#P%ST0)VF(EA4=UJAXWK.:'2((4WP\ 8BO1L6I1&%TEK,:Q@737OP!.V MK6F L8J"R83]1_L5K(L!*)NA[Z/2KX]#=B88C(\@P?&_# R-$9GEH!K*^(_P M)J(AZOZ!/R7%<<)02&JQNK^J#Z8WB!0>RQS=39N,M9!#UY!>21%;X4 *(L " M2T%XPV1T@S9UG.N&ZY@RS)-KF.42LKRP[[#]/@@IJZ9L:'+2"E._AIL7,,:C M!&7%-! "HF;\[]Y^L]ZF*852G@$R"0<7<0-5A$G/N@W0#(B,">$*I)K@T>6! M8'."83O!3R!8U8'FV$-IJP 6( 0#N7;,']@2_B#Q3UIY$/JZ4!Z,2="5");E!8(WO4)462D\S:YF5 MTL-#T+HY%YP3VR6F<1[ZWI3!/D1E LQ*RD:9F/X?,G8BK]^3Q^4":^-KKS?G MF4[LAS4\%)+;84CB]83:&ID.TD2/@/_*0(C8+JQ-3\A ';KSKTGHBK2%A&L@ MP5>U5,!)K45-^/^5&8/P8_8T_/D;4-KR2""*:)T]0:KX)FE##&Q'W-$7/H7 MY$,#;U_[7=%77R!YW.P\S[^A[:L;*4=9F@D%#F5T4BF><)C!-/Y,&0IR*XJS M-\\H1>LX2DIK=#["$2LMO-.TA2?._L@"!'B8@P655"RS%Y9# F'2;A1;7)7/T'139I0CR4XR"[ 4Y,>+,=*S3F8(QZ MCY)3"2\F'/AHO=%O(J"KIB1GL)9"DX) !;V-V =)B)HB; 26('.&%!22-$\, MEC:\YD/7;@AJ("8X"=0FQ&5<9>=$(9^$+09:\-2S*5%*.F'!!IM-IH$WX5HP M2.@[S#IX0UOQ!5'92GYOH8=8@@15,O2.L+#NEVZH7*2_@@$V'1MW!\:-9WD. M_\,&RW5( 49T0J/KE"Q4DCNG(.>&QOD3&X1T=%RC9$+/(?Y(GA4*, M9@F(( MA_CL@=#'#V>V#Q+:JU*%2X7*A83FP=;OQ9ZA@&8 MYV!.":A3I&^)6+!I/)@81"8?@^T.'7,R$=I8[&SA!V!0@,TA2(_9&@ IZ ^C ML>YT@;70"?ZH5IMPE_4T (B.N_B-##) 0/V"\1;8$G\!B%WTUVC%#)RBYE.& MQ5< @2MR <6Z2:+8IK3G('BI[# M),8UF;.]'%<;Z[V0D@0,@-&,P-#4C4_(K+:L AH)^#VLU%%!_VSYWI M>D-[_V[F MR.V?<^B&\.C,\J:1.C#.FA@4/',PYJ*TD -%$?,!XP]3%O8< 2 MFRB.KJ A3^ZMD6]:%$^PV,@'DR.*GX %C.G@TA]VSUP7-4W8 ;^YWM,#C"?L M&?((H&S*?_$KFTS']@N<255X7*!R2?W074;Y(<)6. \Q)D2.=S@V0,L!"QK@Y2Q^-892'43I">=>23B9=,#36IJPM#.F3#J. MAC9Z=R,X[N"D\<%R8\*-?/Z$>2TC)@QY3C%>X5%7&3@R&I]U-)_*1.5;\DU1 MQ,3S)T9W_S7\] 1X?&,9.?3MD9T)HX53SQ441XX@D@=9%$BM$4E7 MRH$PPL#D'68,//.1/UFB&U=E ,E"[[W1$-*X@[&(5.DLZ&-!5#&C)FB=(Q2 MI=3NEJ\;W@!X%XZU=_::D),GV80158K6HV<,L 3<@NEP3I[ (DI6)1>I_MQB MV 2Z!"!A"3#:@MH*'L)7>-)QAPU0-<, C.E3/@J\,S5MTI03[!LYO0%FC4IR MJ"38P'X66YV>&LP@(VWAHNO#0L_>"Z;Z:+QKO@<>LB=]S#95KBS!8%S B_"= M7G^^[8DH)&J^"F1*4<-]]J[1?2_C1%-J!Z+M#IU7XIU 8^ATJ(FM,O5P>ZK# MG,%98_<=5 BF&(NEC 5'1=7T?0 ?HX(0'^^F\*, 8^#;_3 04$^D[H,3X'"D M3DFL[*$Q5H57,LM&N$H920;&%'=)40G$:[W'VBJP=P/0R%V92X - #QQ2X;( M^@:*)U9;%M$S$6$S+L&;WV>JA@M[0\DPWX)A5,5OQAC">%\; M>'@35V8A5()^"2 4NW"L^Q$*+THJ4_$*#@/,CZPH.#]2W[)F@<$$_^I%D?>AZ[CZ:>9AP1L5X\!F[D@QL&=?EG*-HV=/)%CVHFUR98$Z $36"X]AT M@ BN& S_#W+X0/8?TB:(WDBZGZ::JB05(M&1@A)'9:HI'-A"1P;"DX9#_Y7N MWVA@"KN A8RZTDC&-SY07@5H&O;4=.!HITZ(*F8WH+ZOT@H8*\<Z_&J*EHT[* VU-9-ZI;A@2 M$=&< +S[#-8,]" X*LGKCEGRH.!0: ;[C#CD%1?6IC0RXCEK5(RF$9W<6"(' MS91Y&8\^YM"@3QRX*1P(\XI6,$0O/K(5 86VK^CB"6:_C^Y_R@PSN>>2)<6& M8$N)+GH<^_8H!R2] _SO4498X)N6\JF*Y5<.>%Z+4$\B(==1LZHE(3 AC7)/ ML)'"(Z:;YGEI39%22YL*NS<,F%:<"W-$E!)ET5CEZWJ&UW=DC7L$(2Z'#B$E MP)+UL&QK"G!QPU >RTSL#1YR="!(K40G L>4\XJ,CI.!6MN@0]T9.2A$5G=NFD1*5_ M$%M%\$Z1F[25V*-_4MMBY&-7;<5T$E:D4AI#):S 0EMQ-82AHXV#'A02BE9" M:.*&YF/F#"DQ6JOXEPT;(SOO;K]%$M*412GO+C!/ZYNGY2^U6JW]QG&GV6Z! M.#F+\_25QBQ>%&&_5I1<@8FTB&.A&DRWV:W5VYWD^:Q3 POU1=$H*OK2IT7R M/5Z)8N7T03,IJ6LJ:P\[)PE9@.E\3_9$^"\+G?WXN%.KU], N$QDV3_AOJ#N M4,JDWB(HL/)I2$0H0&T^GI)[GUGPB&Y3O8BQ0W(+VSYTTWR4.H*+Y:MFH]9( M __*;-7HO!Y;-=MEX:HUF:H*9+]4<06Q8(;,IT9;@T&H6A4X'I<-/(J5-LWV MP6&F/Z6V52%WT,QVXB!3FGQ,XHO^8''_99DB".JBC"?-1'!#?.F'S(HWU7;W M=6N!#ZJF7&&1A"53#;:WB RC-C$'*I@3!8N\? >9R#@7@,R%CT6_C(1?EZP0 MC-1HL1/E8J<&)7&#,]%X0D3[EC@&N[1N\,>Q:#H;#2"T8S(@I4?=B?HFJVZ# M6DL-&96CCFBB^CC15P['D9G_6 YM88&M]/9C%CO]KNO3(K=JIL)A5( NE4L* M.E'Y4-K'*1MU*B@\7%L'(]M3#ZTJFSI&10GP0]'U&^6] X,@,1]8PF$/]M#4 MH[@Y*O^N,)(]*KS!)N:4K"5"PQ2D5+G[&E6&H :32&?"U MYDE!1-QDB ,;+ M,H@498!AR;,LI?AHC+5*?[Q= ?2)/AE=)FC/@H]4 5B\7*H0##G"-VTN#,J9 M+,70:$-P>]1?#Y@>.S(;;I(>>% M&=^T K8 "D:5=&0:0]/V=>?"4/IL9%J63'T0F0X\JO(\,'HPKI2E\> (.[G0 M9&LM'Z/==); F1,28I3]$G?VC/QR)&87T"096@[P,"*_&^7(37TF&LHM<.S) M8E$\D_S0B5M#WYV?BC0::JPA9V BI60H2Q*Q64F<;6)%-V7PV!7;GQG?#^X. MC"^]W@V12[7/SL2D"C&7"!7!<*K2(W,SQM6!/C,MF2#Y#]DE+N:Q[(U,B0]" MK0&]!;0 .Z684ZE%3Z3?I9(X&O7]WX3FH;8BJI;1U1Y:7F)6!%PE9ZG-;CMQ M4<0#2V]RH3ZC=4"M,*.A0TW7<,,M"O^XUN32-#'-*\TQ4*O-3*N'"\1VZ\N\>& M/T:S57]_8L27[-$C6O!32#Z\V(52.[&L3!ZX/$H^8])=(Z17)%I))B]TZ!B/ M8T8]Q<#V N-,]6UC(]MU5&0=$74E9=-.(%':4V2B5$^G5&M#4?#?N"]?6'/+J=%,*7-1WW>,L M.1ZA;OITK8I(044 HCL^DCV3Z!&**U(#';E&UFH1)FPBBH$JO/!C&37B1<7S MTZY28LN$RJ4;EPLND!+$Q_5C34(@^S"7"\,TNL",+GDT]-^,=[V[4T/(BDZC M"[+B,FY(03OH7.6T4YQG_S.U[KJ1Q2CQF9,A2+@-KV)F %<^274^#:E-'\"R M+SJ!#32(=!.$ JX"$O11>H^BX#$PGT@\Q3TF%HP52Z;(_3DQ+9$(8SYI_8A$ MFK#/H@3( YVN\_)!5G(((XW27.2NCV6%2$#/EAA'M7R1(:=0OVE"0^O)H\N- MFNRE0D(CMA2E>1H5CR7%L/Q"+Q*A.W5D:GRA:F>66-.I')-850PGZML44$GM ME1#016.1$%LV&1;"!C;1(8D-'QT):0H0M^ ;6C)3T9-S5H9OR5&Y3+72JRT0 MW8LO'%L,0'=<"26L M;SKD(.)C)CL12DT-A_F#S9)N'W+FXU@DEGUJ7"E5-85:?(/5O+Z6I=0(*J\H MK[,E=;>V@N3=GIBT4QM>ALVP6!#T[-!4MZ1I?2.3TE#F+0ZBNVJ1()74*#@68C?I8;\8XVXJF#/0.'BI&QBP@;,A]=K/>H6.E7 MCNIIR%):X>C)1&0AH2++#*.B@6S K'I16VH&4+MTV9'X7AUB^\TX=D!X1F3[=*EF# 18"E&LC!55MDN12Z% MCP)'EFFMB)M&]0W-U!C)C;7/%],#V_OU3HX>F!2(D06M)%^1@,;FMM #DU.3 M4ECD=+&"F9Q(5M?+4[50/V)6L6/6\9 J,H@>U'3?Z95E"9$?VQ/WTE&Y<;W MJ26O=SU$AT"RO\@#P\0(JB8XQ6IW,^J'>4HE :!AY@A_'#19.J']0!<0D3;I MLS%FFS\(MYV:5=WV@,(+!-:+4M/L;L-8 "S=D]K\I C\^"WR/DOPI8H3? W7$ M89#\C1)US,$XW=@\2%SO&AU;LK5H.IRJ-VX7P>*:I _>9#!1SED,'U )K[ ) MU$I$'A5RRH*B+A)^B*D&2:92:R#NV?UK"$?FL;I)(V)FT3*5UMRYLG8IQRBIZ;<2!-2F,E2DT+ M90&2VI)!RCP^V%I =?FIHS[@WP'E2O31X>C_NE??4Z \VE8P/FG4ZW_Z:- S M^[ UP#P^&=I/S/JX9^!=.V#"8Z(AO8>?IQ@1$9^C\?WH+RL"1O_3C__$:?#3 M+Q]"OC\RS>G)M>8%.(V6"C[T7$O/>[H>7JBUBX)1_"P2.??L*?B,]\1_^O=_ M^_=_,XQ?U/@8B8*A\#_G<=PHXT62*_#AE@U_W;NI-W[ /[C%[KUZZT=+_+UG MV!:L(1:O63\:Q\=[GU)'?'0L T_7IT]B'<42&JG%KHDO:L8=+KFQMVW-9I%V MP/'JK]&JNL*WZ_MSHVG$SGX*]=5$3% C,$FZ=$!PCF63<[]FF'@]*BR-%6\7 MJ=3$&I"TFTM#$$D#R42&Z#83 M[6[TA-N%JS+>B8J:!W1!G(R6<9,*A3$E4Z8N\+'W&-WLI;F@$QD,)[N_W"_' MN>(]BO=&X Y(,A1Z'A/%>E>77[Z=B-$_&DDB(@E_OSR[_PN^4/_30E@$A\XI M&T\G9AAXT1 =5.D^7]^>G=_NGUY?7?5N[@"2 ?8-F'+VT;C^V_GMQ=7U[R<& M-FV"$7-UO87P^ J8OYQ??OD+JCK-Z9/VNZ5^UTA@*!H(,MW_]Q5 )S*,DV25 M/2;)NB>Z&H#--:S7?]3I?W,[_*,!F-U?GO:NU%2P5F =R@=_ES >U@$C4G]_ MW3ML_RFQU!D,F%"LA6*[(\@U"L!-\M'GZ_O[ZZ\1=$9C^F20LBY9N238=W3L M 7WD>N!K8-WF'"E(R=&*ZQNU1("C4RW^S[OX1S_MXDM[O1+OY4>NB!W^RKA) M 7-_?9,I71:CGK.]=XT.U1I7:_PJPAJO6=J$"I][I[]]N;W^_NT,2#$8,#8< MOI3\/EU4#; !&[PN^A/;LASV@KN_Y*N=@>Y_;H"EC^V!LM&\Z9V=77[[LG\K M)U<^^M='O3Z/>ZO6;+5W;I4KIJZ8>@E3-XYJ]<--S*LWR]4E.<2']+^7.L1O MD][RFHKROQ9C;(S];HJ[[2UVT>AN3^YMD089?M^-TD)U; M\[=_KK^L<3YWKL=%")7.]_P02\DYXN4)\E;,HE=4#ZK]4>V/TN^/UUU: M_6B3K*=J8U4;J]I8I8UYE'%GZ8I+7!9&'[=7+I=5(9?X0 M1ZG*YE@FK%VQ5O;Y6W7S^YM(PL7I)S MO:I?*:'.5^7G%T20MV(65?4KU?ZH]D>958PR;I.2J!A5_4JYA6659O\\.I78 M3JOJ5ZJ-56VL,A&O=#&/,NZL)?4K;Z',9+UJD=7N7.H%IZ;OSP#.OYE.R)(E M)CU^[4:E)4>ITI+&GA&ZMGCR^]W9GF&Q@0U'OE48]/'TZP*^!-QT'=+A$G#;P"Q= MDAZK YT&]=ST\=X\?L/\N['YG O$FO5V66NFN/TO=F)TL3;&:#0.ZK;[:B59 M&]Q/=JC?3W;E<6[ 8AFT6B3PJCO(REU ]=GD]L!P<.&FL' <%XXN@O0FTQ ] M\_V9 6C8=,&HRP+Q:%_#A\P'YILC9K@A76SI#<5 HMS,FTP\%V# M?0NG*]W7B*-9H:_N<11791X89[9#DRZ!)XSNI%23JJFTH<6]KFI<2@ TIU-G MIEX-?&;RT)])J.0ME'B]N1?@W>!X"RN@#<#0_9K:R.)>3GD[+-YC"WBH^<$)+7(0J MKKI%@D3%AE8FY:J+G5^W.I3NU.2P9$-4Q6FM7#9@G.-5=\!N ],9A [>B9OB M>,7 P=AGS #^"<;1?;+,139(7AM(+(X*A?%.W&\;)$]#1B<9_'(LD#T M?57[N08J;[/V\ZBJ_5S9N=RJBH.*##6]-O9Z^5^SI=>.M.=C""B#8WI\16', MX\_G*(ZUG^>+!7]6YGA;Y8&5!-AU";".FW:=^N"J /RG7_^J!KP2\J5'KJH/ MKNJ#=P"W:HU++*Q+GC29);^_2:_U:\74RY@,6$9T2U =6PXT,[)"WK5KQXWZ M^YU;TXJ%*Q96+'Q8ZQX>5BQRG96<=Q3X9M55QT+GK[6AQ2QMRW,J); ME;YN* &;1[5FI[YSZUVQ=\7>*['W8:W5Z.[<>K_]\_UES6V148;Y*-DY294" M6&YT*QMFB0U3/V@V*Q.FY.A6'+R<@RL_TK/+BZKTR)=$Y28[F=H;&JU:_;A3 M.SJNI]P)H6LQ7^1[RV=%WG;Z]A7Q(Q:Q\'32>%::K M XO2>9?F9!M]-C!#CKF];):1!'Y@+$:W66NW#VO==F?M:,'>PJJDQ?= I5\A';GG6K+>X=D70AV5M;AI:7G KHFA*L?_+1]B58Y_ ME>._^\DS6S7Q2I_AF<"^RO'?B8RB,M&AD@"[+@&J'/]J_:L<_TK(5T)^9W&K M\K^K-:[6N$HZ6$=^5SG^NX%N%9JM(K)5H MG,Y7_EVV8&Z^F[YMN<.W?XJ#16&P0^G9@ M,WYJ.@ZS/L_DF.6._)YBGTC_/1;]6/ M.T?'^CTRSP/]Y2AQM 8E&O45&*'=/NRV.UNCQ)G-!Z"=AS[>,.1-ILSEE*5^ MRS IW3KU>,"5KC3F;T*U#FULM*-;5N @O<-Z MGWU:+4-?4#H=$AGRT22O>=7*RI@NR_7?&B;;+F"X=HT+UO=#+ :)BLBPZN.S M9_H6EE:=V3X;!)[/C7?XO:!"M]FL?Z1'HL^-C^^-$>YT6/8KO)D*;TMQS+$I MQD-.,-V9>KS1^]>P,:G!GA@W('QL"^^C0KO]=&RSH7'^!.*$;AZY'@[M M 9COII@# 6O7:YB6D2PO"SSC@?' "*>>N(>$AP,L=AF&5*TV=9@J&8/1 A.H M-[$=>,%S&3\P>J#XX.]XOXI.!O,1_LWH!I;?3/C:MUUF]+#$C7ON8OP$$A>V M:[H#+)>32-2 _ 2Z7NB7?1\->BQ$Y8U$9VC[@)UESO!19@[&\N<^&]DNJE9S MRTGD9/)V&-?X:^CH*RW))4<'R1X-CI_EU$-!] ,CP2VM>791=/IJ#\8F#<+Z057;HW5%+WQ4<'95J7:=65+M-4 M>LV/<[F+Z)@58^F:GOCF$F03D/;>N^0\!"F%E]@%,_%O5 -_1-(6;[ECGC[" MO1V@J09#X+U:P%09>F,S7V]LHUFMV8#%DZNP%1%TN80MXX>TZ-2N9C532U6*W^Q&@4MUIJ4?/D]U?S1T!:KT1*+I72A%%.A 5#D\&PH?Q^.![CM5&BL9 MJ0H*,J)T+DC9J2]]Z6)E?F>SV!5!*4PW4]85IL07-YNRK=(U07\7>B,W7;FN@TEH;:U M=!,8'RAONMO##'M1).5"3,[HKQC196R#;50D872"J'?TA\&PI\XI8(:+.WIE M?R.?F2AX([\"G+;"L<0E)^D7_9+0)]Y$WP,/F.\!#UH,+ 8;V!)M>1A=NID2 M+UBVV6>XW2=@+]M!R U48XJE:S-!U0P@ '&S[P%)##YS+=^;T#7!.LHFYQX8 M02B>3;V1YYH6>C:8>V"\B?%O[_'>YFG(>!FJ_Y1VLL#&]X,V('1 RAL']?:ITF5^FB,/0?6,WCT MTMP@%IV<+P@!-IB"B:FS%&J;'ARXZ&H: ^(9,Q+B'A)", N^+F5X@A0F$A.' MTCA!9#1Q;F0K80(A"D5,O*J M;!+=-W([P"SWOFFQB>G_(9V6QCO-\7MS?YUP^_;)UP^33$$S]>%T"L0NDML+ M"8ENL8GH&D2W0SNF/>$*[Q2H(!0'C.$> 87Q<6P#)1WY'LR,9+> Z_T).F%! MJ@2B+9@<78Y,S;[$_.24@ID>;.!YPM]#_,-^O(VI6QFR+/I$? $%7YW MUQE"=1)\G0)N3K 8L4$LR4,G4,J( M#UJ!S^>!P4O>\2>@FL50>",8,=^MQPU95%!K_,T+<(/ 6 ))188+9M'LI[8_ M -,.]\<=FP;"1]SLDD>Y+@PQ'J@#04-@ B<'GA[)12+2H-1",Y0C!^'*^XB? M'S]Y"CI-$(,4M]W+ .J,#01,C2;!U #9#'L>]U<*)L50T?H+<@KB$ <)06FZ MQOD3K+P/N^26Z=Q^JNT?^-@#@>$8S6.:MU5#A6O G.2\\9Z6QXH.FMKAXL20 MX/D,24?GKX3O&S("_.0PCB(%&P,Z-GPGQ ?J?Q9\^$JXI*?"[ M;)68P(G"'4+X1"(?CS(E]FT>S:]M!AJ8C_&LBR9#Q-5>2+#B@7$YC%O)$5DQ MEB>C$O;( V0X;% XO_!+I)D23)(*!.G$G 'H1A^>1MDGQY=[##R(SI/3*6C@2 . M[-'<<813.T*_"* P_Z YP?,17M"G%>(%!(.$#,?3-NA,PC/#[#RF8\> M89)<)H>5Q9]P>N!,)#DQ#OT))PIN #4-**ZT=0!=QQ8L;Z-+!: 5DP[@&,95 MT">GP3TM\@7SQD#8_V(XD1<&^Q*!)*%"T&FJY(IUG%2_=# M6KFZ1Y.< CB%^:!3C %[LB,XNAY;J H,]VW6=_[U&W':*\'^!IHP^GY"IAW MEV/>T#VZ:P/_ HM^CR8+'K"S1):7, CH^WNTBTRA2GR>Z;]DD.-X.3F:S^4# M?^H_G=PR;&!Q%A^T_ ;-QMDSG-+->EF=TL]U'.Z$2U:LJ*$OZ:XG>1EOTLV< MF>7U5S!\IF,#[7[/\AS^ATT)]NBU0(UXI7RLFE3I0/V$UTR5 2.=JO,Y9#DZ MP0Z0\@VUK;^(,H"^^C$3)!*.P'*&(P-.A%HZ+^OKP=D!F9Y@#'JV*_UAG/D/ M\"RY3Z+,OK[);9"R)E^8U[02KU%*EK 8&W4]'TN.".^Z< X-F+2_SN -":XQ M-L%R8,@O2+N'#J?D /]X^83K.OIDLR1:R%3O!'M=J$^_64_"@ B(Z[^.TKPXFBY$@$!+?$7P!BU[@9 MF[!$ XK7@)1!_/F4H>D"($\3/RH*I*&M1]"*=N6(P#)8,^"Y=/F,&UJL#@ A M?[(:L7XT/TE]S4GNP(0 NT=@7*,^WWFXDOF'E"1@ (QF!$8D[A&X>4C4_(K+ M:L AOF5[#R;'9O!DAMZ9KC>T]^]F+GI.S+[W07QS8'QF0QG1">:'!@X=S[@- M<),E#LOP@-Z>J8\Z&UB%B1=@=@9;PC+&MO2[@=9NA?B"Q4:8K!C=^_#=M=%8 MEWZ>>^:Z8- RV &_N=[3 XPG/.LX$,FF_!=!=08#X07.I*6W#/Q$!\XE1<)< MZ4S$,! ME\/,!_)UN>2,,@<#L/W1$R@>H<@(^D=P^?!YD8-%KKH>\@C^5:,, M5I+J\-1?0Y<9>)$(2:NTASGK?=W97$NU-.%:S9@23R^?/=C"Q29^CS/>LJGGD[\8S.Z)T=W_3<[J:;IE4T%]F;V, MV2L7A0IA-,K5)HHC1Q#)@RP*I-:(I"M&SP0EQX*AQ DL/7N20%X8@*S#H-L[ MDU-LS8V3*++@>T\TI&SR8!QR);)$-GZD0?69"T,)#V46CW-4I.@X/3'>-=Y3 M: B#$TB>J<@"DQG.^>WLM< M]PDRU#O[_6+M#A0F'![#=P8W'5S!=])W[(NL!X,-A^B"M"<3.#%$P*6OI'^< M-:YY3P6Y M,?L0 .,3>,8P]#F^.9@^GGL=-2[>XH3CD WH5C[9V])N0X"^7B M2TT*O=TP'7,MF$ZDO.M8" >W9*_$S]X*I M/AKOFN^!A^Q)'YYA4?A9W-$BX$7X3J\_W_;B7!H%LJ@+A7WVKM%]G[@E9D&% M0;P3: R=#C6Q5:8>;D]UF#,X:_#BCSB*!XA@(&=N'\#'1_+/]YERT1.IT:WD MV_TP$%!/I.Y#P72,'CDQ5O;0B,(U(I"%6@OL]JAV)5F= <1KO1>1GK@(-E6A M LH343RQXB)"Y#-RU#^(B#T5ZCRA9YZ3"]R,:D$R]IF02'TVP(0+X==?,(PL M?LD:(PH4KP<\O(DKLQ J0;\$$(I=^!A.$:'PHJ0R%:_@,,#\R(JR/$6I;UFS MP&""?_70&CZ@""; K[P-)4+E!J1+B,$K*7.S=0$AQ,JEWI VV10NA\-:MCZB M[&4F979BO\!>Z:.''#>22@E3)6$H7%#\N"8)MCCRBQ5S,L!):.)G;#\]L(,H M+OE &0!\D99(?CF4?C AIV06\<3 M:^#HAB\"9>?Y] UMN7O-)@&]P:-Z1=. [>*/HJ0S45$*>J:2RU0T"O_]SR+S M")L'W63RYP0."N1B+9DNWPNY8DBYO%'DU0)AB;#9E0V:#-A'L^='RTK;^."G MB)89T4K^A$&R5>I6DIGA)6"K%<)JO7 $+QG'\3=Z(VDRVNJ MJ6=2"1.91)331QH(!TDH]7(@/&E5]%_IVHZ-:W4'>.$B;+VL7(&PLN ]TBH_T/A$((A1*IE.,7Y"SVB&HL*"-11E5ZJ MWOU7@VKYN$[* VU-;)$WJ!NC1$0T80#O/H,U&U)F''GZA_8@2OOU#0LOP?25 MA2L-FWC.F@'*:U@B)$#9"L"BG+0 M [XP/8T-P7X3784D(9M7B1'E*,,OS#(,IZ9@#L:EGA23'RD.1:F^I0";EWXF1R+B! MS0-@(F.9PCO';*22J&!(*$XQ=EQ0#!":2C4^M1!@6EA)IQ@Y.J?$>6Z4XIR" M16=VZ1CEE*$966+P3I&;M)78HW]2VV)$I=Z*Z22L2*4TADI8@56XXFH(XTH; MAW)W946()C1Q0_,Q@_T,0@M'$ES%549:9%O>[;=(0JJ*A7<78&@:W[P#[<;. M5FN_<=QIMEL@3LY"7_G0E):^Z.YW@6.A]3_=9K=6;W>2Y[-.#>!"F%ETAS-, MZ4<3]SQ'*U&LG#YH)B5UC;Q+,DU7R()$N6*ALQ\?=["E2PH EXFT\:>IR +6 M$KBW!PJL?!H2$7Y0FX^GY-YG%CRBJU8F46C]@;Z"W.JF^2AU!!=<5]:HI4OV M7INM&IW78ZMFNRQL2"&3(?8',BD%U4<:P9B*@(K[T0W)9 MRDVUW7W=6N#WJBGW6R1AR53#(G.*1J,V,0>_ ($C,!Y8($H ]-/4H M5H_*ORN,9&^*L0Q,Z*<$,1&.IL"HM"MTJ@RIX PA$::>*#;2050E5$@ *B&; M)U*4=7;6$YOI 9MRC[U'9)B:*%#&YW%%7$P5YJ'@(P$;TY8KZM"',1+3YL*@ MG,F":HTV!#=:O&1I85X"IIG&)51";\=4A9&'@\#N#JAJVD1K$JMU U-0W/+" M/KS2Q]00VG>RG%"G R6VB8'@NP$LQMOP12_R+J=K6+"Q,[\>]H1(A?G%\\_W M23G(_BSTSI 1HS(5X"XUZWV8-QSW5\ ZC9K*18T%X)$+7A",!3E5- M[LI#%5/ I2L& #='TLDDBH*U87PV=- YA'X3TT+XQ/=1C:],&1^:MJ_[-52- ML\Q"DYD>(K$#1\73")LD]!Q'B?%X<*HBI7X'=)4#>I'@,*< N(DA/T",DGTL M45S)-)<@2?@%-$E&TJG7*KG\*"5PZF- D2W,-I4M7E!H^Z$3MV2].S\564.> M+ EF;63*\Q :%?5T43P6V0146=(3V8:IG)5& M??\WU1-$;$74:J>R@X6>AID5\%>Y:&JSVTY< _+ TIM<:.YHF%"#AFCHT!'Y MB#NO'*VG]Z2U)6!0[0W?$W5)6JC_^7I3J]*;7K_R-5YD([G*E0I51NE]Z29+ M]$0NWT7O[K,*Z/3NOF,DAG[=;W1KZ2YR%/>]TU6?4W0]73C>(S?>W8.F-3": MK?K[$R-N/$N/:!%B(:/Q>BK*N<5Z/ZD:<+U1//FTA)R-#@$Z/19ZO8Q'O$\! M$[W@8(FZZ,0W V@7 :CL;M487\>(AATB1L*-%@&G6=^Z7B.U3'EN>0M/MP.B MKJ0L^K)$;0&>+GA^)/+>-:"'>$K%/8K:6M1"G<-*U43R$#0>9\GQ"'73AS/- MM.0U ;:H_\0 N266)*HCQ4-%4NFR$<\,2V1+60^T0PA;%"5O^VS*#/U M0*?KO'R0)3;"G*1<(+GK8UDA*@.R)<91+5]DR"G4;YK0B'M^)N1&34AD(31B MFU8:TE%57U(,RR_TZAUJ\B=K%@H-LV:)-9W*,8E5*7>B\% !E8P2$ *Z:"P2 M8LLF$TA8ZR9Z;>%AH). - 6(6^C4"VH$DG-6)GK)4;G4ZU%IWV>+[F;-N,)J M"*[+X^YA\[V*5O%P2HTEX0G]@;IZ+T/\4E>]0+8Y)>/=IX(+:E*++B?5Q)7J M]WVM;Z'GCTS7_IV@N3= MGIBT4QM>QA:QBA/T[-",6G7"40O&^+PTE,F=F"L)5KZH[JZD1LE1T4S#&"M@ MQO9"&S'YV#XF8^AWX\F->$<;D:[,%'U/I2/^C V9C\[@>U2L-.LPD:LMI16. MGLS6%A(JLLPP=$QB(,#P+$5RJ.TFS0!JERX[$M_K(L3$9&57A=)%ITT)-SJM M=V-ZO=W+TP*1 C"QH)?F*!#0VMX4>F)R:E,(BIXL5 MS.1$LNV!/%4+37S,JD+-.AX2 %5I=B]J^L^T4M^$Z(_MZ3O)J-SX/J42=7P# M'0+)QB\/#+-'J.0"VV9B/81,Q3^EN@G0,'.$/PZ:K"_1?D#Y1.GV(!C'F)+_ M(-0V7TXLM4C:KA//8HZ4L"2RHIYA(&.5NLFB5RGS!Z2V* 0F#78HXD4C#V47 M^A.8_X#5'=2S1!:",)%_$W4PD;:P4IJ2/?;M0,:0N(2!.JM0ZP!9TRTB2R@> MYV85769(&,'@&E%J<7LL*LC ZA99(F&*$)7/ M^C2@B*;>'W0!UQ&"1_HVPF MNF(T?3G'3@=X3-M20%1%B[)NE3P^PEY9S%\ '55@N;0*U$ MY%$AIRPHZB(K2MQHD60JM0;B_E*ZZU64INEZS(,G?3C #Z9HMQW+_ZC=0D*G M!8,$;X^@T!Z<"#:7)S I^!@2%!%*G3/[#(%D/D)'4-QB@FK1:#F>RV&TB1!H4= B62OIF;:Y9HZ@VL.Y M8BM!:)YB3&1_@I@V&\\W2J@RY9'*H(1&)^ZU(8Y $2!$2=1B7@%&^7OR)I-H M2P8I\_C-!(77#>^FP\/*ORN[,E_%2JML1]'#UM*1NIH(#O?XM:LU@G[>/:Y- M_>K)[W=G>M_G_?;>IT:WGKS=<#W(Y^Z45/G#=-=N8Z5.U\]$L+TX(=LS_CPK&D7I@QT5IV6,D-[(ND[ M(LAJ#)F:LKN$_*V]3\>@,B+UB MMO0[4>7:&>>R &9>?TC.L&NVYALRFPMUD22HT4M70HR^$X8#B$' M=9._/]E]FKX<>XCW*-0?@3N@1B;%YP;VKBZ_?#L1HW\TDD1$$OY^>7;_%WRA M_J>%L C[0$+S^?KV[/QV__/U_?WUUQ/C/XY9_PAL'Y#!!AD['PWYQ-7YQ7WF M[['H?CHQP\"+@.B@H2'?/KV^NNK=W $N ^S,,>7LHW']M_/;BZOKWT\,;,4& M,$5/WU_?+ /E]O++7[)@R;5@%E+$5^3XR[D8N]&[_ M^PJP$XGXR85-'V ?#:#&-7#,?Y#^7)_;R!\-H,S]Y6GO2DT%W!)X$_G@[Q+& MPSI@1$;=KWN'[3\EF"UC"R3,16&N[0ARC0)P2_.Y@,YHQ,Q5)NP[.O: /NX: MX&M@W>8<*2C92FM_T:@EHFN=:O'?\.+/!\W2ZW_TTZZ_=$15$K[\R!6QR5\9 MMX3J,B]@%J.>L\-WC0[5&E=K_"K"&N]?VX0*GWNGOWVYO?[^[0Q(,1@P-AQN M0)J);5EHP:PEOU4#[72SDI,-V*#DZ!>]^W\R='ULYE5F?.O5^E;H5NS\TZUO M2<[M(?WOI>RN&^9SO*?*B8JZ!ACQ?BV^V!CYW11SVUOK#'3_LUCI=M,[.[O\ M]D6YL ]5J//U4<^0>-C-LKUSJUPQ=<742YBZW6CNW!J__?-[8]5FH_/[EG%& M)>JBIB=N9?FJQW@9U;LRHOOBGL;MB;XMTB#K/&]N$@RJ>+OB[1W@[<[ASBWV MVS_67]8LO\8BDDJY>WX&1,G7_N4)\E:,G\-NM3VJ[5%MCP7;X[A5;8_2Z1 O MZQJX]^A.^P6!^4K%7$-8M$!8X/40.']Y*/+L7)[-W:EKTJG$IMG&Q,N,,C0Z MQ]7&JC96M;&*W5B=:ELM4F?BQ@3TL:CB.QI:+S7;VL"9S1_F/Q1 MTZIBKZK8V]%ZCDZ.\?%*>>#/1Z8JTMJ9"KUJL7^NBKS77._=K\"K)/;6<7D1 M6ZE"?3MY[14+5RQ;RK&_%OA7[5NR[RR?QRZ9:JL:"7'5W?2T.4&B70X"]]3RR9P9DGYT^UBYW M^MA&KKUJ&U3;X$UM@_W]GWD7E$0=>(VL26>A>?XSZX=5.E=ITKG6E9NE2N=Z M1>VBVD;5-GHKV^CUM),R[*(E29#Y*85$GU)?+K7A%29S=RT-QLP*\7ZD^=?O M<>#G7'[2^DDO/WGNC0\[=P-%UC/5K1[5K1Y5CG"5([RYJ;UK>1XEH"A/4D7G6KQPZ@6S'U>DQ=W>I1QO.[ MNM6CG.I=&=$M4\7=:WH;O4HIXI9E=F5ILQNIR\?J&[UJ#96M;&J6SU>L:"U MNM6CNM6CJMBK*O:J'O'510]OO4*O6NR?JR+O-==[]ROP*HF]=5RJ*Q&J*Q$J M%JY8N&+A*CA3W>I1);+M9DE9=2U"F=&KV+=BWS>>)E'=ZE$" ?;6\\BJZPQ* MVG>[V@;5-BC+-JAN]2B!.E#=ZE$6_;!*YRI-.M=.7T=0W>I1;:-J&U6W>E2W M>BR^U6/UZSCH(H]?_L?^_H7G!=^\@!EW;!#8GFO'Q\/GOJ^<^#YHP_->KWU 7_^@ _NR>>#V12> MA\F9:S%K[Q,-_F%N=/C^EP\XE'V"_R8H_A]02P,$% @ -(.I2F85/$U< M"0 3%0 !$ !R<')X+3(P,3(L]G4=AJ&@)=HF3J9;R3XZ#?B2,<"R)A\;/J(LE'G'L?A4)/VH=M8[.$5P$J:8FDK%\>EI"\SVR9PP>1WP>9=,<.C+J\9O M(?;IA!*O@R1"YK-$8XKI=).) M8>J*?!X]I%A:FRR"NOD,,)!##@#(YP41N=#HD1Q?A%QP@Q(8R='BD04GKEKW MQOEUWL3YDI9H ,@M E9BR U (I2=^K)XL%99,@OH4':GY?*(-'P([4Q9>'&V-FT)YU M S=4&:;-O!Z35#[?@$0^UWH:B$)PK!0KW8EVCTPHH]K*UG$+'8 Z MN$:#^]Y#>W0#!#6D9DAS@1G*P/TZ"WP/-@6]WT)XC M0>>GSX-^M_M2/:F-#A>L'(N0$;M(ZWJ*UEK=HI0=AV !% MFE!:58VX:0G#BE/_JT3[B'T5*XV5D+ _AM6IQN+%6X32CNAY%E'%\U;_B5)B M8Q 3P7J\!M 8-MU>4B\WG*A,FN\&K,/K;"TCK.PQ.PHX:^#;PA^/Q#BGO#A M#.J%*/(;3^QA;V7#KG@1,"/-70?=$'1='ZH#=H][*<^I7:) MQ-3?X95HE6J?!?L\$$%OUH:D/Q5_A][$QM23:9?7Y\8\*<-@GP([G*#4P.X% MV)>SPLY2K%/@9.NTILP4J!=]U;F1*:$V$#>,V7'<.O[9KJ]J4$H46)VU^L$D M/; !52D..X!;QT;9HBPE'P63S'"]YLK!^W+>+4QMAW7KP"D+:YU#J^*9?SK[ M,K(5^.P8;QTXF4Y\:[2KHVTY\RU01%5DMN.^??YD.TRNP4\+5'^H-?A )DC_ MWO]"_93ZJB'H?.&K/@'];,;)Y*JA^B:S\"" E@2RP!R69B? ,U]^@8(%+6L4T0#],M'X_+N@4LQ#]TWM)=!G"7[D+0C\"M@$O$.&M1I?RW=!;9#,IABZ^=M8A*AN1U;!6Q),V7W.P:E-PNL$+&I!E7=[N: ML]4P5L24%9.^VM6$[6:R(C:LN:)+9RV@DA79#K4B-B0\ZF)G_=GFM4(&)$SZ MJH()VXUP^F7#R%3]%+98YO(YW^!2Z>M*1/D7M3;VP&+FI26 MTEL+J6"AM2FTR$Q)>-2%LV:N%*&MML5" SH00(!J520+NQ=7"K;+DA7I3'QNJ%R+LLA-B,P#R!+8/Z<%X,) M]D5N$*+"5&['("(=1WU[$"PRIK)$9/;AG"%PJLG?"WTRF,0G^7V*Q]2GJO[7 MW^=??6)X\F(&G-P-Q^1F,Q %C*W@)NR4M"+Q_U\#!@J4+[B_'8Y\'!K>$7336X:#E;/3@?7[;5X.1H1KEWC[E\OB7S,>&)4]$_*G'A!7-,V>NF MI&V3#+9?!YS0*3L8PS/V&*S^PCPB@$R].^\YF1!8:)[^L'(PCKQLHL&W&R%" ME9/:2_KZ[S98'AX%8]0_FI19'IMVF5(:T5VT":WHZL@? !PFP\KGK0,J/(I9 M:2JNU%Q4\4C*SWMMV\_8#PFLPI^)D"3U4R)-_H51N8^2V^SZCJ_E'9PJ_9(^ MH(E0R$B#@WWL$38.^70TP_X<,]8);IA[,'G4;IYM^0J5Q!Z@*F,A@<"HWZ7" MIFKE$OBSB)[NIZ LM6A-MKVT5M6JZ 3B-2OCDMO>'%,-3AEZ>)Y'9"D_^2 E M,_MD\GQ/J::H1P7L+)=B]1(5)7*LT RO[/8NQAOB 760H%YT6M0AP<'D&(-= MIH29_.#],*>KV3S[AGP($YRK17L7,/>/LO_.-5KY>=F,CFFUR_\%4$L#!!0 M ( #2#J4I>4V$C6P8 %!* 5 "TR,#$W,#,S,5]C86PN>&UL MW5QM;]LV$/X^8/]!*=[[KD7DJ)\]GX2,6\,4E'!SVNM>K/F 0]$2/G] M>>W+[97_KN:]_^WGG\Y^\7WO=^ @B8;0&TR]#M'D5I+@FUK(>ZUZJW[BX8?F M._\CF?I'S=9;[Z_6T>GK-_CSM_=O[^-_WF7_UO.]AX>'>H@:=**A'HC(\WUS M'T;YMP%1X*%A7)W7AEJ/3AL-,WXRD*PNY'WCJ-D\;BP&UF8C3R>*KHQ^.%Z, M;37^_'C=#X80$9]RI0D/GJ2,FBRYULG)22/Y+PY5]%0E\M_&.:;2W[KR#]NU2QA^!X(*HX143#UL#L*3PT?Z L"!F":QKM'8% M!TPTH,IP@<3<92/"D_3%FS$1K-R F<(AY*JGYOJ3ZG!'U" I$;'R[PD98:EH MO6D TVIQQ?CTC=]LS2O%J_GEKW-+KBD94$8U!7412XE^6-R,D0&PQ(2O%C(+ M?]F"2--MKBSNT,/6(#@'-G=4OFE64DO&+='9EJMV$ADL;H ?4URN5N/YB(:* MHRC1YE,,HX7\G121M>OF-H@*@&*%MHF1N2]A-4_($"3V86S##T#OAQH_;YN2 M&U" H(=M'G9@#$R,3-)4XL=.Q:&298?5+C!!.8Q%-GY M-,2!\,YT[GI(/UF\D_:Q'<]W^1B4-A$[ ]3E&B1>*6 B7\0!9M8C:9V4?.,= M)NE"**VPSSTM_'+)20]U@!2K=$E;7MZ[_;U14CC[*"QCA7(.D)47;.GR5HC$ MX72:;9 Q-+P=1I13I4V?'D,Y>Z62!\1?*1;KJ;,[4ZZG#84]S+C,S=&;YM?E M/S$=$V:,PC4E%2&6/PE$00=FOXLJ>"4U^\D@+.C&OIX48XH,?IA^05*Z?-9< M*;]O!QA)R02^>.9IK<2%O-J WO63=E! ?Q4E#M!?/>37R:\"N)S\_4U]X*E4+\?I<'G/ MP3_?SWI>@F#PF5,#B=I!T82 CIS,J[A M(B$U_9[\6GC5['9YX9H=/&_NKE%-LI7\0%E=_X)22=X:QDI-DEG . MN%;:4UM9TZ&07!F8PQ5TOK#)7-"4UU4KZ4.AU0K,@1P%W?L$?FG5@YY,'CL, M!4-G*9,H>EH05.6B>]HDJP*BQ.Q])8(M+:DML8R1#C>QI8==I1.0U% ':+(G M)FV^P[2TPY#.[.IAH>WR"S*BVAB9/W'/DS@HDG)1.#PQN#7[6K&<6B51UN"# M8B@+0'FKW^<)8$THA_"22([S3-4.@C@R+@:S1TT#6KR342Y\4.S9 "K?F]\; MF7;[[:YMHF\ZE;#8#W>B %9Z*\[1-^$R(JN CMV^<;JU-YF7'[-8O<:<*> 6 M.R5+TSP0;A.UHU?.#X*N:J^2.E'P.C'LT-92"0\\TS<(D_KS?^W"TOT=C/PG">/)Y_\?#U<'9_M[?__U?_^67?SLXV/N5QC0E M.0WV'E_W+DE.'E+B_S-;UM_K?>A]&.[!#T=G!]_(ZT'_J'>Z]U^]_J>3 ?SS MWWO_._KV?WM?[Q_V#O9^_OSY(8 6\K*%#WXRVSLX8-^)POB?CR2C>R!8G'W> MG^;YTZ?#0U;^Y3&-/B3IY+!_='1\N"RX/R_YZ24+UTK_/%Z6[1W^Q[>;>W]* M9^0@C+.Q]>LN!-+B@3Y&^?J3;P\7#^QWU0U][>+VD2T3LZWBME_92_/M'/ M^UDX>XH8QO)WTY2./^^G3^E+R9B_7L?C))V5 M /?W6+L_[J[7D/Z9Q&1"8T;7(?O[H;R)0Y"PI8RWZ83$X9]E@[=/K/?!#]E- M^$<1!O Y^.X=]4& 2_I,H^2)R9*=!_ G*$:BBC27-"=AE&GBLO]9"[JX2.* MQAD-X(^WY:T.#KRQ/[6&;&@*BR!;EN MDBP;T?1^2E)Z02*_B.8\CZM_,)/6K$G+&"ST=_WF+,A^GR=^.?=!_YLQ>LLO M6$#1I&$KXW(V"_/Y'!"S,97#Z@FK:$AM3$6-6]_*C#."#A/G4YJ'/HFL33\; MK;I"<@_[#UIJ]G:\FN7;H!"U: !GZ*L \B"@8U)$N44!.6U;%#>9D3!V(^VBZ=;"ENTO"F HO"&<3D5W$!S:Q^B M+SF%&3Y8?HI)U.*<7=H!X(M1XJ]])F+&BB3E BK!9-3_,$F>#P,: JC>"?N! M3:PG!T>]A3WB;_ K;_GURD5PQ MK!:Y+.X=KXF[XO4\71<<^M:RZ44W,YK0QVDRTU?@XL.)GOQ%!K(D3_.%:7\O M26$_]'F_!\V4W?B3#\<*Z)5?HW*' 4.!3M@/J[]'"6Q'/N_G<"9O1]Z89(^E M)HKL8$+($V-P<$BC/%O^AE$YJ%"Y^+7WM@&ZB$BVW-J=OX2\+JBLXPU//SJD M53(C*FE^(VV=8DU(?*;[79%6%?)R;<'EL%4O#)@&#FD2;096'&EJG4^5" ^? MH^,=YLBK[<]<5K)3]? MXQ^WH_%SD"5@\EQ%9")0^5H9;WATM&LZYP#@*WVPW6X^HFF8P$XWN(2!K.CO M:V4!0V_72) X9-QNETRKL+,)]%_4I)>P6]4&_Z-TH"COZN$<*'P*3GK@I)Y MA]$GI5(>L+@\U6R!EAH8/C'#[1 S/Y3?T4F8Y2F)\^]D)IJW>$4!P@$B3))4/D;62 .!TU\@0PA#PT/(P MKLO#0TI8J-W]Z^PQB00,K)4!H<]V3?<< *M;^DTO9@MD]DLBL'E3R]\NJN,-7%+D M?"70P^?$=]*"P)6(S#AW.X:#6)P1O]S]JOR\ZLK>P*G-4M\U+^5$P*,>.B?^ M%\R$XEC#G#.K6NM:NG/:S;GTCP*V^E^?%[YPC1F74\,;N+27;G6^%:%SXO"Q M2IUZ3(KJ>&=G3OW81I.KB !MRJJ8W#B'$-&&;PJUR)]JXFSK5K+&H_ T(2T/ M$#N,5M <05JT5?&X<34UI^HAS-EJ,<2VG MV^@ RC6V@45(8(D;I10.6/.\H@N:R$UPW,(@<(>12ZV&&<=&)X$HX**!<4? M1<5A>9^3"06!*?PAS.@EJ-0/\W/?+V;L8@D:7!9I&$\V:_#64%M->X,.0SX: MNN2L8A?PWYDMJ,PUCH/-=.3\@J3I*Z#XC42%S/6J5=\;=!ALTM(1JP]00&UG M1B#HD4D1LULP7MGF$4 L+L.Y"Z.[,4X!W0T, M1X*9O+RQ)6,;BCN82N*"CN H 9^'N40T0TNJ>&<85M@F4Z\2E,"/WL 6)&"B M- -?9UG!KI:Y2#+>>.$7! $[# )NHW4!%(&N.[/7 #2?TB"[ M!+::^9@DDT M*AZCT+\=CVG*#\4S;@-4T&'X<,L)SA"E@.CNXL.6_7&YOYIG;LQC#+_3G^6? MY#G<.@T ^-U=PTP@"OCMS"HT%W(N_"@-?;J\1TY&J:@.0-S=':<"E8"XSLPZ MO'GE=EP) S:<>=?J N0.XZ =S+@<= )"NPO8@5U6NESULYYL_*V7!%UTF+K< M=M3QL BHZ2P4Y^OL*4I>*2UM4KRC"1Q;OB>QKSS5F34$RN@P';HEL4V@"G@_ MW6J*@L;UNATD';Q=BG&CD6M0+^R==K90O0FC3"=8*^@Y[?O2W &!^D2;OYK4 M>-(#L%S7M)'?TJ6SMTZ7@EPV!#Y.A: M1@H/ K(LA>TX,C$8!\64M/%@BFV"G?FF-V[$;D&N84O>L(=@\C3EN1%(9(D+ MHY0^D7#Y7 M@N,VG-%W3A-2;3E-@V)(7YD"5DZ*'(9'$\+#@29)%.K-[5,S^T%GJS_EHG.9TF_#. M.KQ&H-')VP@9MK0"CD/'B,O-5?X,09B<$2%*3GD([>4$. E6-8Y+7>Z]SA < MW!2J%\R=8CSV<@:L<=4DC%@03'N&P!S6E#$))&R!_D9L\3 AL'PUHDF !5NT M?D7,U=[5;"6KUX.]+X+]H]W53(327CR^'4(O"_J0+(-/]$YKHBH $,&64H,# M/GER6/:B]ZT/1+UA!S!P;1G-V*DAP1;B+WFY6.;/$=?RSA#8@"U,BBJ(*$/X M34_=,LT@L!1;H%&!$%N@_@C:HC"[S,&J/&^)(!PA9O M_Y!2DA7IJ]90JA?VA@BV[8U($F"1Q\5WX2/+004T^$K2&/8^6?42AOFU#%+? MF*JR-T2PL6_$GR8V 9_=W5M9PVJT,_2&"*R_C?@28!'PTYE-0[7;;>$]\X:X M[, 6+%5BG(*@\*.MYA+J**LT4,FH@L3WFZRJQO);R1Y0_J5O5Z3R(P& MXHJ2A?0J>CVG[RQQLX=,E;C>CTUP_95?M)ETT'/Z;)-6@I$)@:+%2 KOG:4< M]7I.S1$6#X%IHQ6%"FS8\HXTKO(TBK%JUB HM,,X VM;G,;([:5 R1?8MYN;I#%6 MBAH@,H)H@C;J%J^I0KC84I[,X%L;L-X012:;->[;:$&>)[4ER_1-DF7+2P\O M2.07\QOX;\?5/W3X\';;.[!Z7<9@-;L$J]=S.3V:WH)5*E!AO*S(C<=.[?:9 M[%X?SUM&'!K6"1,"V*EGL7O];A_8$VJQKNRZW#OU,C9(C,,&W$+E:&V]WVE^ M'V MR+.)PUJQ!T V*X"<3-W&%9SO#MA-:9DH3UJW9%X0A7SX%L90.+RB+65>6\##++C5BF=\IGW M2BE8V9U&+FG/;!MZE2B_*CBR.:M)KPH)J=.@MC^49>PEDQ4S*R5@X0 M(FE".U:A@[>H4VHS='+J@*DX2Y;LC24NYU'4KX.-&/!<:5YP9[-P>*C?E]J M4C*E3LI]WI?759$1>66_.O])TD!FP;#7N#<<=/<:T5MHCA)')@*B].':^@;T M^ZU;6FS3+#B4VU71>S#:F;M[DNDAS-GD=!T'X7,8%"12S,+<\@#1I4D6 MWX0KT0*V=*::J+^'^;3LI:QS3\.GAT01!-VP)6_XL=NH= VR--G5 8KM;:=. M><R')+H=CT.?IDIB);4 YOL8I=I8L;TQM>Q_2A;7"P(8!"E)%HGCP_,XK=\ M<;1: E$N_L Y 17")I\EHY!.K (CMO;3&P=]S:-FO9?K&=3RB:9@$OZ;R MVVTEM#')D\'.[ZN1?/M&=6&-3EWO8Y.'T%\5WUNAKD./GU4/U'I*?MAXO^['S>%D#AD7&(3.XR%*EVH93]CXB MN0_"D 8UF56 R)*J+)"&Z\SNDCT'Z5>"9?-A&J;SK\MCHS;+@908;I 0]'W. MBL@'@"PWZNTZI5]I,DG)TS3TE5'&PCI>SVE,S':6*@4Z9$E5]_,-4E56M==3 M5 <0XLAY4W @($X."UG6E77B<*U5]AE4K5 -0F($*]15DM)P(K8$UPN!?!AN MS)4/ ,X2Q0&!+)')3@9,SZEE?COKD@09^K2EK64W?$1RI:B$+$UV=8#^EN]6\;'4"9U=*9O>17D' UN[V.8"\ 4]Y54L3!=3Q.V:^#'T])/+]63=(/ MS!H"_7;]8G!3&VH;P/9RFIRS_SW)K74 ?EN@DJZ?5'38!V28Y>E46_,>0?FX M])?%61*% ;.6?"$1>UOP?DHI>VJ./24WI3G;G^[DTVRGW1T:FS[-=NHR(-7X M:3;Q*[(\N?'XC!P_S7;:N?%,1L,Z84( N_4TVVFW]BZA%NO*KLN]6T^SG2(Q M4+50.=HKZBR_HW**Y[H0Y3RD"0>9UZ7UJQRG.(+'%5KG4R7"@\RS8H$C'#.> M [(&)W.9)F)*W;R2USM#<+U->]JJ:+ Y5GCR5EZK M->2M4A/@8DA5;DU>#1(VCPBS"2=QTV50HS; 1G ?D1F3VK"P>3@J@ALL?Y): M !/!I42-V>/#P7:_6TU@Y:HGJ 'PD#Y\;L!6%0JZV]HVA=5;[&35 "B&$*UV MG-7P8+N3[2&E)"O2UXK,LBB/>FF A>!<;D:3$(;\%K8N/;)O +/;\>T33>=1 M)COIC1UVMJ=K[(T]H5KY2\Z$,28*.,CR M[]K:XD_=GHTL^$M*K6N;X$_%AZ*=?6D>,.V*O\28++2>XSOZ3.,"CFZ/69X2 M/Y=0MED4%@ZD1U;Q@L;'@,PY?!T_TZP,'[R.81='KV%!A2VEC!M1%<"'X&H9 MOM;Y#,F1(',1+X%IC!JO?X3 2F["Q+KDR++G+I*L#*[]^L(N9=&:OT15 !]2 M$[AX'I-C0>8$OJ,9!6U,0=Y+Z%-1\L1P+D27#AU)/4"*P-PMYT$TKI2PD/E[ M?Z4Q34D$ I\',U RPYB'SU1-H:(FH$6PA6A"HA8P;([?3: &DR4 0F ];<(4 M'PDV!^]WNMCOW,BO'UPKY_5[.[=R<0!@<]5^)6D(*;$=BN,U3@8_,>"R LIBP3A[)A2Z . M!+ND+?0&N0+D3NGMN3VYWL[2,CM-HN#M5NQ=]'KV.[QONZ'7L]]S&:-MZO4L M%:CE]2SE?E=>SWFW9Q<:)W&9I*[I^>35 _6X=&:W\7Z6Q"DH%D-"Y@'=$%3I M8..6AUZ/XWH<#?T+CB-B6,CL0<=8AHL37\:CR'R*@ V!*818Y9D8) Y5CE'6=DN?K,P M8,(9:BT]F_%1(/.8:J:7K"5B]/L(0G4,V:C)C\WE>1[\3S$/)\H>$L%2R7_C MI_+Z679'H:ME84[O:?H<^G3^9L\=]9/)G"'IGF,K$H#Z<:; 2[K/5E6#S>-; M0I@/G@WE[M,?BS?BE+-Y;*ZW@!I3)-J:E>#PN8M%HB],(TW([)2&4 C MV.M:8;*&"IO;6-8#-UZW+M]X^T[SV_%5DHYIF!?R3+>V37O#WF[NU5ICQN9F MEG9N-[U$OVU0V>YM(NV MN>$%MQ$)>O.(,UO("D--N3] ;H7/EC8N$$ O#-[ M/1M([24YFU$[[X(VN=5H$2#CO 7)D%QMJ/(DZ9T)Q3S9N0TW!X" BS.DD1L[ M?Y7X\<>=2U[OG[C$8=3* !27F[Q6 M(1I4HORHXLM"#1NK',2^UX<'!==V6W'-%^8+U-Y+^D^:K>SVI#P?)/*39_$8M M.$]259"J84N@%9=F=4=S6R.0R((6##"43^(I R>;-0@G!QQ/'3?BM'7WJ&D" M60 %HEZ":_I'T5V4#T]V%N]1C4@9I?-H -7ERL(ZWIG39].:&_5D5@\Y&&Q1 M$%HA("L#\_*L52;UMPVZ$30+BD(0!VS&>GN\.Q56T;V;%4-POZDYU IH>S$; M.^&+PY 2H,>S%:@[%6QA(;AJB"&1P.(XKJ"2QT-@N7OZ@F33JRCYN9-73_<' MNY>$/7 YH1DG80^TD[ 'XMEI2]Z[*GBW#P'W!VAM4X/:O"0$L%,/ ?<'3G.5 M&CT$7&JQKNRZW#OU$#!(C,.BTD+E:/U[L&=G*^HH39Y#6*B_O/Z ">\Z7KSP M$$_._3Q\+HT[&E=?F3<&ND$:I2Q>:)JB1.98;!BU-D 0+MR4 2&?FP"1.2$O MZ5-*_;!,9&(7B,Z2- __)(H\,DDMKX_A+5N[-"KA(O-D\O/45%;G6@7 ]NY& MI PI-N?DRH[Z/8E]T$&Y?CPD+)TP]L.(KDTO#XF]U=;UIT'?""Z@M]NSMJ,S M9*Y1P,,NDJ"7=/[?"H*%I5^CM^DWXIV=(+C3T&Z_,46/SAC&0AX.ZY<_"J; M]U5U 3)>^Z62*L%TKP=:GCN/>8A;&=K>\1&"TYY=YDW1"[I 9Z9")CQL1]A_ MV);DF41LVS(/&-L\T4HZ@4DSH @$B[W9S&Z.3Q#;TMW+?B#ZAO@ Z'Z:I/D# M36>K1W6E;_YI-^(-,5SM:TZR"3H!Q;WMQD]RA5[%[[*_7;(+BZ.=#* <'G=X M=W*S ,KALJ[' $8Z@3@=DH0WV MY&];S^'(DJ:O<#HIKU1,=LL#0K1_-3W"FK"KF:Q-T MTJ!11"?S52+^=3Q.TED9][K+Q_63[L*KFQ[73UP:JHR/Z_6;!&5R_W5 MG<:BMCJN,\*,C^OBX-+=/:X[O1_8RG%='.8GPO/>CNLG@YTYKIN2A?:XKMK' MMMC@ VX$059F"YX>)NGYG+O5^^60?>Z19+14Q_\#4$L#!!0 ( #2#J4HU M$C,><2L $E? @ 5 "TR,#$W,#,S,5]L86(N>&ULU5U[;QQ'\ M>_HUC^X6D)RIW:K>JNY?55>_JG[^C\^["#S!- N3^)=G1R]>/0,P]I,@C+>_ M//MX?[[^X1GXCS_]Z[_\_&_K-?@ 8YAZ.0S PP&<>KEWGWK^[UG%#XY>'+UX M!] ?KWY8_^H=UJ]?'7T/?CMZ_>.W;]'__1W\[\VO_P?.[N[!&GSZ].E%@%K( M20LO_&0'UFO\.U$8__[@91 @P>+LEV>/>;[_\>5+3/_Y(8U>).GVY>M7K]Z\ MK B?4_?N)?D6 MD6;ACQGAOTQ\+R==)94+<"GPO]85V1I_M#YZO7YS].)S%CQ#?0# SVD2P5NX M 42 '_/#'O[R+ MW^P@+3CY[3.%F6(HH35]B_I=^_)#A:2FO&B+BD^;_H<%;:5_IWQ$U MA5E2I#[4TIWV:E4.DZ[0^"E?B4A^E.B54GQTD_0A+S/UQT%-VFRT^[S4I1$NV/:@Z6"JE(G MHD\&_1?;Y.EE $.DU]&W^ ^,N&_7KX[*6?TK]%$M24N >^^AL<\6S,3DQI E MD9H+I@Z""+5%^*AT?848]7[7!'B/E[4L8Y5GU"8;,VQ9D MRH__@>;_'&*!3B(ORZXW=WGB_W[\.3(LZS&^^ L8R<(?HD+5! 'WH/813F(U#=O*8N@7FTS#SHR0K4GB/XLSW M2)K?)P)ZL$4G03VL^P"P24N@; IX* 2LT-YJ#33-H9VB#8PY'*+"#@L8XDD0\;@M+RCOH)I@^)W%7K*'*99"TE MW#,"J;-51) Y,V@\^_7F)-GA.8ZL:&]AA'<23Y(LSXBD^"@B0',$7K1D"DYW M:L/IR3S"['4U8A!:L[29!V28@C:XHFM>D75 U[)2SGP29U9'LR/;8LAI_(58JG7^F -?@\9__"(,B0G,DNV]' MSB55;%2G$?,'A#H:,E%3R0RN-X.;UZ0!9PQSDJKN;57K8Y,Y*!T)3!OVU]_< M06%IZ"//<1I&!;Z5I6^,FBU:M$Q=W;EFBE9][';E"I#VR%13MEC>&P'.+/CF MZXL3+_*+B"YZ47>XMNDY$?!\"Y^ =G/F?IUNO3C\)QD=%!)D210&]*Y8'-P@ M>*%H@?SS>G,>QAX*%KRHONRALF\Z4_O&7<%<_=(WAG:[*]!IF;B#=MO86NK6 M0=.\4RO(60'4-Z8%T&-C)KU)DZ#P52Y":O!:G!WY^HCFP9++K=N2VH/%]_=* M([749=M+N/4B>N&782'>K(]O/QN-#B3% ]9&(1>>KCSL*=1 MNA+-YS$_9]Z<89")31G M<7V*#K-YA*EHQ$"M#:\5P(SXGRU6!WR4_I@Q\-,<,+-^#?Y1H&#][ G]SSWZ M/06O-LAAQ:<-RS[DT2@E(*0 TSKES01C,.3+I ,PY9TB?()1LL<+.+22VT(T M_4+T19C!4[@)_3 _]OUB5Y 3\],B#>-MGV,(/O,U;?B5XRR]P5Q*:6@ (0)- MNZ!L&+1:!K1IP/!QMN27WJ).O!RQ[Q82_Z MS]D?1?B$0@&\,Y:?>&EZ0(+^Q8L*T3Z4(K_Y.PZ*>K%G$=DC/>''?[185\#+ M0<4-"/L*D,0.5B\V3%73QW_ AG4A9?9,Y@YS*N&!>X#;,,:'+3A^I$LJFF3 M7\6LGA!]OK2&BN>#AJ!I])J-CK-D;M?H>TH+;^I;!R4W219*LG_HL=M[:2_6 MBKUX7++A.S3-^5K%Z=3IFL[ <1_E*X^:!4!*#$ZA/9 QCWBJN'DSF'68.]R M\6$UW4<[8X1T[W&(V'SL.22Q++.',_N(_/YF9C1)9UOP%I=A#"_0GTJY8%K$ M]KQ&6V*!Y\!D@- Y !%^=W-="*>O#>;(R#*H="&I3V@^HT5?4N;>*R&0AB%F M5J!R:>_NSN[O[(-V& !,=@C!Z)L&JT;^H6%Z2]!5R"%$$5P2.H5DN?"5U!ZA M=P78JEF-Y$A9.MT?/A+B7$GIDEA)ZU=*QTWEA[]W(W=?NQ^'\O6QG6C.@=U" MA*S0QZ]6)VXP:[=DW.GIZ]H'5],"$.P_ET9KTT7.JBK>W[.[13F[.BO@BP;) MY*PPT@+[\\4D\S/G;V[29 _3_'"#1H=DMD42DM.U*RB*F\1LQCV)1(L^^"KR M%2 ,Q&W4+"N F!PXH=+4Z3S\C&R)AE8K?,"\E.RME.QSR8X^!53^8T="0Q6S MZ%N\NDVX$TYZ@CG=")-%NQ+D@HJ/AN/BA:<+E$$*H*/IR77X+TB\IDE = M/AI$Q)*1A/&78N& M=LQSFU;B .Q4VLR 3-%R8OC]Q>7%_<79W?@^.H4W-U?G_SY/Z\O3\]N M[[[^ZLV[G\#9?WV\N/^;?5O4Q6G?$L>!U(H=JN]].I5B72N3>MNZW-H*U5*C M$CUJF)PR%<6=4>?3NI]((UP>@^VD["?[ )I>^\'M*:1_U8L1(,J$/ MPL4HVH>K*X@!S^.Q@7FN_.,R%QF#N[;<<&&Y539G=.0FNV#5WBQ^NZ&@A6&[ M%6-_P'15@&\S=-,*V9P(U<0A6GT L_"FJ@KV1X#>\>A,/2IS .'-CH7>^F2( MSR;N!_40FD##X=Y*14V;)-ZN4U+CU?D:V^W_ZF7V?=YG.00O/W&OKDH@$PCNZV]4VNX@0ZN(_3$.8!9N8_*LNZ?#"OS[BU>OCM!B M/P5/]/GG=ZM7KU[A_P<9SM^(K+_('Y,T_"<,R"$.!&&6X94&]@I)D6/UV]?V[ M[U??OWU'#.+U=ZMW;WY8O7WUNB*FUK+"1[M[Z.,4 ]'A)\SV]H?O5M\>U6P_ MH(]>?U>SM2RKRVO?SGB('9J<^' UN D7!.3YGQ?=>&%P$9]X^Q"M(D5;<#P. M\QMP7-F9;:R:$F!2$,:@)';@PM0H-?:(=(W4\"FQ?>!+@,3L9ZF@R)P9W*?0 MRXKTH#35#!$;!_^@Q,R.4$FTY(3SCLH;PRT.HF1@5Q(;%S["+R7S2OR,3C]' M1Z]7;[ZKIAK[F.>CI@]W&61,WJS+O3"&096+O)VIAN:N$2!?A=G"33H%C=@K M6)2IR<7_O)/?BC)R%KZF%O.C-&NK$5 JN]?_EM3![,4X5D#BP4J"O6MKQWF>A@]%3FX=Y D*!!TYVU'2B)[M9"U2>E,- M$@;[29R4E'COH7_Z2RUY5-!8I5 $#6%%( M@S4=*68S'_ <))OY0.P=;3IUI8Q.#MU@UKK.Z^X=Y=%JE+>0!?9JUP;DB:;F MNVG,20LLK9LV@'551K,I?54TT2WZ)TP\-5D=I62TD]1*1JAE+*NL,O0Z.6,U M<;>0:5P*\B7I,+MC(I>B?$HR,[F495FR;RM*^O'L1:J?$T;#@%+9<#B(G& \ MY6_^8S8]4LZ->NR*!*WY@X>&3Y TR[21T3''(8^C;H<%2N?DC3,<\8Y(Q MFB]N*].$J5J+&09C3@<>](W3QOY&BQJ>F)*X&F R9QM7,+^(_60'<75O@2GT MZ(PCOR_G4(X?2@">8Y)O[!PDJ115/:#UVC,; V\*K8O< T^L-.6F[;BYTOO>RT,>3?1@5B%K@.<8V M:-S%C-:\#[NJ(5"V!&A3>'?KCMZ,O6[?C"4-TC"1-FG3.:PZ[-N;7J3L\- M3(F$ZOY+RFG<41*\J(+.BF^+,8&ZT3/I^1?_7 M=_):SF_"AG#_=TYK^Q)>$I"RF=WXE6LA=\R@87+D'%UQ;#J[@EH#8_!6/>I[ M6:7R%HWY._(M^9@-<_R=,]7'F9YD+E,/=Z/Q^F1_]=+4B_/K]!:'JW64"OTB MI?MO7A3!X/VAI,M*0F%.A*DMVZI\-J$ON&722EJ0I( 0KZK5+BZA5K<,:-/@ MX5 Q9#6'[50,L_?-<9R':S+SXV+ ?\V?$G+PVD%33G^PWS-X-G[!_1;2K"N7[ K*#=/FC_ /8Z;<+R1P#Y M%?M!UF*88J[[+@,H@WE9$ ZNO)TL@NN2F<_$TI62N?F$_@7P]\[$&75IOM$UJ# +?*; L$SA28'>Y>'A#L%I;]"\QPFBB)(^A0&0=!5\8^ M LIOG7$" SW:'WIN=QH?=ZD'Z-'9&GNN_=>C[XSU#_8L!P%V;?^67AB^\=+\ M<(\BELSSZ+)![*TO8AOR!O=#ZGX1M8BOV9^H;A(GPT>TDN6B<)5X@J4O[<" M]!?Q63_]3?R)]9M0AKJ1[%QU>\*%PZT%#8]90R]M=1,.T0295(6G:'(^L\=H M"GIHI?IUX9FM69V,G0VJ0JYS.*B'-SN!I72%,41L-5#DKC5Z :$S*PY^=XM" MO[%K#X[/O'\,4]KPKQ ?.O!\)$MGUB<.R,EDE,$DU2A3*BMI-1R45\E%SRJR M,0_, W#'XXK1:S+E#;)C/! ?8+)-O?UCZ'N19*4NX+&0\(8O?Q\K;1)GEN'2 M 6!3Q"CUOD$(P6U?'.E<+> Q#R&!_&((.3-Q2X> 9%:_T^8QL^3%(;;6#R' M]XC,3N!]"?MC77YO?^9V1%"E*5M15LM3]" X._.S )D&DVN'.;X;,-T^-)(0^G,O"SL>R9+M;SCS:'F W+CS1+^<(/"!;2N M/T^*.+B(-RG^./BX3V)ZITL )]V&C.-,6U-F.O=P08.FA14HVP"D$5"W @K4 M3'61TN[&\F2EF]N@>\IKW]C&0;9OA5/P.B'2:9="ZI8 $@<_=@A\NFH#EJNE"323%%##+CS% M-]DI-RW=T3SF<:>RVA05ZT)2]EVW'B+%)=/4X&C+VNB[\N.Z3)>RE;&,EJUK M0!-96<+R47W#XXXAZ6NS8FNNN69(/+")#4B,-+N&4N&T6O-58!G1+RCJ[S)E#.8<6.!KX$]2J M=6UITQ)-8UTCY+)I10IK@$X%::>6,^/U<'(AHP M@:&XLH1A1)*N7[@<]@V# M&_-WP42)5PXL7,9JT"F/[J IB):I0%9/+81SF?-G[F"FSU=>DTF*8)H$C&8(^>)3ZW^1# MGB<8%RBNER.');7PB(>1EGW"0TF6+YBJ7/)>76;\=BTA=4A" A/[Z.;A@WUW M) *'28?X!#/R8(X:VD6,YB[TB= C\E@LN$2N]*Q/K$C+8AYH=5A2V\6[E@[T M*V?0+D,/Z\Q5H&/>FRMX<8O>6^ !%TZLKE+/12 E+42?ZGEKT_/,7'+;F&5D MLXN]#9>,/, NB[2I1$M\%@L;+5SIV8V)K'Q"7Q$[4GA>0X>*Q'*N7'V!?[1O MB#*@LUL^*B@W.0$*:BL*9T4AGX6I4JR'L$3H8 E-ZP5+)JG4JGIJ>Y9=4@NS MA&2Z3C8A7&(71#.)RXW>RFG^9=34EW8E\^$@P"L MR^.0\4]3R^OP6'[E->, V7<"BJ;#/.C2L1M[8;I&>.Y 6*X4CCNP0%:0FRXX MX;*!^*AU@RUA1ZX:1HIK<\F@NE1PL6IK^\1:88VOWY13E5HYVDZJT>K,L1%!@V8'UPE2UR>=? MA@.2CIPWKCRTB]ZG8XUC7<^ *5KW.V613YW;F-HMN>)[!+I.]#[N%G77T'EA M)516:&X-G ..2&:>BJY(S38MY A%7A+?17Q,H@"!_.R/(LP/"NL717Y[N4,E M>K%)]ZL+@GAMTN+\^JLW[WX"E-^IRX-:(\A-.*H^?!:P2<7!)0"2F.0Q5\QA M.\QG#XL'++,.100EMA MU_?!H]#O5AY-<=._"6AM/H_BIGGK/)VUF0YW(:$MO7@:SC^G" YSB#X.@A!O M/WK1C1<&%_&)MP_1ZD"*;@F?<:3+]&"*AM?T #.L<:I0RN*$#1A3QZ1U*&&M M;RD:0+/T(E!J*X/4=E\$\DMN=%\$NF +"PAN[5&@&.M2H!@NKBA/BV Y%X(D M?8"1E =[4EH.K7'27(9DB;CO/?1/'X+G8;5#_\VB,I_%@2F)C:Y1%9(QN)"! MX3CXGX(^_,GN$\XT-US_D/B'LL+A+40+I"S,X1U,GT(?TDJ'M]!/MG$X5,RA M,R$;DL!".&BJ;]E(K/YE<)^ 7F &+NK K,P_L7[/E$E=E7-87?FSE@.4@I2U M4$%+%+L'E?;ZFW85K2'KM]JU[X<,VS<;.%LP;I-[PTA(ZL!/"YS^GTI&\J]= MXX=IPOUA*:^%/6*Y/L/8ITR ;)?GG5=L8]UQ!2FQU6KLS,F08E)!G@ M"*4#AQH*O=X9=94N-_C6$==1EVY@=:C,OV/LR,@\CL/?.H #08\R#^!XW6EP M[5GX.'C[U4M_AWF3&QKZ:(+)0YC1M%1HGH&RLW;MELRO!;5U9=9TM 5 FVC7 M0JH;J=9LM!WK,]#$<6;6$E,&VSR/DD\J:1;$;#9O+@UI(;RPA!D MX7#UBA)W8 0WDR2C8@Y@5S#'LMRDR5,8P.#]X2-:.E_$UWN(WR[&VV-D)D_$ M(A1@-Z8QXV %GR'ODC0/_SE8 ;G54T(NX_8IUH&Y5]ZB M7@'TKPB2P(8\*V^QKL!5$N_3)*#S_K*/>12WF,=K:M^Z%)#6-R-EF!D^$V9V MBV6GPP,,=LZ)AR0?/#%>/PP%XU]0U^&UVV5J6I(),2:0C0EA:RP7=4^QANF17.U@G/JY:^ 4'9 M%NZ$?=D)56Z&5J)%M-A.\3+/(TW:M^)IEC"0TWJR&=CT L>^GQ1QGMUX!^\A MPF*B3]("(2KT'L*(!+Q:7D"M00>\@*+FBEZ@:@V4S='8E#8(6BTZ,",OT!5! MNRN\JBOVK:[PRJYP)WG+-%N0^P%]0[!RAZL,NRYRN,ON$WQ#(O;#"*+E,,WK M?)EDZ//YMH^6_VF;M[:6ZDW1=:TJ<"8_BB]OU3\+\ Y664$"_S+^\DO/^%P\ZYD_"?-)Y!,UT[T#KD ? MNO)(1PVWUH^[:,6*F8Z[A(VYC)5FD0?#N#Y1[H^_&9P4G$@K_5DE3NKX+!6TI/,G%;OPRRNG9MQ MP?1XP#'7 5]F-"]Y 'G9,59/03#-Z); MF:+L+JXGZ45L+N2\BURY^N91&9I,^*Z'2Q>GSEFF3*>G2OVH?6C2<#=J5U>9 MQ+7[ELJ;6M$O(+85@'?\K&@M12,2#RWO\7_P$O_)B_ V 'TRW=]Q%YBH7C/F M$SOJ:3D8S.&=+/)'JX55E5EDX.C) 4.=J#8VU?9E.VRV*VJ\L&F.= RNP)V& M/DXS@+^W;[MC<,UDG1P-:G/V>YUNO;B\Z'Z2Q%D2A4%U"?X&C0J2F/SS>E,Z M'2^J7XIEIV'F1TE6I/ >?L[?1^+@=_Z?,NX'%NBMOM&T?P)T?H,82OM7<+Q= M_PYH?@@TOP1^P[\%R(]9/NPRW7?D/C,]X46_9M^C+&5I?:^SK)D9O.NG< _Q MA-[1%EW;TVG%_ T\+1V9NU[*=W?+-BPG+9M'6;=OYXY +7/[;"QDG$&5TE^$6_POB ,/NZ3F)8B$H!_1%OFBYR/T)>IJNV%)*2M&D&K M7]H,(.T U!"H6P+%GCR,)HU9KA\^@^Y-,2YR\2/>HGDL)\_+]OLH]%T)4D?# MFBDW/@W3$U*RX5WKD%[>QHOO6@;D-R[#&)*;W /&J,%K-EV;HCY#)3M*-KKU MU&8$OV%6^O+"REGI%ZU9D/C%KEI&.::L@M9V)3KT'?4]BW;E2M[^,=]5IVQ7WJM4?8^(IZPYV#BYW!7[*1'"CTZ MXXN OIQ]#)7?.[3K/MBS_8!2T*W6W^(-Y+D3 $2G$5?>X@UKJ/D6;RA-I0-) M=2>K+,TCZ>!+P\6U<^"5H< LQY>0L5H*HZP??Y/2NLCD,]$>%I_'3D$,COR# M-3&R0#826+-+]4=[.:J1:[)_C04 "X:;!@%N$;O/LLWJ5GL%\'HOX<2-) ISH&-4<7@E:$Q8'E]Z 8P?BG1[ M_^A%.R^.3Y*+V.>&] H\9A?$$OG[@*S)046/$(8?6B]]9TAE!3R'+B\4E#&V MYE4!5V>QJXZLJ7?!LPP9VRU\@G&!IQX?;QENAR('.8N%F]]J#3$%HZJ&E)RC^ J2,%)PX5!"(W./9V^#EG_)WW%)> Q;U\" M^1F3JFD!(0:8VJ&'6=*Q8*"E-A#6T"0]&.70VT81=\>!09#]?0:EKI< 9^;] MA5N(UVVG:!47):2Z07:3H"#C($J'ILIH=A6FH@F[Q,$\H,T$?J-LP'K:L3FU MLKG6'*-"ZUH,"C?*NJ8DYP0='+SF3*F:0:MAVPM/96OJ+$0U34EWBLB@_V*; M/+T,8(AGAV_Q']@3?-N:%-!'_SA&/QW@GS^/O*&EY@"-,0L?DH\YOZF^!YC M'A*X?5D-NJ0CEQK?T])8:4Q[%@>G7CZTB2R@-3K>/'D97U'259EH$27 I'81 M(.SM-A(4NGII1)PC;^M%?X->>HX^&5J["ZFMH(*5F8L+2@HP+2#$;B"#T^M# MV!!VN1ET4'BJXZ-#;Q$A7;EE&"E=B',H&>A]/DZX7;\44FCND%NX#7%ADSB_ M\G:\B668U"@^.-(RE[5I+IB&#F!"NZ 0=70;#_)>7A8*)PB+J1==Q '\_&=X M$&*!H;4 !E9>#AI*0D H 2)U 0^SJI1!1)GIMIC!QY,DG-XH+@=3, MM05*V@DSW(A!95W?1HA:OR_K-L[#"*8GZ$>W22IV&CU*"RZC+RO'81 R4-&Y MX"T&.YGU%8(>7@H$]ZF'\XK>'78/"=/YI0X]&J,#WY>O/^3E]X 2V!WKP;YL MC[*@(Q>.#9J:7&6"GR+/"-&J+U<=#X,6IPL^0F6, M!L(+Y0$R>;<&[KTP.*/I]8_C@*23.LXRF"O47E#BMG"?1D4G]B8-X0(E&ZTN M@AD!Y5RZQH+28ZYIJE5%%(AN"='-+X,SCS1A_^A/ X_LS2!-,!I\CT*$$!A2 M16#^C4@E&7-:4()^R?>+JF5%>#(2V830G6Z5*H\0)PAH]-U+!X7,"Y8!")JS MD%;E$V2Y9(Y\3*( ^41<6"T?6NVHLQJW*@5MF <@#0MQSY30@1*!(W2AL(]Z M&F4MUJ^_>O/N)U(C,+>XZ-,%7]]D])!GSIA."WB?G.WV47* ,+M"G2"-Y/@L MQHU'(#US/%% DI:$EZ!AMQFF*:A0E7-*X,XL2V"JWUSD,&G;P9JV+$REZA- M&W9G"/%DX(CK5_'R]I$[,/("GVUW-:!0V=#R.EJVK.RMBQV(56024\BZMN95 M6MU.7,?J98^DVU-SIH]4:M&)_)%JNH]YXO+%9I 4EBNRGFL3?(JY6DMVL23=I^Q;O=*>ADE92VV.8F\!Q+J5>S7>\ M_GM,TOP>IKN+& \AN:@LF-UU&C$^]6MIR!SX(\85S936XE^130#2Q!HMHG:@ MUEA8;\5]Y4E:"V)=D[&COBOJ!Y9C_9!9=XL+"?:$?,!W]WS1 DK&:,6M M"C49LBU:);+G3<%O%9<#[_74!F@(>*JC8QMLS7LKT<._$6TX L%A_=31V$[3 M;/UAX%RJLC$,4;ZU=L/?NVI^ LBJ6:(4KP;?8ON/,"APB^]ATC),G4; M,O]Z6U=39B.B; '68+9@[1C_PVO6;7MF^HX(#-/WB>@V&2UVLI/#DLI,%,Y MJX4*ME)MV'?FG8G"44BJ#A-;'E9GC QGDG[O94BN9(>O@I'MON,T14,#\3KF M_:$AN?$.^"-2HHF>V5_$2"VR34@K:]X_>O$U+1'X 3\5RBYBNC\EFF6,B6 G MS[69WAU,F[U^P V#]H^#UJ_CC/QMNE*"JF(;%0*TI"BO>.9(#E *L@)4%)S1 M^$:P36$$;=!4 ]F^#:.:(-'LEA6G'/H^',HO*?9I3-_)-N3DSF2Q=^7N: P MB0.; X-=RYQN\OMUPNGF#1J",,!01+,33,2)L#G$9L\D>1(/W.BF=. 8!Q5G MUPYD;Y)W>>?81Z&_S=D_=4;DX2<,[A-R&E7=XJ/_*W$,J@T8]QC*FO4A1AE! MR8D/)BDON;J955.I*UY&;P#[[F?,Z#D4T6:\V;=QJW%P@T87OW.7IT18T3*&/?B([>?3"=.?% MTO2/,D;C^)=JTD8 CZ%J'EBF\*/!24+M[SL;=6X*H],CLV^".%-*>'S:S;5IS M,./&=A1>+DG7\*H-.+4=U=%LU';4RK4R"'H#J;,MQ1M%**@T" M!#S&H2B2G]GE*6G+]4H)1G?B!.E8]*&E.!!3BI&&"*$BI'RY MV6>Z):EC11'&J&#SS96&O"J%#Z)Z6! )S3$!POH$VO;K*9E==&NH*AF%P>U1 M+PNSZ\UQW>]4+KF)ZS9@?KM453-FVQ0S8J0UK"M0N@-GW,)\6M[0FI?$GNW/ M>WIX9':%1X#1G*U=P4\MR=(D1G_ZL%7_1-WJ])LR;G\CM&5>V\)/+2,$W4;< MMP#*FO(V!M95 @=IZB8;VP)Z \G;*Q@SBD:KA >%GU_$: FX(^&IRKF"D,M& M)7"!#@.UOS$U:)$K[.V;"FM,Z&(V,[$47P.URM7 M72)*D6CD+-8*52E"*&Z M5I5[&%(=BZ&:5?.C9\(S"9JLPLX64YT"3YJ5P4R, M/$:M2@.O5*_*%?^C?<^KC#KF58D>Y(S:$5["9FB!@I_JHOB)%;6)J-2,:U2# M-BQNG.8#9D@: F5+Y'7MH&TVS;ECGO/TP642;VDN+3>M=@+&!TQY,L G'&:6 M/U:OSX6K7RF'V0--H>R\V:W91+&;47N\!I*$VF9.-K4DORMV^(0%9X7TO30] MX'W<)R\J"TR,#$W,#,S,5]P&UL[5UM;^-((/_!\7WVV)(UMK78S<'CEX$1SUBP-;L)@H"@R9;468K4 MD91GO$'^>ZI)R::D?B5;ZA(SP!UN3NYN]E-/]5M5=?6O?_\QC0Y>2)K1)/[M ML//AY/" Q$$2TGC\V^&WX>W1Q>'!W__UG__IUW\Y.CKX3&*2^CD)#YY?#Z[] MW!^F?O!GMJQ_T/G0^= _@'^<7!Q]\5^/NB>=\X/_['1_Z9W!?_[KX'\&7_[W MX.9I>'!T\/W[]P\AM) 7+7P(DNG!T1'[3D3C/Y_]C!Q Q^+LM\-)GL]^.3YF MY7\\I]&')!T?=T].3H^7!0_+DK_\R.A*Z>^GR[*=XW__#GA:B4_3H0EF#_[VA9[(C]=-3I'IUV M/OS(PD.0P<'!KVD2D4L':_/=ZM=/^O)/;')&8<'+._ M'\N;.(8>-NSCE9]-V']O_C&G+WX$G\K@6X\DRU,:@'JQOVGV5:\I"WV^#()T M3L*;'S,29R33[-Y&+0L]N4^R;$#2IXF?$LUNK%:QT(>G/ D*]0VODBG#9J)? MHLHV-"N93FD^7:C!50+J&\.W ZK-F+0%"SU\2,=^3/\J(#_,V'0*_\CN*>AO M"$.M4-X OGY-7DB4S(J.#)*(&D!H]HD=C>^A_QSIDV+0H/VQ;M1505W+X]ZH M2[R*CC3Y,H0_03$_JJPIUR3W:;1-[99_ULJ\$X>,;S9A9#"40K9+^N1';*OQ M-"$DUY]^U WM:(2:T6+4XHX06-"VYI^Q/Q^9(1!5MCPC7?E1,(_*43FJ_L&L MMV9-6L9@05_TF]O:+LP"BCH-;W?W9F,HUVU])^O# !0FSB"GHM8]0%@!1W[D!.04+N&Q#S:P M$!46+/AFE 0KGXF8[2Q)54)DOWBR#UP^9\QJF"\;BOQG$A7->]IUO>Z[<'2[ MNA!(80^][[!\,1N_HI+.PY/T-?GKK2Z4+Q0F,TW=9<>]T MI;M5-B_3U:[[:;!L'/ZY0>6J)7)1XGA6#.6C8$*C-RT8IPX,DA>GEM\/.X0% ')$T)>%]*2$AA*+_A1B;,3KRL^>BU7EV-/;] M&:/U[)A$>;;\A?%[5N%W\;/W-I]<17ZVG"DO?]",0[*RCM<__^B2:Q5AJ_1J MPN&SW-TKEJO(KI.I3V,)O9N%01!G+GG59(I/KP@.G]=3![PVF(]A.21W(!/> M<%55\7K[,U9UL/ )[>T!H4-H5D$@*^)=]/L(*5LA04S;.P(^41\1$W4) $(& MXC;RQP*F5LIX_9.3_:.* X'/U1EBKI:P!R2E"6SWPFM8-!2C:Z4L ._L'W<2 M*'P.S_> PUN:P?'\/XB?WL(OJD5NK32 [^XOCUPP?"8O]H;)4CGUN:R4!P$X M/4?:8',##I_//F(^R^/S(QE3=FJ.\Z_^5#2Y\HH";(R[3@6+8B0"$\ )>@:O M0 I\QB$Y,>_D5 8)ZE\0*Z4!-3G^\>A$(B /LQVF6'JLY#C MI]?IQU0R@?"V4 M5 29[*%]1A>7@.LF9AL0T?&ZP6D=)-D_)$-C[!-__TQ@=IPT ZM188T*'P#]A!M62T_&%I,]) M1NZ=#,;UBP4.QAUT(9FST''_E7D<@(!%I^ZI_TPCFE.2+?:9&H.Q1FM>MZ$7 M?[O8S89KS1:]KE.33E/V^..YB2PL#>ZQJ@>O MJ(K7_>AJA*YW26<,"NMX713.>ZF8^4-)#JD-*Z'@-IF#@?,^)3V,JGUY)!&+ M.[Q*LCPK2"AZ"Y/;5'.CVJQAKWOA:A!J=_Q3M>,Z0[5ARU[7Z3'3(K'\86]# M/&V8'&2W.5T<5<7=>6=,Y^1JTHZW=KS#AE?K,&O4D'?JU&M=GR7!\=8<_/[O M@AM=8G8PM*O]?;]MP!0N#@<5T3R,;FGL WE^]'X106/(6VG?.[VHL2$7Q.@+ MY/\J&\]Z%;W^F5-_S!9DOCJR3<2PM678@@J\#4=-YD7E :E3;\YN")>CMQ0D MWXQG.W,A;"II]C!:F'%@L2H!JY7$K &0&XI=_-:TIHXX+,7D8U"CK^1[!7*: MQ/#/@%1F2GV%,FW*.^T[#=#9F6K5$XRE>P)NCX;Z.65:Y=1TYC-A&=C">43* M6[>;?2R$K3.8S1H"R"A<)#K$\,=H';QM,-[P4RG]O_1TGIZ['[6;O:PQ8E6- MP%J%8;#6Y4@U@+7@[[_QAI-Q;,\=F3UGL4#ORK/>.78L"$ UKVDTAPU+C=%H MU*+70Q$F)*5(-?[, ;=A(;6>,N^G?55PTOK8=S]-P"DNG TZWIG3J_B MVN=(-4_(Y( G9XENP/8]&?M1&:0LR$O"*>6=H9CN]3A9Y5.$!D\>$K-0>V&^ MD?4BWIGSZ[H\N6^RL]%IMZE$1.X-/R3Q\SP=#R=^-/5CF'3NXN +F3Z3E,.& MLHYW<>[\ NZ&Y'F."B6&K1D '2R<\^<,MD%^^OKDLVE&*WV3J(YWAL+65&?2 MU,.&)_%( \;?<;%KR ^C8>K'&6P-V Y7E=I)7=D[A Q/YA.K7*O'N:B.=W&!8V,L(4V; MYBHD/)E1K#$MW*I)RX,X4,0/*OC2(KF*"$^JE/H$#VG.YKB[.*0O-)S[D6+2 MYI8'<:"P9S29LR7 $&54L4CT'S2?%.'KS'8YH;-AHC@5DU:H%L<"SB#>9X)3Q;F5ZV$AQ<\28]Y?Z8@)X3^ /-R#49T8#FET$PG\Z+ M"TG7\Y3&X_4:/.IM->WA"#%74LR9"VRAMY5Z!H,53Q!=E5_Y:?H*$OC=C^8R M%YA6?0]'E+JASIA#M)6G9CT"!77DEIV(+>_T=!_GE=I(!:IB; O*QR&YV1 4A;G #.@:&615/$N<&PIZRP92E@"'G=EYQ,06%BB[[)LSEZT M8I>61;1M% 14* +XZY E ".@:+\,=""/@) PNP5)+2'>Q3"O^-%@_AS1X&$$ M4/@IY(S; +FAL,W7G(P-<0KT8[_L>V^ZO]RZE@F?RX1Z7\GWXD_REW5T&@") M[?,R;0)2$/2R7]; $EF)>)#2@+R_9B[6!%$=D,L^[^,5N 1\[]>;6KRIK\AD MLLRP:;@\K-0%.:&X-VIQ6>#@$^C!?ID%GV"WFBZW05E'-MI72X( 4;AXZHYQ M'AH!HR[R.C>XE#&=1Z=N[MJM.R>\L+ 2D$/Q]#2 M%JYH3[V!"4^D/Y;729'XU#:I4G#*!8+G.H"[9TEQQ#K(>1*X,_A@\+Q):F', MZOC -PM[..S4YJ-T%0&>QT@;^)^RC&A=/UPMZ.$P7@N($;B.-A%8NBR P(U8 M8#-(\< K[^$P1G-XDA'* V$I_M\]K[N)&L!A:A;3V21<0&QA-G8=NE>'U>1/ M313#L"6OWT$QX9OJ2"V8ENX9N%>704IF/EWF)P+T#_F$I"LRE)JIE;4]''X* M4ZW016;I/H)[1="E?$T$*)P0IN1N8K!UW2!/6%T*_$5C\4)A)M57!%)JM>PCN M-:,4D7(B]W!<$S0\T'GBJX#F%P?Z]SG$-QIN$!AHJW+M@24K?A^]X0;,!T@F*?;G?U%N&T=0O _4"_GI-AL@Q\TSN-BZJ :%!L MW37XXQ,O!V8KQ-\]YQ4!Z0UW$ "VK;D9LQM8;,7ONY_-98]O2GRJXEK>!0I_ MB(6)7 725O ^AJOYM6PR,JFB\)M84 (%1EOA_NYG]<&ROP5BE>^<4]KKH_"B M* @3>D.Y<&R%Y[NGMW+U2!DPLU84EKR])9:+1<#J/AK0WAZ &/@TO(NO_!G- M&2:Q685?P^NC.'[5XE@&24#U'MK0ABGQLWGZJC6$-PM[?12'JUH$"] (N-4W ME_5+;F,R+NYKN?5SYSZ-2;A\^Z::':K,%R7U;ZLJ>WT4![!:[&NB$VB#L8$- MYV[<:!?NX7@7M1;; C0"=LTM9LX/W*HS20,?N-?'YAFQ8$,5(Q7<(FHP_<]MQ-K?6NS_9/4'[>G5V_RM@_13&%\LA2 MT,J'\O/Z; R"0.%-5C EL%\(X/R\06L5VE)_9' M[!7#C>TJ/5RV,CY3^G:5GMBGL%>\-K:K]'#9R_3'ZAJ&-MA55%O^!J-O4X' MEXV9SY3VWK> XW;O6V/.ENUO]2L#>*>FX/KCU11C&_;##?@Z^!#D/17SBF< MW@@(C)W;*N\=&Q<P1( X7[IC';^F!;D^"W3$1:(V.,O")("84)NI9*F$!L M3>I>NUF#.AT4UNI&]"O0V^5' KIE"RP^CZA\<^F.6=V"77=%8^D158,FX<&YO-PP6ZG10 M3--RD2ILZA4D>%PG&0D^C).7XY!0QF*/_8.1UZN0!S]Y]V3L1S=QSFYQ\MTC MG%)>IXMBEN11L$J6L/-X7!ZZ3)4(A*Z-]2( TZD17"CY38(VN_TS:(<)"X7! M2SW&5!C:X*3X2O*[UA&T;)#RNE /X*"S4(F+X-'(@(' LV*'Q#T+'DYR$ ME^S\-"9?Y]-GDCZ,BC7_89YGN1^'L _XY&T0&W)D>'H%(GMZHG5$V377FS>^D>N M:19$239/B30R3U$-NH@B+D\N0H[I3@L7GO,CFM"[KOO0.RWJ%'MB/C \IU"' M@7>GN&P)?*;X](K@M.'\^NC'8Z(8MV]E +;3HT[3<;H&I U'U@+2%\(VZ2H& MRU+>.8YK0FM<2 BK]MO^_9#=4_;%_T&G\ZF2M)5R !_%CFB#$3YQG+Y;.AS: M#5,63R8R>YYN50#N-'BE[GQIAJ]-V2K*E?X//TW].']('YDMY,T$0H)Y6D;O M^%%$PD^OBW+9HJ TA46SEF&2=&I+,M,(Z3:JF0C:D/JBV$@^^QD)KY(IBP@M M641F<7AG]V%4[>I$5RT&X%%$9UAFDZ\RF\#;8)Q9HE(:9E8+>AT<&?>#S<+> M.8Y78TRI4RM %9\E&Y-3HHQJXM-T MZL=*/Z"\HM<_0W&(MZ &)H!MW8%T&U0SH61T2V,_#J@?/8Q&-""I4A\DM4 V M;9D3M-':NK[H5!.6NJXD?[4@2 "%1< BWSR HKWR\I7;GGA*XIM_THYD!2* MV7TGVWT.<@'S^V7LJR^R=XG$H;:1?QN? S90'#LY*B+P#6Y-" *5W#?;X]$T=2"BK!Y,UBF/E]K@7&:V40A$HS7Y9*A^*_L,B3WZ0<)C< M9=G\[67?Q1/!\J5-KP$0-8I-S4[6/!.1")1HOZR@,L!LY"F7-[T&8-BA,(N; M\&NN(>MX!1JR7V;1F^DL2EX)*2;3$KUR71+6 ;F@<)^9L,C7 P5$ ?6[,G/N M:*$!2FH2? M4WE^B2U\S>O@N/9C2ZLLZZQ*< (EWB]SV#=<2=AXS M^=']O4L]=M5A<#I0VW")H6D<9.!VWP2B-9V$%LC9< M9G@BXW6 :O^RJ Z(!<7N3,&;@&PY*I39*VZ3E-"QV#J^60C H'"+**3-F7DY M,%KS=)*=FP$=MYZ.QM.M!-7/:/\FT78?<>1>D_"KJ1 Z.%%&^TN&AP8P'XM\D\#N_B4&GN:$,(>CV($3$C.MN4N'"!O![B']YL? M@R0KG#0:?@^=ZAXLT4GE%P-6WM2Z=RI%4LH^4V"-KO=AG1(EE/+G^,(V5...$TH;!\4@L$A"O.RY1Y/B!;6880,JYHN[K!J(")=EK1[?&XALY>QQ3_HP)7XV3U\K:&61 M8INE02 H3&]F% N!V$JLX_#9::Y#_DT\VDK?^:/C? M!36 L OG-DU3E_L%"J.&5*)Z7O8+OPK(!H4+F,\9 MGU\Y%DM^?0P\+X6B,6(]Z/F^\;C:=UM7!)/[(BUOWF!\OSHS7OBJJ M9'!M>K7F7SF:UGCG'X$*$.,$D%Z#)D?)C$EH 5HZ9"7U0$8HMDYR#D7C60FL M-0[ZSR0FJ1\!U,MP2F/*I)/3%Z*F7U$3Y(1BRU5' ;2@M<=KORXB@PD>1('" M>E^'93X6:^YXY^OW5[+85][+4W^NE/.ZG3UKHB8("L4:;<:U%BA;CO7P+;7>YSD-V7U%5UKP!Z'C">"[ MA .=/R;E'=%%-N:J]U%CEV[:%(@4Q5)NIB?U4-KRU6,X=NM*H!A!%O2E: ?$ MB")^HQ[]S52I(H#VN/\%X!?3K4D8B&%+($@4>\L=:))ITD2 MA6\O4SB^_+_9(;/;_^+ZP.6Y@$7CT0#XH(%!YI"GK%<-H0I;"&3AFHP"WO=;LH'"P:G G.?V)4;0A9 MJ$26JI]E7B\+8D!AO9%P)++%<9&T)LOQ^WL/ Y^&=_&5/Z.Y'RD9EM8#&:&P MWQBSK8'*4I2#>^97PHB5?'-*@SQ06%^,619BL139X)[;1_9@2TS"I4E2XRU; M7@60"@J3B3'#,CBMR93<-(:PVT5AQ:BQFU[#T(:,R!Q[@XS,]<(@"*PW60J* M1(3R<5@*8I@5#W9!E]+<[4#5NW>X:HV>R2@[!G-R1-)7VA RI?E'DF0C..B1>G&>R<] /IP6=BT M%'"GPFE3&N4"?CEPK^@U M#:TW<;A_9M;>/IY)-Q (@HAJFEE7B409C(GI6:9M1F;V/CKW+II&9O9P'='5 M\E4X&RNPW$9F"K:Z;!Y@.R-!9.5&&8""ZV1;$3!G*[K9=;<1DP(6;DBA6 M9L(82$EI@.?^.<%->7-(D?6_#;&.CWX\%@VHC3( &]?Y3CB@!%UO10XF!DD= MYO1>RNM^1!%NO,:%A+!JO]V^D&3)ESX/6/^_^.F?)'_/2$^">0I'?I*5^4UA M1TI4MP8,6P(1XMKU*P=L+8!M>'_) 'CQ0KKRZD&]!KU3'!I32P\:J]2&(-KP M&%33Z,G3C[@,0@CK>!?(WA9>(TQM%.+ L112 MZ78QT(GN>O=<+$\G13J=IA%U@F9!N+BF 2U=:8[85ERG^YAKO $(.&[,& M-KGRL\EME'QW\K1)Q6'RU@\S/]9&-:][UG%^O#-U7YWAFE:%8M7S6IV)YTT' MTV9&@@_CY.4X))0QV6/_8 3V*@3"3]X]&?O139PS5QW?\L3RX07:9*!$*KVWH1@.GT0K%0\IL$;7:[#8ZMQG>&SU#>&=X<8RH,;?!Y MP=F)+0Z#-'FAL!/Y]/H--A=W\>*)M'A\&>3TI3#F:BSDYHV!('&%>JQ1S%>( MNCA;D_>C9B3K&8J@D;KL"75A'6)K4H!<$^AQ0$N"XO!RFJ0Y__-9Y2+9J !R:>%<(,/:FA=5*H;_KTD<@/2*]7*8 ML,OM<4 CLC(E#A-[^XMM?QJ80A'/8U[)7LQ'OHH?B.&17YTSQV_(%8E@B-[$/4C+S:7B]0+)XDP6V"H5=^C++B-2Y M7*]!KWN!PI9EJ@JZ"J4O@\:>P'ZI7#$9,W,[,N6Z#()D#G/[P']EA@RV 0V" M= []I/XSC8HA:Z1<.@V"8%%D]=N6*52HC#ZC8 4>3:J$L]7Y%,\3=.SX)H3Z0O22LSCM?M8UZX:BJ0 M*7YK[_9@7;AN:>S'@:6%2](8B+,]"Y<2IZVL+NZWRP ]("3,;D&2R^CFAU'E MK0?9:J6J"\+";!]7TBQ8I/1@V\H4@V%SHR] *Y.*=WJ"XEQN5V],\=O*2>-^ M;6*P8?/&_H=MX%[\B&WRRM#6=:N%1(%,F@$1HMC>F*U'Y@AMY;O!H21KP$$4 M3Y,DS86023$._'C-PS[";*AC[/U!+ 0(4 Q0 ( M #2#J4IKP<6O)EL $BJ P 1 " 0 !R<')X+3(P,3
4V$C M6P8 %!* 5 " >!D !R<')X+3(P,3"TR,#$W,#,S,5]D968N>&UL4$L! A0#% @ -(.I2C42,QYQ M*P 25\" !4 ( !LX@ ')PT M !R<')X+3(P,3